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Abstract 
 
Bone morphogenetic protein-4 (BMP4) is highly expressed at sites of haematopoietic stem 
cell (HSC) formation.  During HSC formation in humans, BMP4 is strongly expressed by 
cells underlying the ventral floor of the dorsal aorta. BMP4 in combination with other 
factors has been shown to play a role in haematopoietic differentiation.  The genes Runx1, 
Scl,  Gata2 and Lmo2 are vital to the development of the haematopoietic system, and 
deletion of these genes produces an embryonic lethal phenotype due to the absence of 
blood formation. This study investigated whether BMP4 alone upregulates the expression 
of these genes.  The role of BMP4 was explored during HSC development in an embryonic 
stem (ES) cell differentiation model and at later developmental stages using ex vivo foetal 
liver and bone marrow serum free cultures.  Differentiating ES cells cultured in serum-free 
medium were found to express BMP4 and the BMP receptor endogenously.  To establish a 
model for exogenous BMP4 addition in isolation, lentiviral vectors were used to deliver 
short hairpin RNA (shRNA) for sustained RNAi knockdown of endogenous Bmp4 
expression during ES cell differentiation.  Differentiating shRNA treated ES cells were 
cultured and the expression of Runx1, Scl, Gata2 and Lmo2 was measured over time by 
real time reverse transcription PCR.  With the addition of exogenous BMP4 alone, 
expression of Runx1, Scl, Gata2 and Lmo2 was unchanged at days 2 and 4 but increased at 
day 6 of differentiation.  This demonstrates that BMP4 up regulates the expression of these 
genes which are critical to the development of the haematopoietic system.  The use of 
lentiviral shRNA knockdown provides a model for the control of endogenous growth 
factors in future investigations of growth factors in ES cell differentiation. 
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Chapter 1  Introduction 
 
Among the many different types of stem cells, haematopoietic stem cells (HSCs) are the 
most extensively studied.  Probably the most successful therapy to have arisen out of stem 
cell research to date is the bone marrow transplant.  As with all forms of transplant there 
is often inadequate supply of appropriately matched donors.  For this reason research has 
focused on methods of expanding HSCs ex vivo and more recently the formation of HSCs 
from ES cells or alternative reprogrammed somatic cells.   
 
1.1  Haematopoietic stem cells 
 
1.1.1  Properties of stem cells  
Stem cells are long lived cells, thought to be involved in repair processes within the body’s 
tissues.  They are unique in their ability to self renew, thereby surviving over long periods, 
and in their ability to give rise to specialised cell types.  It is these properties that have 
drawn so much attention.  It is hoped that the manipulation of these cells could one day 
give rise to an unlimited source of tissue that could be matched to a specific individual for 
transplantation. 
 
Stem cells can be totipotent, pluripotent or multipotent (Figure 1.1).  Totipotent cells are 
cells that are able to give rise to all the tissues necessary for foetal development including 
all the cells of the body and the placenta.  Pluripotent cells can give rise to all the cells of Chapter 1 
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the body.  Multipotent stem cells give rise to a more restricted range of cell types.  HSCs 
give rise to the lymphoid, myeloid and erythroid constituents of the blood and are therefore 
considered to be multipotent stem cells.  However there is data that suggests that the HSC 
containing fraction of bone marrow can give rise to a diverse range of tissues including: 
skeletal muscle fibres (Gussoni et al. 1999), cardiac muscle (Orlic et al. 2001), 
pneumocytes (Theise et al. 2002), renal cells (Kale et al. 2003) and neurones (Bonilla et al. 
2002).  However other experiments using more thoroughly purified HSC populations cast 
doubt on these results suggesting that the differentiation of non-haematopoietic cell types 
is a rarity if it happens at all (Wagers et al. 2002).  Further experiments have suggested that 
the differentiation of non-haematopoietic cell types results from fusion after co-culture or 
in vivo injection (Terada et al. 2002;Vassilopoulos, Wang, & Russell 2003).  Whether 
HSCs are in fact pluripotent or not is therefore a matter of debate. 
 Chapter 1 
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Figure 1.1 Types of stem cells   
Totipotent, pluripotent and multipotent (tissue specific) stem cells differ in the range of tissues that they give 
rise to.  HSCs are multipotent stem cells (Adapted from www.scq.ubc.ca). 
 
1.1.2  Haematopoietic stem cells 
Mature blood cells are replaced constantly by the process of haematopoiesis.  This 
involves differentiation of multipotent HSCs to the erythroid, myeloid and lymphoid 
lineages as shown in Figure 1.2B.   
 
The first evidence of the existence of HSCs came from experiments by Ray Owen and co-
workers in 1945 which showed that bovine fraternal twins sharing a single placenta and Chapter 1 
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blood circulation retained production of blood cells genetically defined to be from both 
throughout their life.   
 
1.1.3 Measuring  haematopoietic stem cell activity 
Over the many years since HSCs were first discovered a variety of ways have been found 
of identifying them and measuring their activity.   
 
1.1.3.1 In vivo repopulation assays 
HSCs are cells with the ability to self renew and to differentiate to produce cells of all the 
blood lineages.  There can be no clearer demonstration of the presence of an HSC than by 
its ability to reconstitute the haematopoietic system in recipients whom have had the cells 
of the bone marrow destroyed by irradiation.  Even before the advent of cell surface 
markers these assays were used to determine the presence of HSCs in a sample.  Several 
different forms of repopulation assay have been developed for this purpose. 
 
Competitive repopulation assays are used to acquire quantitative data about the stem cell 
content of a given population (Harrison 1980).  In these assays irradiated mice are 
transplanted with limiting numbers of test cells and bone marrow that ensures short term 
engraftment and survival.  The frequency of repopulating cells in these assays is back 
calculated using Poisson statistics and expressed as competitive repopulating units.  For 
human HSCs non obese diabetic/severe combined immunodeficient (NOD/SCID) mice are 
used because they do not reject xenogenic cells (Bhatia et al. 1997). Chapter 1 
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Serial repopulation assays are used to obtain information about the ability of HSCs to self 
renew.  In these assays bone marrow cells are transplanted to a recipient and are then used 
in a subsequent serial bone marrow transplant to a second recipient.  The principle is that 
the transplant will only be successful if the HSCs were able to undergo substantial self 
renewal in the first recipient.  The number of serial transplants that the original donor’s 
bone marrow can undergo is a measure of the self renewal capacity of its HSCs (Harrison 
& Astle 1982). 
 
The murine HSC population can be subdivided based on their self renewal capacity.  Long-
term stem cells (LT-HSC) have the ability to repopulate indefinitely.  In contrast, short-
term stem cells (ST-HSC) have a productive self renewal life span of approximately six to 
eight weeks and then disappear from the bone marrow.  Multipotent progenitor (MPP) 
cells self-renew for less than two weeks (Morrison & Weissman 1994).   
 
1.1.3.2 Cell surface markers 
It was the advent of monoclonal antibody technology by Kohler and Milstein in 1975 and 
the development of the multiparameter fluorescence activated cell sorter by the Herzenberg 
group (Hulett et al. 1969) that facilitated the purification and analysis of the HSC.  In vivo 
repopulation assays were used to quantify the number of HSCs in purified samples. 
 
Initially bone marrow cells were depleted for differentiated blood cells using monoclonal 
antibodies shown in Figure 1.2B that identify erythroid, myeloid and lymphoid cells.   
These lineage negative (Lin
-) cells were enriched for marrow reconstituting activity.  Work Chapter 1 
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done by Weissman and colleagues (Spangrude, Heimfeld, & Weissman 1988) identified 
the positive selection markers: stem cell antigen-1 (Sca-1) and low level expression of 
thymic antigen-1 (Thy-1 lo).    Subsequently C-kit was also identified as a cell surface 
marker for the HSC (Ikuta & Weissman 1992).  In human bone marrow, repopulating 
activity is enriched in the CD34 positive fraction of bone marrow (Bhatia et al. 1997).  The 
cell surface marker phenotype of HSCs is summarised in Figure 1.2A. 
Murine
Haematopoietic 
Stem Cell
Markers
C kit +
Sca1 +
Lin -
Also:
CD34 low
Thy1 low
A
HSC
CMP CLP
NK B T
Lymphoid
Neutrophil
Osteoclast
Monocyte
Erythrocyte
Megakaryocyte
Mast cell
Myeloid Erythroid
B
CD11b/GR-1 Ter119
CD3
Ly6C
B220
CD19
CD11b
Ly6C
B220
 
Figure 1.2 Cell surface markers of murine haematopoietic cells   
A HSC cell surface markers (source information from NIH stem cells registry) B HSCs differentiate to 
produce the three main blood lineages: myeloid, erythroid and lymphoid cells.  Lineage markers are shown in 
the boxes.  It is the absence of these markers that identify a progenitor population.  CMP: Common Myeloid 
Progenitor, CLP: Common Lymphoid Progenitor 
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HSCs giving rise to the early embryonic haematopoietic system appear to differ from adult 
HSCs in the cell surface markers they express.  Embryonic HSCs express low levels of 
Sca-1 (de Bruijn et al. 2002) and are C-Kit, CD11b positive (Sanchez et al. 1996) and 
AA4.1 positive (Jordan et al. 1995).   
1.1.3.3 Hoechst side population 
When unpurified bone marrow cells are labeled with the membrane permeable DNA 
binding dye Hoechst 33342 a small fraction of cells are found to extrude this dye using a 
membrane pump.  The cells can be separated using fluorescence activated cell sorting with 
an ultraviolet laser source.  These cells have been found to be able to reconstitute the bone 
marrow of mice with fewer than 100 cells indicating a high level of enrichment for HSCs 
in this population (Goodell et al. 1996).  The dye efflux has been found to be dependent on 
the ABC membrane protein ABCG2 (Zhou et al. 2001).     
 
1.1.3.4 Colony assays 
Colony assays are used to quantify the multipotent and lineage restricted progenitors.  In 
this assay a single cell suspension is plated in methylcellulose culture in the presence of 
cytokines.  This culture system supports the proliferation and differentiation of progenitor 
cells into recognisable progeny.  Colony forming cells can then be counted and classified 
based on the types of mature cells visible within the colony.  Colonies with two or more 
lineages present are thought to arise from a more primitive progenitor than those with only 
a single lineage present (Hara & Ogawa 1978).   
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1.1.4  The HSC cell cycle 
HSCs are rare in the adult bone marrow (BM) typically numbering 1 HSC per 100,000 
total murine BM cells (Szilvassy et al. 1990).   Most HSCs in vivo are quiescent as 
demonstrated by their resistance to 5-fluorouracil compared to lineage-committed 
haematopoietic progenitor cells.  5-fluorouracil inhibits DNA synthesis targeting dividing 
cells in the S phase of the cell cycle causing cell death.  Cells that are quiescent therefore 
are not affected by 5-fluorouracil. 
 
When HSCs enter the cell cycle they can divide symmetrically or asymmetrically resulting 
in different HSC fates (Figure 1.3).   
HSC
D
HSC
D D
Symmetric
Asymmetric
HSC
HSC HSC
HSC
A B
C
 
 
 Figure 1.3 HSC Division  
Symmetrical divisions give rise to two haematopoietic stem cells (A) or two differentiated cells (B).   
Asymmetric stem cell maintenance divisions give rise to one daughter HSC with identical properties and one 
committed daughter cell (C).  The committed daughter cell then rapidly proliferates until exhaustion, 
withdraws from the cell cycle and progressively acquires the characteristics of a specialised blood cell 
(Lessard, Faubert, & Sauvageau 1994).  HSC=Haematopoietic Stem Cell, D=Differentiated cell 
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HSCs have a slow rate of turnover and it is their descendent cells known as ‘transit’ or 
amplifying cells that are the drivers of large scale proliferation.  It is these progenitor cells 
that provide the 10 billion blood cells per day necessary to maintain homeostasis (Attar & 
Scadden 2004). 
1.1.5  Haematopoietic stem cell niche 
The idea of the stem cell niche was first proposed by Schofield in 1978 (Schofield 1978).  
The stem cell niche was a defined anatomical site in which stem cells could self renew and 
differentiation was inhibited.  At this site the space for stem cells would be limited thereby 
limiting the number of stem cells present.  Most controversial of all he proposed that in this 
place, a more mature cell could revert back to a stem cell phenotype.  The first evidence 
for this concept was provided by experiments in Drosophila (Xie & Spradling 1998).  In 
this work, female germ cells were shown to reside in a location within the ovary necessary 
for the preservation of the stem cell phenotype.  Signals including bone morphogenetic 
protein 4 were shown to be important to inhibiting differentiation.  Evidence was also 
provided to show that cells introduced to this environment could gain stem cell 
characteristics. 
 
Ex vivo studies showed that primitive human haematopoietic cells could be supported long 
term on primary osteoblasts (Taichman, Reilly, & Emerson 1996).  This led to two 
separate studies in which animal models were generated.  In one study the Bmp1a receptor 
was conditionally deleted (Zhang et al. 2003) and in the other Parathyroid hormone was 
constitutively expressed (Calvi et al. 2003). The aim of both of these animal models was to 
increase the number of osteoblasts.  This resulted in an increase in the trabecular bone and Chapter 1 
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the number of HSCs.  These experiments demonstrated that the osteoblast was a central 
participant in regulating the size of the stem cell compartment and therefore was a central 
component of the stem cell niche.  N-cadherin and the Notch ligand Jagged 1 were 
identified as being critical to the interaction between the osteoblast and the stem cell.   
 
From further experiments the HSC niche can be said to be comprised of four key 
components: the stem cell, the niche cell in this case the osteoblast, extra cellular matrix 
molecules and a link to the circulatory system (see Figure 1.4).   
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Figure 1.4 The main components of the bone marrow stem cell niche   
HSC= Haematopoietic stem cell, ECM=Extracellular Matrix 
Jagged 1 and N-cadherin have been shown to be critical to the interaction between the osteoblast and the 
stem cell.  Other work has shown that Tie1 which is expressed on osteoblasts is important to regulating stem 
cell quiescence through interaction with Angiopoietin-1.  Osteopontin an extracellular matrix protein in bone 
has been shown to negatively regulate stem cell number.  Also a calcium sensing receptor expressed on stem 
cells has been shown to play a role in stem cell engraftment and localisation to the endosteal surface 
(Papayannopoulou & Scadden 2008).  The signalling lymphocytic activation molecules (SLAM) family has 
been used to identify HSCs in situ in the bone marrow.  Stem cells were found at greatest abundance around 
marrow blood vessels leading to suggestions that this is the site of the stem cell niche (Kiel et al. 2005).  
However stem cells are known to enter and exit the circulation and so there is some debate about whether this 
just reflects cells moving from their niche to the circulation. 
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1.2  Development of the mammalian haematopoietic system 
 
After fertilisation the zygote undergoes a series of cell divisions with no significant growth 
known as cleavage.  This results in the formation of a ball of cells known as the morula.  
As the morula grows, a fluid filled cavity forms known as the blastocoel.  On one side of 
the blastocoel there is a layer of pluripotent cells known as the inner cell mass (see Figure 
1.5).  From these cells all of the tissues of the body are formed.  A cell migration process 
known as gastrulation now occurs within the inner cell mass that results in the formation of 
the three germ layers: ectoderm, endoderm and mesoderm.  It is the mesoderm that gives 
rise to blood cells.  The extra-embryonic mesoderm gives rise to the yolk sac blood islands 
and the lateral plate mesoderm gives rise to the aorta gonad mesonephros (AGM) blood 
cells. 
 
Fertilised
Egg
8 cell
stage Blastocyst Morula
 
Figure 1.5 Early stages of embryo development  
The fertilised egg undergoes a series of cleavage stages culminating in the formation of a ball of cells known 
as the morula.  A fluid filled cavity forms within the ball of cells known as the blastocoel cavity.  On one side 
of the blastocyst is the inner cell mass (shown in red) which after gastrulation gives rise to the endoderm, 
mesoderm and ectoderm.  It is from the mesoderm that blood formation occurs. 
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1.2.1  Murine embryonic haematopoiesis 
Yolk sac blood islands form by 7 days post coitum (dpc) and at 8.5 dpc they differentiate 
into endothelial and haematopoietic cells (Silver & Palis 1997).  Mainly nucleated 
erythroid cells and macrophages form at this stage and vascular connections between the 
embryo and yolk sac are established.  This initial wave of haematopoietic development that 
occurs in the yolk sac has become known as ‘primitive’ haematopoiesis.  This is to provide 
spatial, functional and temporal distinction from ‘definitive’ haematopoiesis that gives rise 
to long-term multilineage reconstitution of irradiated recipients.   
 
At 8.5dpc the first intra embryonic haematopoietic precursors appear in the para-aortic 
splanchnopleure (Godin, Dieterlen-Lievre, & Cumano 1995).  This region gives rise to the 
aorta gonad mesonephros (AGM) region where HSC generation reaches its peak at 10.5 
dpc with between 500 and 1000 cells being produced as clusters of cells associated with 
the vessel wall (Wood et al. 1997).  It is these AGM cells that give rise to the long-term 
multilineage reconstituting HSCs (Muller et al. 1994;Cumano et al. 2001).  Cumano and 
colleagues transplanted yolk sac or AGM cells into Ragγc deletion mutant mice which lack 
Natural Killer (NK) cells.  Since embryonic cells have low levels of MHC class I 
expression they are susceptible to destruction by NK cells.  The use of Ragγc deletion 
mutant mice prevents this from occurring.  Six to eight months post transplantation AGM 
cells alone were able to provide long term multilineage reconstitution whereas yolk sac 
cells showed only short term erythro-myeloid reconstitution. 
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At 12 dpc there is cessation of HSC generation in the AGM and haematopoiesis is 
sustained in the foetal liver (Godin & Cumano 2002).  AGM cells seed the foetal liver 
where there is expansion of the HSC pool (Kumaravelu et al. 2002).   These HSCs 
subsequently establish the adult blood system.  Evidence for this comes from experiments 
in which quail embryos were grafted onto the chick yolk sac before the emergence of 
blood cells and the onset of circulation.  These experiments showed that the adult 
haematopoietic system was seeded by cells from within the embryo (Dieterlen-Lievre 
1975).  Similar previous experiments using amphibian embryos support this conclusion 
(Turpen, Knudson, & Hoefen 1981).  
 
It likely however that the yolk sac and placenta contribute to the large numbers of HSCs 
found in the foetal liver (Gekas et al. 2005).  More recent experiments in the avian system 
in which unvascularised quail allantoic rudiment was grafted in a chicken host showed that 
up to 8% of the host bone marrow was colonised by quail haematopoietic cells (Caprioli et 
al. 1998).  This supports a role for the allantois in de novo generation of definitive 
haematopoietic stem cells.  Thus sites traditionally thought to be involved in primitive 
haematopoiesis have been shown to contribute to definitive haematopoiesis as well.  The 
anatomical sites of haematopoiesis in the embryo are summarised in Figure 1.6. 
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Figure 1.6  The sites of haematopoiesis in a mouse embryo  
AGM cells colonise the foetal liver.  However it is likely the yolk sac and allantois contributes to foetal liver 
colonisation as well (Dzierzak 2002). 
 
In  Xenopus laevis, experiments have provided evidence that the distinction between 
definitive and primitive haematopoiesis is based on environmental cues.  Blood is specified 
in three compartments: the anterior ventral blood islands (the equivalent of the yolk sac), 
the posterior blood islands and the dorsal lateral plate (the intra-body region).  They have 
been shown to encounter different amounts of bone morphogenetic protein 4 (Walmsley, 
Ciau-Uitz, & Patient 2002).  By grafting the ventral blood islands or dorsal lateral plate 
cells to the reciprocal site the prospective haematopoietic cells can be reprogrammed to the 
alternative adult or primitive haematopoietic fate (Turpen et al. 1997).   
 
1.2.2  Foetal liver haematopoiesis 
It is thought that foetal liver activity is a consequence of colonisation and no further HSCs 
are generated de novo (Delassus & Cumano 1996;Dzierzak, Medvinsky, & de Bruijn 
1998).  Evidence for this is supported by the finding that HSC numbers increase up to 14 
dpc but under normal conditions remains constant thereafter (Morrison et al. 1995;Sanchez 
et al. 1996).  The foetal liver is therefore likely to be an environment conducive to the Chapter 1 
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expansion of HSCs by symmetric self-renewing divisions (Lessard, Faubert, & Sauvageau 
1994;Takeuchi et al. 2002). 
 
1.2.3 Adult  haematopoiesis 
In the mouse HSCs colonise the spleen as early as 12 dpc (Godin et al. 1999) and finally 
the bone marrow at 15-16 dpc (Isabelle Godin & Ana Cumano 2002).  The adult system is 
generally static (Dzierzak 2002).  The absolute number of HSCs does not seem to vary 
although during tissue damage there is some capacity for HSCs to expand (Iscove & Nawa 
1997).   
 
1.3  Genetic Control of Haematopoiesis 
 
In the study of the genetic factors which underlie the processes of development already 
described, four genes have been identified as being critical. Murine gene deletion studies 
have shown that the expression of Scl,  Lmo2,  Runx1 and Gata2 are required for the 
development of the haematopoietic system and the absence of expression is lethal to the 
embryo (Figure 1.7).  Recent studies have focused on developing a greater understanding 
of the effects caused by the absence of these factors and how these proteins interact.   
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Gene   Deletion  Mutant 
Survival 
Phenotype of Deletion Mutant 
Scl  8.5-10.5 dpc  Bloodless – no yolk sac or liver 
haematopoiesis 
Lmo2  10.5 dpc  No yolk sac haematopoiesis 
Gata2  11.5 dpc  Almost bloodless   
Runx1  12.5 dpc  Foetal liver anaemia 
Figure 1.7 Gene deletion studies 
The deletion of these genes is lethal at early time points due to the absence of blood formation.  Analysis of 
the phenotype of the deletion mutants gives clues as to the role these genes play in haematopoiesis 
 
1.3.1 Scl 
The Scl (Stem Cell Leukaemia) gene is also known as Tal-1 as it is the most frequent target 
of chromosomal rearrangements in children with T cell acute lymphoblastic leukaemia 
(Begley & Green 1999).   
 
SCL is a transcription factor of the basic Helix-Loop-Helix family.  These proteins 
heterodimerize with E-proteins in order to bind E-box DNA motifs.  SCL can either 
activate or repress transcription depending on its integration within multifactorial 
complexes.   Scl expression follows a differentiation-dependent gradient.  It is expressed at 
high levels in HSCs and primitive progenitors and is down regulated as differentiation 
proceeds except in cells differentiating towards erythroid, megakaryocytic and mastocytic 
pathways (Lecuyer & Hoang 2004).   
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Scl deletion mutant mice do not survive beyond 8.5-10.5 dpc due to a complete absence of 
blood formation.  Scl is therefore one of the earliest acting regulators of haematopoiesis, 
essential for primitive and definitive haematopoiesis (Shivdasani, Mayer, & Orkin 
1995;Robb et al. 1995;Robb et al. 1996;Porcher et al. 1996). 
 
Analysis of the zebrafish Scl deletion mutant reveals that Scl is critical to the development 
of arteries where HSCs emerge (Patterson, Gering, & Patient 2005).  Ectopic expression of 
Scl in zebrafish embryos leads to the expansion of both haematopoietic and endothelial 
markers (Gering et al. 1998).   
 
In Xenopus embryo animal cap explants, ectopic expression of Scl ventralised embryos and 
induced haematopoiesis throughout (Mead et al. 2001).   
 
Using a conditional gene targeting approach, Orkin and co-workers have shown that Scl is 
critical to the formation of HSCs (Mikkola et al. 2003).  However when Scl was deleted in 
adult mice, anaemia and thrombocytopenia developed as erythropoiesis and 
megakaryopoiesis was completely disrupted.  Scl deleted HSCs exhibited stem cell activity 
on serial transplantation.  This suggests that once HSCs are formed Scl is dispensable for 
adult function.  However given the importance of the HSC pool to the life long production 
of blood cells, it seems likely that a network of genes would be involved in maintaining 
HSC function.  The network probably adjusts as an adaptive response to the total absence 
of Scl.  Proof that Scl does play a role in adult haematopoiesis is provided by experiments 
in which transgenic expression of Scl leads to expansion of the bone marrow Hoescht side Chapter 1 
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population which is known to be enriched for HSCs as previously described (Herblot, 
Aplan, & Hoang 2002).   
 
1.3.2  Lmo2 
Lmo2 (LIM domain only 2) was first discovered through its homology with Lmo1.  Both of 
these genes are involved in chromosomal translocations that cause T cell leukaemia (Look 
1997).  It has recently gained attention due to retroviral insertion of the IL2 receptor γc 
chain into the Lmo2 gene in patients being treated with gene therapy to correct X-linked 
severe combined immunodeficiency (Hacein-Bey-Abina et al. 2003;Howe et al. 2008). 
 
LMO proteins are comprised of zinc finger like domains that mediate protein interactions 
but lack any DNA binding capability.  LMO proteins are therefore thought to function as 
adapters allowing the proper assembly of larger protein complexes.   
 
Scl and Lmo2 show overlapping expression patterns in early haematopoietic sites and in 
adult haematopoietic lineages.  In Lmo2 deletion mutant mice there is a complete absence 
of haematopoietic cells leading to death at 9.5 dpc.  In addition there is abnormal blood 
vessel development where HSCs first emerge closely resembling the phenotype in Scl 
deletion mutant mice (Warren et al. 1994).   
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1.3.3 Gata2 
Gata2, a member of the Gata family of transcription factors is a zinc finger transcription 
factor.  These factors bind a common DNA sequence motif: T/A GATA A/G.   
 
Gene expression analysis shows that Gata2 is highly expressed in murine HSCs and adult 
haematopoietic progenitors.  Immunohistochemistry shows that Gata2 expression occurs 
in the murine AGM region as early as 8 dpc.  At 11.5 dpc Gata2 is expressed in the aortic 
endothelium and neighbouring mesenchymal cells where HSCs first emerge (Minegishi et 
al. 1999).  
 
Gata2 deletion mutant murine embryos have impaired primitive erythropoiesis and a 
complete lack of any other committed progenitors causing death from anaemia at 10.5 dpc 
(Tsai et al. 1994).  Gata2 haploinsufficiency profoundly decreases the number of AGM 
HSCs but yolk sac HSCs are only slightly affected.  Furthermore adult HSCs although 
normal in numbers were defective in competitive repopulation experiments.  HSCs 
exhibited a delay in regeneration of the haematopoietic system implicating Gata2 in HSC 
proliferation (Ling et al. 2004).   
 
Gata2 is involved in the SCL – Lmo2 complex as already described in 1.3.2. 
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1.3.4 SCL-Lmo2-Gata  complex 
The similarities in expression patterns and deletion mutant phenotypes of Scl and Lmo2 led 
to the hypothesis that SCL and Lmo2 worked together as a complex.  This was 
demonstrated in extracts from leukemic cells (Valge-Archer et al. 1994) and more recently 
in zebrafish (Patterson et al. 2007).  In fact, in addition to its association with SCL, Lmo2 
has been shown to interact with the Gata family of proteins (Osada et al. 1995).   
 
The SCL - Lmo2 - Gata2 complex is known to target the promoter of the tyrosine kinase 
receptor C-kit that is commonly used as a cell surface marker for HSCs.  SCL is known to 
support survival of haematopoietic progenitors and this is thought to be due to its role in 
activating C-kit (Lecuyer et al. 2002).  Unless all components of the transcription factor 
complex are present there is little if any effect on the C-kit promoter.   
 
In the context of erythroid differentiation, SCL - Lmo2 complexes with GATA1.  This 
complex has been shown to activate a key erythroid membrane glycoprotein glycophorin 
A. 
 
SCL DNA binding defective mutant protein was able to rescue haematopoietic 
specification in SCL deletion mutant mice but was unable to restore differentiation of the 
erythroid and megakaryocytic lineages (Kassouf et al. 2008).  SCL DNA binding activity 
was found to be dispensable for c-kit promoter activation but not for glycophorin A 
(Lecuyer et al. 2002).  This data indicates that SCL in early haematopoietic cells acts as a 
protein that recruits other factors into a complex which provides DNA binding activity. Chapter 1 
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The role of the SCL-Lmo2-Gata complexes in HSCs and erythroid cells is summarised in 
Figure 1.8. 
Gata2
Scl Lmo2
↑ C-kit
Haematopoietic stem cells
Gata1 Scl
Lmo2
↑ glycophorin A
Erythroid cells
 
Figure 1.8 The role of the SCL-Lmo2-Gata complex in HSCs and erythroid cells 
In HSCs the complex up regulates C-kit expression.  Scl DNA binding activity is dispensable for this to 
occur.  In erythroid cells this complex up regulates glycophorin A.  Scl DNA binding activity is required for 
this to occur. 
 
 
1.3.5 Runx1 
Runx1 is the mouse homolog of AML1.  This gene was initially identified in translocations 
in human leukaemia.  Translocations at the AML1 locus account for 30% of acute myeloid 
leukaemia and 25-30% of acute lymphoblastic leukaemia.  AML1 is a member of a family 
of proteins known as core binding factors which are heterodimeric transcription factors 
consisting of a DNA binding subunit (CBFα) and a non DNA binding subunit (CBFβ).    
The CBFα subunit consists of a transactivation domain required for DNA binding and a 
runt domain required for association with the CBFβ subunit.   Chapter 1 
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Complete ablation of Runx1 leads to embryonic lethality at 12.5 dpc and foetal liver 
anaemia in mice (Okuda et al. 1996;Sasaki et al. 1996;Wang et al. 1996a;Wang et al. 
1996b).  Primitive yolk sac erythropoiesis is normal but definitive erythroid, myeloid and 
megakaryocytic cells are absent indicating a complete block in the definitive 
haematopoietic program.  Thus no haematopoietic clusters are observed in the aorta or 
vitteline/umbilical arteries and no functional HSCs are found in the AGM at 10 or 11 dpc 
(Cai et al. 2000).  Runx1 is therefore thought to be important in the generation of adult 
HSCs and progenitors.   
 
Since Runx1 is embryonic-lethal it is not possible to determine the role of runx1 in vivo at 
later developmental stages using Runx1 knockout mice.  To overcome this, Runx1 +/βgal 
knock-in mice have been created by replacing one copy of Runx1 with a gene encoding β-
galactosidase.  Tissue sections could be stained by adding β galactosidase substrate 
enabling the visualisation of Runx1 expressing cells.  Runx1 expression was first seen at 
7.5 dpc in the mesoderm precursors of primitive erythrocytes and then transiently in 
primitive erythrocytes of the developing blood islands at 8 dpc in the yolk sac.  By day 8.5 
only a small population of endothelial and haematopoietic cells retained Runx1 expression 
in the yolk sac.    Runx1 expression in the dorsal aorta was seen at endothelial sites where 
haematopoietic cells emerge at 8.5 dpc prior to the emergence of haematopoietic clusters 
as shown in Figure 1.9 (North et al. 1999).   
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Figure 1.9 Runx1 expression in the ventrolateral wall of dorsal aorta in a Runx1+/βgal mouse.   
Runx1  is expressed in the cells lining the aorta (shown by arrows) at 8.5dpc prior to emergence of 
haematopoietic clusters in AGM region (North et al. 1999). 
 
The expression of Runx1 in emerging primitive erythrocytes is puzzling given that no 
defects are reported in primitive haematopoiesis in the Runx1 deletion mutant mice.  This 
may suggest Runx1 is expressed but not essential to primitive haematopoiesis.   
Alternatively a defect in primitive haematopoiesis in the Runx1 deletion mutant mice may 
not have been detected.  Support for this theory is provided by work using transgenic mice 
expressing CFBβ-MYH11.  In humans CFBβ-MYH11 results from a translocation which 
causes leukemia.  It is thought to function by sequestering Runx1 proteins in the cytoplasm 
(Adya et al. 1998).  The expression of this protein impaired both primitive and definitive 
haematopoiesis (Miller et al. 2001). 
 
In the amphibian system, Xaml-1 is the Xenopus homolog of Runx1.  Forced expression of 
the runt domain of Xaml-1 is thought to compete with Xaml-1 for DNA binding inhibiting 
its function.  In these Xenopus embryos there is a block in both primitive and definitive 
haematopoiesis (Ciau-Uitz, Walmsley, & Patient 2000;Walmsley, Ciau-Uitz, & Patient Chapter 1 
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2002).  This data again supports the idea that Runx1 plays a role in both primitive and 
definitive haematopoiesis. 
 
Most recently Runx1 deletion mutant mice have been reanalysed and primitive 
erythrocytes did in fact display abnormal morphology and reduced expression of markers 
Ter119, Erythroid Kruppel-like factor and Gata1 (Yokomizo et al. 2008). 
 
Inducible gene targeting experiments provide a further method of studying the effects of 
Runx1 in vivo at later developmental stages.  Ichikawa and colleagues used the Cre-loxP 
recombination system to generate mutant mice in which exon 5 on the Runx1 gene could 
be selectively deleted by the expression of Cre recombinase.  Adult mutant mice were 
injected with polyinosinic-polycytidylic acid in order to induce expression of Cre 
recombinase and delete Runx1 expression.  These experiments suggest that Runx1 was 
dispensable for adult HSC function  (Ichikawa et al. 2004).  In the absence of Runx1 
(AML-1), haematopoietic progenitors were maintained. However, the bone marrow 
showed inhibition of megakaryocytic maturation, increased haematopoietic progenitor 
cells and defective T- and B-lymphocyte development. They therefore concluded Runx1 is 
required for maturation of megakaryocytes and differentiation of T and B cells, but not for 
maintenance of HSCs in adult haematopoiesis. 
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1.3.6 Integrated  genetic  control 
The downstream genetics effects of Scl have been studied by introducing SCL protein into 
a Scl null murine yolk sac cell line and then performing global gene expression profiling.  
The results have shown that Runx1 is a target of SCL.  Furthermore there was evidence to 
suggest that binding of an SCL-Lmo2-Gata2 complex transactivated Runx1 expression 
(Landry et al. 2008).  This data suggests Runx1 up regulation is downstream of these 
transcription factors in HSC development. 
 
Studies in the sea urchin of transcription factor expression and the cis regulatory sequences 
that they bind, has led to the idea that there are gene regulatory networks.  The hypothesis 
is that each gene network has a distinct regulatory function in development.  The 
disruption of a transcription factor component leads to total loss of the particular body part 
that the network is involved in developing (Davidson & Erwin 2006).  The genes Gata2, 
Fli1 and Scl and their enhancers Gata2-3, Fli1+12 and Scl+19 are hypothesised to act as 
such a network in the specification of haematopoiesis in the mouse embryo.  The three 
enhancers were found to be bound by each of these transcription factors forming a fully 
connected triad as shown in Figure 1.10 (Pimanda et al. 2007b).   
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Figure 1.10 The Gata2, Fli1, Scl gene regulatory circuit 
This triad of genes is proposed to form a gene regulatory circuit.  The arrows indicate the ability of each gene 
to increase the expression of all the components of the circuit.  This triad is hypothesised to be locked in an 
‘ON’ state in a newly specified HSC so that it retains its multipotency in transition from its site of generation 
to the foetal liver.  Gata1 was shown to disrupt Gata2 positive autoregulation (adapted from Pimanda et al. 
2007). 
 
Scl,  Lmo2,  Runx1  and  Gata2 are therefore closely related both in the functions they 
perform and in the control of their expression.   
 
1.4  Environmental control of haematopoiesis 
 
Considerable attention has been given to the environment that supports the development of 
the haematopoietic stem cell.  In particular there is great interest in the environmental 
stimuli that cause the expression of the genes Scl,  Lmo2,  Gata2 and Runx1.  Several 
different growth factors and intracellular pathways have been implicated in HSC 
specification.  However a number of studies suggest that bone morphogenetic protein 4 
(BMP4) plays an important role in early haematopoietic development.  There is also some 
evidence of a role for BMP4 in adult haematopoiesis.  Its precise function has yet to be 
fully understood.   
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1.4.1  Bone morphogenetic protein 4 
BMP4 is a member of the transforming growth factor superfamily of growth factors.  The 
potential role of BMP4 in haematopoietic development has been studied in a number of 
different species. 
 
1.4.1.1  The BMP4 signalling pathway 
BMP signals are transduced across the cell membrane via serine threonine protein kinase 
receptors (Figure 1.11).  Type I receptors also known as activin receptor like kinases 
(ALKs) have an inactive kinase domain whilst type II receptors are constitutively active.  
When the ligand binds the type II receptor, a type I receptor is recruited and 
phosphorylation of the type I receptor by the type II kinase occurs resulting in activation of 
the type I receptor kinase domain (Wrana et al. 1994).  There are several ALKs and 
different combinations of receptor allow the binding of different ligands to be 
distinguished (Massague 1996).  In the case of BMP4, signals are transduced by ALK3 or 
ALK6 combining with Type II receptor (Shi & Massague 2003). 
 
The type I kinase phosphorylates Smad intracellular signalling proteins.  There are three 
different groups of Smads: receptor activated Smads, the common partner Smad (Smad4) 
and the inhibitory Smads.  Receptor Smads are phosphorylated by activated type I 
receptors after which they oligomerise with Smad4 and translocate to the nucleus where 
they interact with other transcription factors to regulate gene expression.  The receptor 
activated Smads for BMP signal transduction are Smads 1, 5 and 8 (Shi & Massague 
2003). Chapter 1 
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The inhibitory Smads act by inhibiting the phosphorylation of receptor Smads, degrading 
activated type I receptors or by dephosphorylating activated type I receptor.  Inhibitory 
Smads may also compete with other receptor Smads for binding the common partner 
Smad, Smad4.  Inhibitory Smads include Smad7 which inhibits the activity of all receptor 
activated Smads and Smad6 which shows a more preferential inhibition of BMP Smads 
(Larsson & Karlsson 2005;Shi & Massague 2003). 
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Figure 1.11 BMP4 signalling   
BMPs activate heteromeric cell surface receptors consisting of type I (ALK) and type II serine threonine 
protein kinase subunits.  Phosphorylation of the type I receptor by the constitutively active type II kinase 
results in activation of the type I receptor kinase domain.  The type I kinase phosphorylates Smad 
intracellular signalling proteins.  These phosphorylated receptor regulated Smads interact with co-Smad 4 
resulting in translocation of the heteromeric complex to the nucleus where, by interaction with transcription 
factors, gene expression changes.  Smad 6 is an inhibitory Smad.  Inhibitory Smads are thought to act by 
inhibiting type I receptor mediated phosphorylation of Smads and also competing in binding co-Smad 4 
(Nakao et al. 1997;Hata et al. 1998).  ALK: Activin like kinase, TII: Type II, K:kinase, P:phosphate group, 
TF:Transcription factors  
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1.4.1.2  Xenopus experiments 
Some of the earliest development experiments were carried out in the Xenopus frog.   
Xenopus produce large oocytes and therefore are well suited to manipulation and analysis 
during development. 
 
Mesoderm specification occurs in the ventral region of the blastula.  Mesoderm is induced 
by the secretion of BMP4.  The ‘Spemanns organiser’ located in the dorsal region secretes 
molecules such as noggin and chordin which inhibits the action of BMP4 that result in the 
induction of dorsal fates (Figure 1.12A).  Blood formation occurs in the ventral mesoderm 
and therefore requires high levels of BMP4 (Sadlon, Lewis, & D'Andrea 2004).     
 
Thus Xenopus experiments have shown that BMP4 induces haematopoietic differentiation 
in  Xenopus embryos (Kumano, Belluzzi, & Smith 1999).  Furthermore, primitive and 
definitive haematopoiesis in Xenopus is inhibited by expression of a dominant negative 
BMP type I receptor in the ventral blood islands (Walmsley, Ciau-Uitz, & Patient 2002).  
BMP4 together with basic fibroblast growth factor and activin A can induce the formation 
of red blood cells from non-mesodermal structures (Huber et al. 1998). 
 
In Xenopus BMP signalling induces a number of genes including the Vent (ventralizing) 
family members Xvent1 and 2.  These genes induce ventral cell fate in addition to 
suppressing dorsal genes.  BMP signalling also induces the haematopoietic specific genes 
such as Gata1, Gata2, Scl, Lmo2 and Xfli1 (Sadlon, Lewis, & D'Andrea 2004).   
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In Xenopus, BMP4 is proposed to lead to the formation of the complex of SCL-Lmo2-
Gata1 complex which drives blood formation in developing blood islands (Mead et al. 
2001).  BMP4 may also drive the expression of the Xenopus Runx1 orthologue, Xaml 
(Tracey & Speck 2000).  Xaml expression is lost when BMP4 signalling is inhibited in 
Xenopus embryos (Walmsley, Ciau-Uitz, & Patient 2002).  The effects of BMP4 on 
haematopoietic genes are summarised in Figure 1.12B.   
BMP4
Xaml
Gata2, Xfli1, Elf1
Scl Gata1, Lmo2
Ventral
fates
(blood)
Dorsal
(nervous 
system)
SO
A B
 
Figure 1.12 The role of BMP4 in Xenopus mesoderm patterning 
A shows that secretion of BMP4 in the ventral region of the blastula induces ventral mesoderm fates whilst 
the Spemann’s organiser (SO) in the dorsal region secretes inhibitors such as Noggin and Chordin which 
induces dorsal fates.  B shows the haematopoietic genes shown to be induced by BMP4 in Xenopus 
experiments .  The arrows indicate up regulation of gene expression. 
 
 
1.4.1.3  Mouse experiments 
Mice lacking BMP4 die in utero at the gastrulation stage.  The few embryos that do 
develop show severe defects including disorganised and truncated structures (Winnier et Chapter 1 
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al. 1995).  The rescue of some embryos is possibly due to the presence of related BMP 
ligands.  Ablation of the BMP type I receptor (ALK3) or the type II receptor results in a 
more severe phenotype with no mesoderm formed (Beppu et al. 2000).  Because death in 
these mutants occurs before blood formation, it is not possible to decipher the function of 
BMP4 in mammalian haematopoiesis in vivo.  Research into the role of BMP4 in 
haematopoiesis has therefore mainly focused on lower vertebrates and in vitro studies. 
 
In the AGM region of the mouse, BMP4 is highly expressed in the mesenchyme 
underlying the haematopoietic clusters that emerge from the ventral wall of the dorsal aorta 
during embryogenesis.  BMP4 also increases the number of HSCs in AGM explants 
(Durand et al. 2007).  This suggests that BMP4 is involved in HSC specification.   
 
The co-expression of BMP4 and Runx1 in the AGM has recently been demonstrated at 
10.5 dpc.  Furthermore Smad1 was shown to bind the Runx1 promoter in a haematopoietic 
progenitor cell line transactivating Runx1 expression.  After 12 dpc Runx1 expression is 
rapidly down regulated in the AGM whereas Smad6 continues to be expressed down 
regulating Runx1 expression (Pimanda et al. 2007a).   
 
1.4.1.4  Human experiments 
BMPs are highly conserved and human homologues have been identified (Maeno et al. 
1996).  BMP4 is expressed by cells surrounding blood islands in the human yolk sac and is 
strikingly restricted to the two of three layers of stromal cells beneath the ventral floor of 
the dorsal aorta in 28 day old human embryos when intra-aortic haematopoietic clusters are Chapter 1 
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forming (Marshall, Kinnon, & Thrasher 2000).  By day 34 a gradient of BMP4 expression 
has been established across the dorsal-ventral axis of the AGM region with expression 
polarised to the ventral wall of the dorsal aorta (Figure 1.13).  This gradient of BMP4 
expression disappears at the same time as the haematopoietic clusters at around 38 days 
gestation.  
 
 
Figure 1.13 BMP4 staining in the AGM region of the human embryo 
Transverse section through a 34 day human embryo (A) BMP4 is expressed in a gradient across the dorsal 
(D) – ventral (V) axis. (B) Higher magnification of (A).   BMP4 is expressed at high levels underlying the 
ventral floor of the dorsal aorta in the AGM.  Haematopoietic clusters can be seen within the dorsal aorta 
(Marshall, Kinnon, & Thrasher 2000) hc: haematopoietic clusters, s: stromal region underlying the clusters, 
da: dorsal aorta, m: mesonephros, cv: cardinal veins, nt: neural tube,  
 
 
 
1.4.2  In vitro experiments – the role of BMP4 in adult 
haematopoiesis 
Serum free expansion cultures suggest that high levels of BMP4 can enhance human  bone 
marrow derived haematopoietic stem cell survival and increase engraftment in NOD SCID 
mice (Bhatia et al. 1999).  Treatment of cord blood cells with high doses of BMP4 
(25ng/ml) increased the length of time an HSC could be maintained in serum-free culture.  
BMP4 effects are highly dependent on concentration.  A lower dose of BMP4 resulted in Chapter 1 
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complete differentiation of the CD34+ CD38- lineage- HSC population (Bhatia et al. 
1999). 
 
The observed stimulatory effects of other factors such as sonic hedgehog, which induce 
HSC proliferation, are mediated through modulation of BMP4 signalling pathways.   
Noggin, an inhibitor of BMP4, inhibited sonic hedgehog induced proliferation of primitive 
human progenitors (Bhardwaj et al. 2001).   
  
Varying effects of BMP4 on the differentiation of CD34+ cells have been reported in vitro.  
In one study, BMP4 increased the frequency of erythroid burst forming units (BFU-E) in 
cord blood-derived CD34+ cells cultured in serum free conditions (Fuchs et al. 2002).  
However in a separate study using bone marrow-derived CD34+ cells, BMP4 had no effect 
on BFU-E formation (Maguer-Satta et al. 2003).  The role of BMP4 in adult 
haematopoiesis has therefore yet to be fully defined. 
 
1.5  Embryonic stem cells as a model for mammalian 
haematopoietic development 
 
1.5.1  Embryonic stem cells 
Teratomas are composed of a variety of tissues derived from all three germ layers.  Skin, 
muscle, fat, gut epithelium, tooth structures, indeed any tissue of the body may be found.  
It was noted that the cells present represented those produced in embryonic development Chapter 1 
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except that they were present in a disorganised manner (DIXON & MOORE 1952).  It was 
in the highly malignant form of teratoma that occurs in the testis known as teratocarcinoma 
that an undifferentiated cell type with a pluripotent phenotype was first identified.  These 
cells became known as Embryonic Carcinoma (EC) cells (Kleinsmith & Pierce, Jr. 1964).  
During the 1970s it was found that murine EC cells had features similar to the inner cell 
mass of the early mouse embryo (Artzt et al. 1973;Jacob 1978).  This culminated in 1981 
with the isolation of the non-malignant version of these stem cells, the Embryonic Stem 
(ES) cell.  These pluripotent stem cells were first isolated from early mouse embryos 
(Evans & Kaufman 1981;Martin 1981) and eventually from human embryos (Thomson et 
al. 1998).   
 
Murine ES cells are isolated from the inner cell mass of blastocysts at day 3.5 of mouse 
development.  When mouse blastocysts are cultured on a feeder layer of mitotically 
inactivated embryonic fibroblasts the outer layer of cells attach and the undifferentiated 
inner cell mass cells form clumps that can be passaged to yield ES cells (Evans & 
Kaufman 1981).  These cells can be injected back into blastocysts and will contribute to 
the formation of all tissues (Bradley et al. 1984).  Maintenance of ES cells in vitro is 
achieved by co-culture with irradiated fibroblasts (Martin 1981).  Upon withdrawal of 
stromal contact the mouse ES cells differentiate into complex three dimensional cell 
aggregates called Embryoid bodies (EBs). 
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1.5.1.1 The molecular basis of pluripotency 
Pluripotency of ES cells has been found to be dependent upon extrinsic growth factor 
signals and intrinsic transcription factor expression (Chambers 2004). 
 
1.5.1.1.1  Growth factors 
Although ES cells are typically maintained on mitotically inactive fibroblasts this co-
culture is unnecessary if Leukemia Inhibitory factor (LIF) is added to the medium 
(Williams et al. 1988).  LIF has been shown to activate transcription of STAT3.  In the 
absence of LIF signalling ES cells differentiate to endoderm and mesoderm (Niwa et al. 
1998). 
 
The requirement for serum in the de novo isolation and expansion of ES cells has been 
shown to be replaceable by BMP4 (Ying et al. 2003).    BMP4 appears to blocks neural 
differentiation.  This occurs via the induction of Id genes.  BMP4 is no longer required 
when cells express Id1 transgene.  Excision of a loxP flanked Id1 transgene restores BMP4 
dependence (Ying et al. 2003). 
 
1.5.1.1.2   Transcription Factors 
Several transcription factors have been implicated in pluripotency however the best 
characterised is Oct4.  When Oct4 was deleted in vivo although cells moved to the interior 
of the blastocyst they failed to adopt a pluripotent identity and instead differentiated to Chapter 1 
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trophectoderm (Nichols et al. 1998).  Similarly when Oct4 was deleted in ES cells, the 
cells differentiated to trophectoderm (Niwa, Miyazaki, & Smith 2000).    
 
Oct4 acts on DNA in conjunction with Sox2 (Pevny & Lovell-Badge 1997).  Sox2 
knockout ES cells differentiate to trophectoderm and do not have a pluripotent phenotype 
(Li et al. 2007).   
 
Nanog a homeodomain protein maintains self renewal in the absence of STAT3 activation.  
ES cell self renewal however occurs with greatest efficiency with the expression of both 
STAT3 and Nanog.  Nanog does not appear to be downstream of STAT3 or Oct4 or vice 
versa.  Gene deletion of Nanog results in cell differentiation to primitive endoderm 
(Chambers et al. 2003).   
 
The growth factors and transcription factors involved in maintaining the pluripotent state 
have been summarized in Figure 1.14. Chapter 1 
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Figure 1.14 The molecular basis of pluripotency 
Extrinsic growth factors and intrinsic transcription factors responsible for pluripotency in ES cells.  While 
Oct4 and Sox2 require the presence of LIF to maintain self renewal and pluripotency Nanog does not.   
 
1.5.2  The potential use of ES cells in clinical therapy 
In the clinical setting suitable donor bone marrow is often in short supply and cord blood 
contains a much lower absolute number of haematopoietic stem cells.  Furthermore at 
present it is not possible to reliably expand ex vivo LT-HSCs.  ES cells can be indefinitely 
expanded in vitro.  This unlimited expansion allows the generation of large numbers of 
HSCs (Kyba & Daley 2003).   
 
It has been demonstrated by Shinya Yamanaka and colleagues that mouse fibroblasts can 
be induced to a pluripotent phenotype via the retroviral mediated expression of Oct4, Sox2, 
Myc and Klf1.  These cells are then known as induced pluripotent stem cells (Takahashi & 
Yamanaka 2006).  The same has been demonstrated using human fibroblasts and other 
adult somatic tissues (Takahashi et al. 2007;Yu et al. 2007;Lowry et al. 2008).  This is an Chapter 1 
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exciting discovery as this provides a means of generating pluripotent stem cells without the 
difficulties of nuclear transfer or the controversy of destroying embryos.  Once there is an 
understanding of how to differentiate particular tissues, it seems a real possibility that 
patient specific tissue lines could be generated.  This would circumvent the need for anti-
rejection drugs following transplant. 
 
1.5.3  ES cells as a model for haematopoietic development 
In addition to these potential clinical applications ES cells provide a system in which 
haematopoietic development can be studied.  Mammalian haematopoiesis commences at 
an early stage in development and the small size of embryos in addition to the limited 
number of haematopoietic cells at this stage make it difficult to study in vivo.  The main 
advantage in using ES cells therefore is accessibility of the cellular material.   
 
ES cells can be differentiated to form embryoid bodies (EBs), containing multiple cell 
types, by withdrawal of Leukaemia Inhibitory Factor (LIF) from the culture medium.   
Embryoid bodies develop blood islands in vitro (Doetschman et al. 1985).   
 
Haematopoietic cells develop within the first six days of EB culture.  By disrupting EBs at 
earlier time points, it is possible to investigate the development of haematopoietic 
precursors.   
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1.5.3.1 Primitive or definitive haematopoiesis? 
The capacity of EBs to generate primitive erythrocyte colony forming cells, as well as the 
time course of ‘blood island’ formation, suggests that EB haematopoiesis recapitulates 
primitive haematopoiesis.   
 
The many failed attempts to generate long-term adult haematopoietic repopulation using 
EB derived cells are thought to support this conclusion (Kyba & Daley 2003). However a 
few attempts have achieved repopulation successfully(Muller & Dzierzak 1993;Potocnik, 
Kohler, & Eichmann 1997).  This may result from EBs that occasionally generate 
populations resembling AGM splanchnopleural mesoderm.  The AGM arises as part of a 
highly organised process and its development in the relatively disorganised EB could only 
ever be haphazard and incomplete (Kyba & Daley 2003). 
 
As an alternative to EB differentiation, ES cells can also be differentiated on stromal cell 
lines for efficient haematopoietic differentiation.  Most stromal cell lines result in abundant 
macrophage growth.  The OP9 stromal cell line is derived from a macrophage colony 
stimulating factor deficient (op/op) mouse.  ES cells grown on an OP9 layer differentiate 
first to mesoderm colonies and then when replated on a fresh OP9 layer to haematopoietic 
blast colonies.  These colonies contain erythroid, myeloid and lymphoid lineages (Nakano, 
Kodama, & Honjo 1994).  This presence of lymphoid cells implies that definitive 
haematopoiesis is taking place.  However ES cells cultured on OP9 cells are unable to 
engraft conditioned adult mice (Kyba, Perlingeiro, & Daley 2002). 
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The generation of lymphoid cells and the ability to produce long term adult repopulation 
are the two characteristics that separate definitive haematopoiesis from primitive 
haematopoiesis.  A model therefore proposing the independent origin of primitive and 
definitive haematopoietic stem cells therefore seems inadequate.  Instead it may well be 
the case that EB cells and yolk sac cells if given the appropriate environmental stimuli 
could take on a definitive stem cell phenotype.   
 
Multilineage long-term repopulation by transplantation of day 9 and day 10 yolk sac tissue 
into the conditioned livers of new born mice has been achieved (Yoder, Hiatt, & 
Mukherjee 1997).  Furthermore yolk sac cells presumably reprogrammed by several days 
exposure to an AGM-derived stromal line were able to produce long-term multilineage 
reconstitution (Matsuoka et al. 2001).  This provides considerable support to the notion 
that in the right environment yolk sac cells can develop to give rise to definitive 
haematopoietic cells. 
 
The inability of EB derived blood cells to achieve engraftment in adult recipients could 
either be the result of limited developmental potential or inability to survive in the adult 
environment.  In order to study this ES cells were transduced with the oncogene 
responsible for Chronic Myeloid leukaemia, Bcr/Abl.  This oncogene drives HSC 
proliferation blocking apoptosis whilst still allowing differentiation.  These cells were able 
to engraft sub-lethally irradiated adult recipients causing a leukaemia with erythroid, 
myeloid and lymphoid components (Perlingeiro, Kyba, & Daley 2001).  This suggests that Chapter 1 
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in fact ES derived HSCs do have definitive haematopoietic potential but it is cell survival 
in the adult environment that normally prevents this. 
 
The screening of proteins involved in Bcr/Abl signalling pathways led to the identification 
of HoxB4 as a potential mediator of normal engraftment in the adult environment 
(Helgason et al. 1996).  In order to investigate this further ES cells were created with 
tetracycline dependent HoxB4 expression and adult repopulation of myeloablated 
recipients was attempted.  HoxB4 expressing cells engrafted generating both lymphoid and 
myeloid populations.  The cells from primary animals could be transplanted into secondary 
animals suggesting the self renewal of a long term reconstituting haematopoietic stem cell.  
Furthermore continued expression of HoxB4 expression was not required post-transplant 
for graft maintenance (Kyba, Perlingeiro, & Daley 2002).   
 
This data suggests HoxB4 endows embryonic haematopoietic cells with adult 
haematopoietic characteristics.  This provides further support for the idea that the primitive 
HSC can mature into a definitive HSC in response to the appropriate signal.   
 
1.5.3.2 Haemangioblast 
One of the main achievements of the ES system has been identification of the 
haemangioblast, a common precursor for both haematopoietic and endothelial lineages. 
 
In murine embryos, histological analysis of developing blood islands in the yolk sac 
showed that haematopoietic and endothelial lineages developed in parallel from common Chapter 1 
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clusters of undifferentiated cells (Haar & Ackerman 1971).  In avian embryos fate 
mapping experiments have shown that ventral mesoderm possesses both endothelial and 
haematopoietic potential (Pardanaud et al. 1996;Pardanaud & Dieterlen-Lievre 1999).   
Therefore the fact that endothelial and haematopoietic cells appear at similar time points 
and in close juxtaposition has resulted in the proposal that there may be a common 
mesodermal precursor for both the endothelial and haematopoietic lineages (Sabin 
1920;Murray 1932). 
 
The most direct evidence for the existence of the haemangioblast has come from studies 
using EB cultures.  When grown in methylcellulose culture in the presence of vascular-
endothelial derived growth factor (VEGF) these precursors emerge as blast colonies.  The 
blast-colony forming cells (BL-CFCs) appear transiently, between day 2.5 and day 3.5 of 
differentiation.  By replating BL-CFCs into other conditions it has been shown that these 
cells can differentiate into primitive and definitive erythroid and myeloid haematopoietic 
precursors as well as endothelial cells (Kennedy et al. 1997;Choi et al. 1998).  BL-CFCs 
are foetal liver kinase1 (Flk-1) positive (Faloon et al. 2000). 
 
Gene targeting experiments have provided further evidence for the existence of a common 
haemangiogenic precursor.  Flk-1 is a tyrosine kinase receptor that is activated by vascular 
endothelial derived growth factor (VEGF).  Ablation of Flk-1 (Shalaby et al. 1995;Shalaby 
et al. 1997) and Vegf in mouse embryos result in an embryonic lethal phenotype and, most 
importantly, blocks both vascular and haematopoietic development (Carmeliet et al. 
1996;Ferrara et al. 1996).  Chapter 1 
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One day before the emergence of the Flk-1 positive haemangioblast, a more primitive cell 
type gives rise to transitional colonies.  These transitional colonies express the mesodermal 
marker Brachyury.  Transitional colonies give rise to BL-CFC (Robertson et al. 2000).  
This result has been reinforced by work in which a green fluorescent protein was targeted 
to the brachyury locus.  GFP expression is seen to occur first and then later only in the 
GFP and Flk-1 positive population are BL-CFCs detected (Fehling et al. 2003).   
 
Despite all of this work the haemangioblast has proved relatively difficult to find in vivo.  
However experiments in murine embryos in which Brachyury is coexpressed with GFP 
have demonstrated blast colony forming cells expressing Flk-1 can be found in the 
posterior region of the primitive streak prior to yolk sac blood island formation (Huber et 
al. 2004).  These haemangioblasts are hypothesised to migrate to the yolk sac at which 
point they become committed haematopoietic and endothelial progenitors contributing to 
the formation of the blood island (Dzierzak & Speck 2008).   
 
1.5.3.3 Subsequent Differentiation of Haemangioblasts 
Scl null EBs are completely devoid of haematopoietic cells and give rise to BL-CFCs with 
endothelial but not haematopoietic potential (Robertson et al. 2000).  Although this 
suggests Scl expression is necessary for haematopoietic cell formation, this contradicts 
evidence from studies in zebrafish which shows that Scl expression is upstream of the 
haemangioblast.  In this study forced expression of Scl in Xenopus embryos resulted in 
expansion of haematopoietic and endothelial lineages (Gering et al. 1998).   Chapter 1 
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In order to shed light on the relationship between Flk1, SCL and the formation of the 
haemangioblast a transgenic mouse in which one copy of the Scl gene has been replaced 
with a copy of the gene for the cell surface molecule CD4 has been generated (Chung et al. 
2002).  This has the advantage of allowing Scl expressing cells to be isolated via cell 
sorting for CD4 expression.  BL-CFCs were highly enriched in this Flk1/Scl double-
positive population.  Later maintenance of Flk1 expression was associated with endothelial 
differentiation whereas the maintenance of Scl expression was associated with 
haematopoietic differentiation.   
 
Another group has generated an ES cell line with a CRE inducible allele of Scl on a null 
background and studied the time dependence of the requirement for Scl.  While no 
haematopoietic cells were detected in Scl null ES cells, only Scl gene reactivation between 
days 2 to day 4 could rescue haematopoiesis.  Scl reactivation at later stages was 
ineffective.  Flk-1 positive cells were generated but in the absence of Scl expression they 
were unable to differentiate to haematopoietic cells (Endoh et al. 2002). 
 
Taken together these results suggest that sustained high levels of Scl expression promote 
haematopoietic differentiation of Flk1 positive mesoderm at the expense of the endothelial 
program.  The findings by Gering et al. (1998) however suggest that Scl can function in 
promoting haemangioblast differentiation although it is not a critical factor at this stage.  
This work has been summarised in Figure 1.15. Chapter 1 
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Figure 1.15 ES cell model of haematopoietic development 
The undifferentiated ES cell differentiates to mesoderm.  The brachyury positive mesodermal population are 
haemangioblast precursors.  The haemangioblast is detected in vitro as a BL-CFC.  These cells express Flk-1.  
Maintenance of Flk-1 expression is associated with endothelial differentiation.  Scl expression is associated 
with haematopoietic differentiation.   
 
1.5.4  The role of BMP4 in the haematopoietic development of ES cells 
Johansson and Wiles were the first to demonstrate a role for BMP4 in haematopoietic 
differentiation of ES cells.  In serum free chemically defined medium BMP4 induced 
haematopoietic differentiation in a concentration dependent manner (Johansson & Wiles 
1995).   
 
More recently BMP4 was shown to be required for Flk-1 and Scl expression.  However 
VEGF in combination with BMP4 was necessary for optimal expansion and differentiation 
of Scl expressing haematopoietic progenitors.  The effects of BMP4 were mediated by 
Smad1 and inhibited by Smad6 signalling molecules whilst the effects of VEGF were 
mediated by the mitogen activated protein kinase pathway (Park et al. 2004).   Chapter 1 
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These results are in broad agreement with a more recent paper that has postulated the need 
for sequential exposure to growth factors: BMP4, activin A, basic Fibroblast growth factor 
and VEGF in order to achieve optimal haematopoietic differentiation.  In this paper ES 
cells were differentiated as EBs initially with BMP4 which induced Brachyury expression.  
However BMP4 was needed in combination with Activin A and basic fibroblast growth 
factor at day 2.5 to achieve a maximal percentage of Brachyury and Flk-1 expressing cells, 
representing the haemangioblast.  Runx1, Hhex, Scl, Fli1 and Lmo2 expression increased 
within the first six hours after addition of activin A and basic fibroblast growth factor.  The 
addition of VEGF at day 2.5 was required to achieve maximal haematopoietic commitment 
measured by CD41 expression and numbers of haematopoietic colonies.  VEGF 
maintained the expression of Scl, Fli1, and Lmo2 but Runx1 was not significantly affected.  
No effect was seen on Gata2 with BMP4 and either VEGF or basic fibroblast growth 
factor and activin A added at day 2.5 (Pearson et al. 2008).   
 
Lugus et al. (2007) however have provided evidence that BMP4 up regulates expression of 
Gata2.  By generating an ES cell line with inducible Gata2 expression they also showed 
that Gata2 expression caused an increase in Flk-1 positive mesoderm even when the effect 
of BMP4 was blocked by the presence of the BMP4 antagonist noggin.  This paper further 
proposes that Gata2 induced Flk-1 Scl double positive cells independent of VEGF.  This 
correlated to an increase in BL-CFCs which was maximal when Gata2 expression was 
induced at day 2.75.  Haematopoietic colony assays showed an increase in primitive Chapter 1 
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erythroid precursors (Lugus et al. 2007).  This data contrasts with the results of Pearson et 
al. 2008.   
 
BMP signals are transduced by the Smad family of transcriptional cofactors.  Smad1 
knockout mice in a similar way to Bmp4 knockout mice die too early to enable study of its 
role in the development of the haematopoietic system.  An inducible Smad1 ES cell line 
has therefore been generated.  A pulse of Smad1 expression between day 2 and 2.25 
resulted in an increase in primitive erythrocyte and other haematopoietic colonies.  Further 
analysis showed that Smad1 caused an up regulation of Gata2, Runx1 and Scl transcripts 
but not Brachyury or Flk-1.  This correlated with an increase in BL-CFC formation.  A 
pulse of Smad1 expression therefore appears to result in an increase in haemangioblast 
formation.  The authors of this paper stated that this alone accounted for the increase in the 
numbers of haematopoietic colonies seen (Zafonte et al. 2007).   
 
Given that BMP4 is likely to signal via Smad1 it is unexpected that Brachyury and Flk-1 
are not up regulated when Smad1 expression is induced.   
 
1.5.5  Human ES cell differentiation to haematopoietic cells 
In recent years most work has focused on the differentiation of human ES cells to 
haematopoietic lineages.  If cell replacement therapy is to become a reality it is important 
that the developmental pathways involved in human haematopoietic differentiation are 
understood.   
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Independent of other cytokines BMP4 appears to support haematopoietic differentiation 
consistently in several human ES cell lines (Chadwick et al. 2003).   
 
1.5.5.1 The human haemangioblast 
Recent work has characterised a transient population that appears in BMP4 stimulated EBs 
between 72 and 96 hours of differentiation that expresses KDR, the human homolog of 
Flk1.  These cells form blast colonies with haematopoietic and vascular potential.  These 
cells appear prior to the appearance of primitive erythroid cells (Kennedy et al. 2007).  
This population seems to correspond well to the haemangioblast population that appears in 
the mouse.     
 
1.5.5.2 The repopulating potential of human ES cell derived 
haematopoietic cells 
The in vivo repopulating potential of CD34+ve, CD45+ve cells derived from human ES 
cells has been assessed in NOD-SCID mice. 
 Direct femoral injection allowed recipient 
survival and resulted
  in multilineage hematopoietic repopulation for up to 10 weeks.   
However analysis of the SCID repopulating cells revealed limited
  proliferative and 
migratory capacity.  Ectopic expression of HoxB4 had no effect on repopulating
 capacity 
(Wang et al. 2005).   
This and other efforts made to replicate the strategy of ectopically expressing HoxB4 to 
improve in vivo engraftment have failed.  The genetic modification of human ES cells 
remains less advanced and less stable transgene expression could explain the lack of Chapter 1 
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benefit of HoxB4 over expression (Papapetrou, Zoumbos, & Athanassiadou 2005).   
However this result could also reflect that the role of HoxB4 may vary in different species 
(Tian & Kaufman 2008). 
 
The most successful repopulation to date using human ES cells has been achieved by 
differentiating cells in co-culture with the stromal cell line AM20.1B4 derived from the 
AGM region of 10dpc murine embryos.  The whole cell mixture was transplanted after 12 
days into NOD SCID mice achieving 2-16% engraftment efficiency (Ledran et al. 2008).   
This strategy has mimicked experiments that have shown mouse ES cells have definitive 
potential.  Clearly by exposing ES cells during differentiation to an environment that 
promotes definitive haematopoiesis there is an increase in repopulating potential. 
 
1.6 Summary 
 
In order to expand HSCs ex-vivo, knowledge of the conditions in the bone marrow that 
allow their survival and expansion is necessary.  The concept of the bone marrow niche is 
central to the future construction of a suitable environment where HSCs might be 
expanded for use in bone marrow transplant.  Likewise if ES cells are to be differentiated 
to form HSCs it is necessary to understand the dynamic processes which lead to HSC 
formation.   
There is strong evidence to support a central role for BMP4 in haematopoietic 
development.  Perhaps the most persuasive evidence of this comes from 
immunohistochemistry staining that has shown that BMP4 is transiently expressed at high Chapter 1 
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levels in the human AGM region (Marshall, Kinnon, & Thrasher 2000).  Experiments in 
the mouse also have shown that BMP4 becomes highly expressed just before Runx1 
expressing haematopoietic clusters appear in the AGM  (North et al. 1999;Durand et al. 
2007).  However the role BMP4 plays at this stage in haematopoietic differentiation 
remains unclear.   
 
Experiments in the ES cell system have begun to investigate this.  However thus far the 
consensus from experiments carried out using ES cells is that optimal haematopoietic 
differentiation requires a combination of factors including BMP4 (Park et al. 2004;Pearson 
et al. 2008).  This implies BMP4 is necessary but not sufficient for optimal haematopoietic 
differentiation.  These results suggest that BMP4 at least has a role to play in the up 
regulation of Flk-1 expressing cells and the haematopoietic genes Scl, Lmo2, Gata2 and 
Runx1.   
 
Scl, Lmo2, Gata2 and Runx1 clearly are essential to haematopoietic development.  From 
research done so far it appears that they are closely related and the regulation of their 
expression is at least in part dependent on each other.  Although the timing of lethality is 
clear in deletion mutant studies this only defines the processes for which these genes are 
critical.  There remains a lack of clarity as to the kinetics of gene expression for each of 
these genes.   
Few published experiments have been done to establish the effects of BMP4 on bone 
marrow and foetal liver cells.  Of the few experiments that have been performed on mouse Chapter 1 
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bone marrow (Fuchs et al. 2002;Maguer-Satta et al. 2003) the results have been 
inconclusive.   
 
1.7 Aims 
 
Previous ES experiments have investigated optimal haematopoietic differentiation using a 
combination of growth factors.  The main aim of this work was to determine the role 
BMP4 alone plays in early development.  In particular these experiments were aimed at 
determining whether BMP4 up regulated the haematopoietic genes Runx1, Scl, Gata2 or 
Lmo2.   
 
Few experiments have investigated the role of BMP4 in developmentally more mature 
haematopoietic populations.  Therefore in these experiments foetal liver and bone marrow 
serum free culture systems were developed in order to determine the effects of BMP4.  In 
particular the aim was to see if there was up regulation of the same haematopoietic genes 
and thus if the effects of BMP4 were the same regardless of the developmental maturity of 
the haematopoietic population being investigated. 
 
The genes Runx1,  Scl,  Gata2 and Lmo2 clearly are important to haematopoietic 
development.  ES differentiation experiments sought to investigate the timing and 
sequence of expression in development.  In the foetal liver and bone marrow cultures these 
experiments sought to characterise whether these genes play a role in HSC expansion or 
differentiation.    
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Chapter 2  Materials and Methods 
 
2.1 Materials 
 
Unless otherwise stated all tissue culture reagents were supplied by Gibco/Invitrogen, all 
general chemicals were supplied by Sigma and all plastics were from Nunc. 
 
 
2.2 Methods 
 
2.2.1 Cell  Culture 
 
2.2.1.1 ES cell culture 
2.2.1.1.1 SNH stromal cell culture and irradiation 
Murine SNH stromal cells (donated by Dr. Martinez Barbera, ICH) were maintained at 
low passage number in culture at 37ºC, 5% CO2 and passaged every 3 -4 days at 
subconfluence.  Cells were cultured in Dulbecco’s Modified Eagles medium (DMEM) 
supplemented with 10% foetal calf serum (FCS).  For use as feeder cells in embryonic 
stem (ES) cell culture, SNH cells were irradiated at 2500cGy using a 
137Caesium source.   Chapter 2 
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Irradiated cells were either plated at 3x10
6 cells/dish in 10cm tissue culture plates 
precoated with 0.1% gelatin (porcine 300 bloom) for use the following day or stored at -
80ºC in FCS supplemented with 10% dimethyl sulfoxide (DMSO) for future use.  
2.2.1.1.2 Undifferentiated ES cell culture 
The murine CCE ES cell line (donated by Juan Pedro Martinez Barbera, Neural 
Development Unit, ICH) was maintained in ES medium.  ES medium consisted of 
DMEM, 15% FCS, Penicillin (50µg/ml), 0.1mM MEM non essential amino acids, 1mM 
Sodium Pyruvate, 1000U Leukaemia Inhibitory Factor (LIF, Chemicon International) and 
100 µM beta-mercaptoethanol (β-ME).  Cells were incubated at 37ºC, 5% CO2.  Fresh 
medium was added each day and cells were passaged every 2-3 days.  Prior to 
differentiation CCE ES cells were passaged onto gelatin coated tissue culture plates in the 
absence of irradiated SNH cells to remove feeder cells. 
2.2.1.1.3 EB differentiation 
CCE ES cells were suspended as  20µL ‘hanging’ drops on the lid of a non tissue culture 
treated plate (VWR International) in DMEM supplemented with either 10% FCS, 10% 
Serum Replacement (SR) or 10% SR and BMP4 (5ng/ml, R&D Systems).  Cells were 
incubated at 37ºC, 5% CO2.  After 2 days developing EBs were washed from the lid, in 
the same medium as above, into a 10cm non tissue culture treated plate.   
2.2.1.1.4 BMP4 titration experiments 
Cells were differentiated as described above in DMEM supplemented with 15% SR and 
0, 5, 10 and 25ng/ml of BMP4.   Chapter 2 
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2.2.1.1.5 BMP receptor experiments 
Cells were differentiated as described above in DMEM supplemented with 15% SR and 
0, 25, 100 and 250ng/ml of BMP receptor 1α (R&D Systems).   
 
 
2.2.1.2 Bone marrow Culture 
2.2.1.2.1 Isolation of bone marrow (BM) cells 
The hind legs of sacrificed adult CD1 mice were obtained and under sterile conditions the 
thigh, femur and tibia were dissected away.  Bone marrow cells were flushed using 
CellGro stem cell growth medium (CellGenix, Germany) and passed through a 70µm cell 
strainer.  1ml of red cell lysis buffer (Qiagen) was added and incubated on ice for 10 
minutes to remove erythrocytes.   
2.2.1.2.2 Culture of bone marrow  
The isolated bone marrow cells were seeded into a 6 well tissue culture plate at 1x10
6 
cells per ml in CellGro medium and 10
-4M beta-mercaptoethanol supplemented with 10% 
FCS or BMP4 (10ng/ml).  Cells were incubated at 37ºC, 5% CO2.  In some experiments a 
further culture condition was added: BMP4 (10ng/ml) and BMP receptor (200ng/ml).  In 
later experiments IGF-1 (20ng/ml) and TPO (20ng/ml) were added.   
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2.2.1.3 Foetal liver culture 
2.2.1.3.1 Isolation of foetal Liver (FL) cells 
Under sterile conditions foetal livers were dissected from day 14.5 CD1 mouse embryos.  
Liver cells were dissociated by placing them in 1ml of cell dissociation buffer for 10 
minutes at 37ºC.  They were then triturated using 21, 23 and 25 guage needles and passed 
through a 70 µm cell strainer.  Red cell lysis buffer was added for 10 minutes and 
incubated on ice to remove erythrocytes.     
2.2.1.3.2 Culture of foetal Liver Cells 
1x10
6 cells/ml were seeded into a 6 well tissue culture plate in CellGro medium and     
10
-4M beta-mercaptoethanol supplemented with 10% FCS or BMP4 (10ng/ml).  In some 
experiments a further culture condition was added: BMP4 (10ng/ml) and BMP receptor 
(200ng/ml).  The cells were incubated at 37ºC, 5% CO2.   
 
2.2.1.4 Maintenance of other cell lines 
ST2 cells were cultured in RPMI medium supplemented with 10% FCS and penicillin 
(50µg/ml).  SVEC and 293T cells were cultured in DMEM supplemented with 10% FCS 
and penicillin (50µg/ml).  Cells were incubated at 37ºC, 5% CO2.  Cells were passaged at 
80-90% confluency.   
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2.2.1.5 Long term storage of cell lines 
Cell line cells were stored in vials containing 1x10
6 cells in 1ml of freezing medium.  
Freezing medium contained 90% FCS and 10% DMSO.   
 
In order to revive frozen cells, cells were thawed quickly in a 37ºC waterbath and then 
the appropriate culture medium was added slowly.  Cells were then pelleted using a 
tabletop centrifuge (Heraeus) to remove the freezing medium and resuspended in culture 
medium. 
 
 
2.2.2   Sample  Analysis 
 
2.2.2.1 Reverse transcription - PCR 
2.2.2.1.1 Total RNA extraction 
 
EBs were placed in cell dissociation buffer for 10minutes at 37ºC and triturated using a 
23G needle.  1 x 10
6 cells per sample were collected in lysis buffer.  RNA was then 
extracted using an RNAeasy mini kit (Qiagen).  RNA was dissolved in 40µL RNase free 
water (Qiagen) and quantified using a Nanodrop ND-1000 spectrophotometer.  
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2.2.2.1.2 Reverse transcription 
RNA was treated with DNase prior to the reverse transcription reaction in order to 
eliminate any contaminating genomic DNA.  16µL of the RNA sample was added to 2µL 
DNaseI and 2µL DNaseI 10x buffer and incubated at room temperature for 15 minutes.  
EDTA was used to inactivate the enzyme.  The sample was incubated at 65ºC for 5 
minutes to ensure DNase inactivation.   
The reverse transcription (RT) reaction was performed on DNAse treated RNA by adding 
8µL first strand buffer, 4µL DTT, 2µL random primers, 2µL dNTPs, 2µL RNase out and 
2µL MMLV reverse transcriptase.  The sample was incubated for 2 hours at 37ºC.   
Following incubation the reverse transcriptase enzyme was heat inactivated at 70ºC for 
15 minutes. 
2.2.2.1.3 PCR 
The expression of Hprt, Alk3, Bmpr2 and Bmp4 was determined using PCR.  A 25 µL 
reaction was performed using 100ng of cDNA template, 12.5µL of PCR mastermix, 
2.5µL of upstream primer, 2.5µL of downstream primer and nuclease free water.  40 
cycles of PCR were performed at 95ºC for 30 seconds, 56ºC for 30 seconds and 72ºC for 
2 minutes in an Eppendorf Mastercycler PCR machine.  Alk3 and BmprII primer 
sequences were taken from Pesce et al. (2002) and Bmp4 primer sequences were taken 
from Peretto et al. (2004).    Primers were designed so that contaminant genomic DNA 
would not produce a band of equal size to those produced by amplification of cDNA.    
Primer sequences were as follows:   
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Hprt     forward TCCCCAGACTTTTGATTTGC,  
reverse GGAAAATACAGCCAACACTGC;  
 
Alk3     forward ACTTTAGCACCAGAGGATACC,  
reverse TTTTCACCACGCCATTTACCC;  
 
BmprII   forward TGCGGCTATAAGTGAGGTTGG,  
reverse AGCAGTTGACATTGGGTTGAC;  
 
Bmp4    forward CTCCCAAGAATCATGGACTG,  
reverse AAAGCAGAGCTCTCACTGGT.   
2.2.2.1.4 Real Time PCR 
A 25µL reaction was performed using 1.4µL of cDNA sample, PCR mastermix (2x, 
Applied Biosystems), primers and probe (20x) and DNase free water.  Runx1, Scl, Gata2 
and Lmo2 expression was analysed.  Gapdh was used as the internal standard.  Primers 
and probes were obtained from Applied Biosystems.  Each reaction was performed in 
triplicate. 45 cycles of PCR were performed in a Real Time ABI Prism 7000 PCR 
machine using default settings: cycling at 95º for 15 seconds and 60ºC for 1 minute.  Data 
was analysed using ABI Prism software.   
 
Relative quantification values were obtained using the comparative CT method (∆∆CT).  
For this calculation the CT was calculated for the treated sample and the day 0 sample for 
the gene of interest.  The CT was also calculated for each sample for the endogenous Chapter 2 
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control.  For each sample, reactions were performed in triplicate and the CT value is 
calculated as an average of these values.  The following calculations are then performed: 
 
∆CT  = CT (gene of interest)- CT (endogenous control) 
 
∆∆CT = ∆CT (gene of interest : treated sample) - ∆CT (gene of interest : day 0) 
 
Fold difference in gene expression = 2
-∆∆C
T
 
 
2.2.2.2 Flow cytometry (FC) Analysis 
2.2.2.2.1 4 colour flow cytometry 
Where necessary, cells were dissociated in cell dissociation buffer for 10 minutes at 37ºC 
and triturated using a 23G needle.  Samples collected (each containing up to 1x10
6 cells) 
were suspended in PBS/10% bovine serum albumin (BSA) and divided between 3 flow 
cytometry (FC) tubes.  Samples were incubated in the dark on ice for 30 minutes with 
fluorescence conjugated antibodies against murine stem cell markers: CD34 
fluoroisothiocyanate (FITC), Flk-1 phycoerythrin (PE), Sca-1 PerCP and C-kit APC or 
murine haematopoietic differentiation markers: CD45 FITC, Ter119 PE, CD11b PerCP 
and CD19 APC.  An isotype control tube contained IgG FITC, IgG PE, IgG PerCP and 
IgG APC.  All antibodies used were directly conjugated.  Antibody manufacturer details 
are as listed in table 2.1.   Chapter 2 
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1µL of each antibody was added and the sample was diluted in PBS/10%BSA to 100µL.  
Samples were washed once and fixed in 1% paraformaldehyde (PFA, Polysciences Inc.).  
Samples were analysed on a CyAn ADP flow cytometer (Dako Cytomation) using 
Summit 4.2 software.  A 488 nm argon laser was used to excite PE, FITC and PerCP 
fluorochromes and emission was collected.  A 633 nm He Ne laser was used to excite 
APC which was collected at 675 nm.  Cells were gated on the basis of their forward 
scatter and side scatter to exclude dead cells and debris.  All antibodies were titrated prior 
to use and a minimum of 20000 events were collected.   The isotype control was used for 
quadrant placement. 
 
Table 2.1 Antibody Manufacturer Information 
Specificity Catalogue 
Number 
Source Raised  in  Type 
Stem Cell 
Markers 
    
CD34  553733 BD  Pharmingen Rat  FITC 
CD117 (C-kit)  12-1171 eBioscience  Rat  PE 
  553356 BD  Pharmingen Rat  APC 
Flk-1  555308 BD  Pharmingen Rat  PE 
Sca-1  12-5981 eBioscience  Rat  PE 
  MSCA18 Caltag  Labs  Rat  Cy5.5 
Differentiation 
Markers 
    
CD45  553079 BD  Pharmingen Rat  FITC 
CD11b  12-0112 eBioscience  Rat  PE 
  550993 BD  Pharmingen Rat  Cy5.5 
Ter119  553673 BD  Pharmingen Rat  PE 
CD19  550992 BD  Pharmingen Rat  APC 
Isotype 
Controls 
    
IgG2a  12-4321-81 BD  Pharmingen Rat  PE 
IgG2a  555929 BD  Pharmingen Rat  FITC 
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2.2.2.2.2 Cell cycle analysis 
Cells were collected and washed in phosphate buffered saline (PBS, Gibco/Invitrogen). 
Where necessary, cells were dissociated in cell dissociation buffer for 10 minutes at 37ºC 
and triturated using a 23G needle.  Cells were then washed again and resuspended in 
Propidium Iodide buffer.  Propidium Iodide was then added at 50µg/ml (BD 
Pharmingen).  Cells were analysed on a CyAn ADP flow cytometer within 15 minutes for 
DNA levels.  A minimum of 20,000 events were collected.  Linear gates were set to 
quantify cells at each phase of the cycle. 
 
2.2.2.2.3 Cell death analysis 
Cells were collected and washed in PBS. Where necessary, cells were dissociated in cell 
dissociation buffer for 10 minutes at 37ºC and triturated using a 23G needle.  Cells were 
then washed again and resuspended in Annexin V buffer (BD Pharmingen).  Cells were 
then incubated with Annexin V antibody (BD Pharmingen) for 30 minutes in the dark on 
ice.  After this Propidium Iodide was added and cells were analysed on a CyAn ADP 
flow cytometer within 15 minutes.  A minimum of 20,000 events were collected.  
 
 
 
 
 Chapter 2 
 
  84
2.2.2.3 Methylcellulose cultures: 
2.2.2.3.1 Bone marrow and foetal Liver methylcellulose cultures 
Bone marrow and foetal liver samples were replated at a density of 1500 cells in 1.5ml of 
complete methylcellulose medium containing haematopoietic cytokines (Methocult GF 
M3434, Stemcell Technologies Inc).  Cultures were incubated for 14 days after which 
colonies were counted under the microscope and identified by morphology.   
2.2.2.3.2 ES methylcellulose cultures 
Embryoid body samples were replated at a density of 1500 cells/1.5 ml in 0.9% base 
methylcellulose medium (ES Cult M3120, Stem Cell Technologies Inc) containing FCS 
(15%), Insulin-transferrin (25µg/ml), MTG (4.5x10
-4M), IL1α (5ng/µl), IL3 (10ng/ml), 
IL6 (5ng/ml), IL11 (25ng/ml), SCF (25ng/ml), GM-CSF (5ng/ml) and Erythropoietin (2 
units/ml).    Cytokine and growth factor manufacturer details are as listed in table 2.2 
Cultures were incubated for 14 days after which colonies were counted and identified by 
morphology.   
 
Table 2.2 Cytokine and Growth Factor Manufacturer information 
Cytokine/Growth Factor  Catalogue Number  Source 
Erythropoietin  hBA-165 Santa  Cruz  Biotechnology 
ES tested Foetal Calf 
Serum 
06592 StemCell  Technologies 
GM-CSF  14-8331 eBioscience 
IL1α    
IL3  14-8031 eBioscience 
IL6  14-8061 eBioscience 
IL11  418-ML  R and D systems 
Insulin-Transferrin  51500-056 Invitrogen 
MTG  M-3148 Sigma 
SCF  14-8341 eBioscience 
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2.2.2.3.3 Cytospin and May Grumwald Giemsa Staining 
Individual colonies were collected and transferred to microscope slides using a cytospin 
centrifuge (1000rpm for 5minutes).  Cells were fixed using methanol (5 minutes, room 
temperature) and stained using May Grumwald Giemsa stain.   
2.2.2.3.4 F4/80 immunocytochemical analysis of methylcellulose colonies 
Individual colonies were collected and transferred to microscope slides using a cytospin 
centrifuge (1000rpm for 5 minutes).  Cells were fixed in 4% PFA in PBS for 15 minutes 
at room temperature.  Endogenous peroxidase activity was blocked by immersion in 0.3% 
hydrogen peroxide in PBS for 30 minutes at room temperature.  After washing in PBS 
non-specific antibody binding was blocked by incubating sections with 3% normal goat 
serum in PBS for 30 minutes at room temperature.  Cells were then incubated with rat 
anti-mouse F4/80 primary antibody (eBioscience), diluted 1:50 with 0.1% BSA in PBS, 
overnight at 4°C.  After washing cells in PBS, cells were incubated with biotinylated goat 
anti-rat antibody (Vector Laboratories) diluted 1:100 in PBS-BSA for 30 minutes at room 
temperature followed by avidin biotinylated peroxidase complex (ABC reagent, Vector 
Laboratories) diluted 1:200 in PBS-BSA for 1 hour at room temperature.  Peroxidase 
activity was visualised using 0.025% 3,3’diaminobenzidine in PBS containing 0.03% 
hydrogen peroxide.  After washing cells in PBS, slides were rinsed through a series of 
ethanol and Histoclear.  They were then mounted with DPX and viewed using a Leica 
light microscope.   
 
 Chapter 2 
 
  86
2.2.3  ES cell staining 
 
2.2.3.1 Alkaline phosphatase staining 
ES cells were cultured to confluency in 12 well plates.  Culture media was aspirated and 
cells were fixed using 4% PFA in PBS for 2 minutes.  Cells were then washed using Tris 
buffered saline tween 20 (TBST) composed of 20mM Tris-HCl, 0.15M NaCl, 0.05% 
Tween-20 at pH 7.4.  Napthol phosphate and fast red violet solution (Chemicon 
International) was mixed in water in the ratio 2:1:1 and added to each well and incubated 
in the dark at room temperature for 15 minutes.  After aspirating staining solution cells 
were washed with TBST and then PBS.  The cells were visualised using a Nikon light 
microscope. 
 
2.2.3.2 SSEA-1 staining 
ES cells were cultured to confluency in 12 well plates.  After aspirating culture media 
cells were fixed in 4% PFA in PBS for 15-20 minutes at room temperature.  Cells were 
washed twice in TBST and permeabilised with 0.1% Triton in PBS for 10 minutes at 
room temperature.  Cells were again washed twice using TBST.  Non specific antibody 
binding was blocked by applying 4% normal goat serum in PBS for 30 minutes at room 
temperature.  Primary anti-mouse SSEA-1 antibody (Chemicon International) was diluted 
1in 20 in blocking solution and added to the cells for 1 hour at room temperature.  Cells 
were then washed three times in TBST.  Goat anti mouse FITC IgM antibody was diluted Chapter 2 
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1in 20 in PBS and incubated for 1 hour at room temperature.  After washing cells three 
times in TBST cells were visualised using an Olympus fluorescent microscope.   
 
2.2.4 Transfection 
 
2.2.4.1 pEGFP-N1 transfection of ES cells 
On the day of transfection ES cells were resuspended in EB differentiation medium 
containing DMEM and 15% SR in a 12 well plate.  Cells were seeded at 200,000 cells per 
well in 1ml of EB differentiation medium.  For each well 1.6µg of plasmid DNA was 
diluted in 100µL of Optimem medium and 4µl of lipofectamine 2000 was diluted in 
100µL of Optimem.  These dilutions were incubated for 5 minutes at room temperature 
and then mixed together to make a total volume of 200µL per well.  The mixture was 
then incubated for 20 minutes at room temperature to allow formation of DNA-
lipofectamine complexes.  The complexes were then added to the medium and incubated 
for 4 hours at 37C, 5% CO2.  After this the medium was replaced with EB differentiation 
medium.  In each experiment the pEGFP-N1 plasmid was transfected.  Also an 
untransfected control, plasmid DNA alone and lipofectamine 2000 alone control wells 
were included. 
2.2.4.2 pKLO.1 transfection of ST2 cells 
One day before transfection 100,000 cells were plated out in 500µL of culture medium 
per well without antibiotics in a 24 well plate.  On the day of transfection lipofectamine – 
DNA complexes were prepared as follows.  For each well 0.8µg of plasmid DNA was Chapter 2 
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diluted in 50µL of Optimem medium and 2µL of lipofectamine 2000 was diluted in 50µL 
of Optimem.  These dilutions were incubated for 5 minutes at room temperature and then 
mixed together to make a total volume of 100µL per well and left for 20 minutes at room 
temperature.  This mixture was then added to the medium and incubated for 4 hours at 
37ºC, 5% CO2.  After this the medium was replaced with ST2 culture medium without 
antibiotics.  In each experiment the 5 plasmids and a scramble sequence plasmid were 
transfected in separate wells.  Also an untransfected control and lipofectamine 2000 alone 
control wells were included. 
 
2.2.5 DNA  manipulation 
 
2.2.5.1 Restriction enzyme digestion 
Plasmid DNA was single or double digested using restriction enzymes (Promega) added 
at no more than 10% of total reaction volume.  An appropriate enzyme buffer was chosen 
depending on the restriction enzymes being used according to manufacturer’s 
instructions.  Total reaction volume was made up to 15-20µL.  The reaction was 
incubated in a water bath at 37ºC for 2 hours.   
2.2.5.2 Dephosphorylation of digested plasmid DNA ends 
Digested plasmid DNA was treated with calf intestinal alkaline phosphatase (CIAP, New 
England Biolabs) to dephosphorylate the DNA ends prior to ligation.  The reaction was 
performed in CIAP buffer incubated at 37ºC.  5 units of enzyme were added at the start of 
the reaction and after 30 minutes, a further 5 units of enzyme were added.  The total Chapter 2 
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incubation period was for 1 hour.  The enzyme was heat inactivated following the 
reaction by incubation for 15 minutes at 65ºC. 
 
2.2.5.3 Agarose gel electrophoresis 
DNA fragments were resolved by gel electrophoresis using 1% agarose gels in 1x TAE 
(40mM Tris acetate, 5mM ethylenediaminetetraacetic acid).  Gels were prepared by 
dissolving agarose in 1x TAE by boiling the mixture in a microwave.  After cooling 
ethidium bromide was added at 0.5µg/ml to enable visualization of DNA.  Before loading 
DNA onto the gel, DNA samples were mixed with loading buffer (10mM Tris-HCl pH 
7.5, 50mM EDTA, 10% Ficoll 400, 0.4% Orange G).  A 1kb plus ladder was loaded onto 
each gel to enable size determination of DNA fragments.  Gels were electrophoresed by 
applying a voltage of 100V across the gel.  The separated fragments were visualized by 
exposure to UV light using an UVIdoc gel documentation system.  
2.2.5.4 Gel purification of DNA 
Following gel electrophoresis DNA fragments were visualised under UV light and 
excised using a scalpel blade.  The DNA was then extracted from agarose using a 
QIAquick gel extraction kit (Qiagen) as per the manufacturer’s instruction. 
2.2.5.5 Ligation 
Ligation was carried out using T4 DNA ligase (Promega) in T4 DNA ligase buffer.  A 
vector insert ratio of 1:3 was used with 100ng of vector DNA added per reaction.   
Ligation reactions contained 1 unit of T4 DNA ligase and were made up to a total volume Chapter 2 
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of 10µL.  The reaction was incubated overnight in a water bath at 16ºC.  The ligation 
reaction was then immediately transformed into competent bacteria. 
 
2.2.6 Bacterial  manipulation 
 
2.2.6.1 E. coli bacterial culture 
E. coli were grown in flasks containing LB media incubated at 37ºC and agitated at 250 
rpm or streaked out on LB plates containing 1.5% bacto agar (Merck) and incubated at 
37ºC.  E. coli carrying plasmids with ampicillin resistance were grown on media 
supplemented with ampicillin (50µg/ml, Stratagene).   
For long term storage bacterial culture was made up with 15% glycerol and stored at -
70ºC. 
2.2.6.2 Preparation of electrocompetent bacteria 
E. coli DH5α were cultured in LB media and incubated at 37ºC with agitation until the 
optical density was between 0.7 and 0.8.  At this point the culture was pelleted by 
centrifugation at 5000 rpm for 15 minutes.  The supernatant was discarded and the 
resulting pellet was resuspended in 1L of cold sterile 10% glycerol.  Following this the 
bacteria were centrifuged again and resuspended in 1L of cold sterile glycerol.  The 
bacteria were then centrifuged a final time and the supernatant was discarded and the 
bacteria resuspended in the small remaining volume of glycerol.  The bacteria were 
transferred to a smaller centrifuge tube and centrifuged again at 7000 rpm for 10 minutes.  
The supernatant was removed and the cell pellet resuspended in 2ml cold sterile 10% Chapter 2 
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glycerol.  The bacteria were snap frozen in dry ice into 100µL aliquots and stored at -
70ºC. 
2.2.6.3 Heat shock bacterial transformation 
10µL of ligated DNA was incubated on ice with 100µL of competent bacteria for 30 
minutes.  The mixture was then incubated for 1 minute at 42ºC and then for a further 5 
minutes on ice.  500µL of LB was then added to the transformed bacteria which were 
then incubated at 37ºC for 1 hour.  After incubation the bacteria were spread onto an LB 
agar plate containing ampicillin (50µg/ml) and placed in an incubator at 37ºC overnight.   
2.2.6.4 Plasmid DNA preparation 
2.2.6.4.1 Small scale 
Colonies were picked using 20µL pipette tips from LB agar plate cultures and grown 
overnight in 5ml liquid LB cultures containing ampicillin (50µg/ml).    Plasmid DNA was 
then harvested from these cultures using a Qiagen mini-prep kit as per the manufacturer’s 
instructions. 
2.2.6.4.2 Large scale 
Colonies were picked using 20µL pipette tips from LB agar plate cultures and grown 
overnight in 5ml liquid LB cultures containing ampicillin (50µg/ml).    500µL of this 
culture was then used to inoculate 500ml LB media containing ampicillin (50µg/ml).  
This culture was incubated overnight at 37ºC with agitation.  A Qiagen mega-prep kit 
was used to harvest plasmid DNA as per manufacturer’s instructions.   Chapter 2 
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2.2.6.4.3 Measurement of DNA concentration 
The plasmid DNA concentration was established using a NanoDrop ND-1000 
spectrophotometer. 
 
2.2.7  Lentivirus preparation and transduction 
 
2.2.7.1 Lentivirus production 
The day before transfection 1.2 x 10
7 293T cells were seeded into a 175 cm
2 tissue 
culture flask in culture media so that the next day cells were 80-90% confluent.  On the 
day of transfection per flask 5mls of Optimem medium was prepared containing 50µg 
plasmid, 17.5µg pMDG2 (VSV-G) and 32.5µg p8.74 (gag-pol).  Separately 5 ml of 
Optimem medium containing 1µL polyethylenimine (PEI, 10mM) was prepared.  These 
two solutions were then filtered using a 0.22µm filter, mixed together and left for 20 
minutes.  The media on the 293T cells in culture was removed and the cells were washed 
using Optimem medium.  The 10ml Optimem solution containing the PEI-DNA 
complexes were added to the flask of 293T cells.  The cells were then incubated for 4 
hours at 37ºC before replacing the media on the cells with culture media.  After 48 hours 
the supernatant was harvested and fresh culture media was replaced on to the cells.  The 
supernatant was centrifuged at 4000 rpm for 10 minutes and then filtered through a 
0.22µm filter to remove any cell debris.  The virus was concentrated by 
ultracentrifugation of the medium at 23,000rpm for 2 hours.  After this the supernatant Chapter 2 
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was carefully decanted off so as not disturb the virus containing pellet.  Virus was then 
resuspended in 150µL of Optimem which was stored as 20µL aliquots at -70ºC.   
 
2.2.7.2 Titration of lentivirus supernatants 
One day before transduction 100,000 293T cells were seeded per well in a 24 well plate 
in 500µl of culture medium.  The next day a 5 fold series of dilutions of virus was 
prepared in 500µl aliquots of culture medium.  The aliquots were used to replace the 
medium on the cells.  Green fluorescent protein (GFP) expression was measured 48 hours 
after transduction by flow cytometry.  Expression titre was then calculated by 
determining the well that produced 5-15% of GFP expression and then dividing the 
number of transduced cells in this well by the volume of virus used to transduce them.   
2.2.7.3 Lentiviral ST2 transduction 
100,000 ST2 cells in 500µL ST2 culture medium per well were seeded onto a 24 well 
plate the day before transduction.  On the day of transduction virus was added at the 
required MOI to the culture media.   
2.2.7.4 Lentiviral ES cell transduction 
On the day of transfection ES cells were collected and resuspended in EB differentiation 
medium.  Cells were transduced by adding virus at the required MOI to the medium.  The 
ES cells were then differentiated by the hanging body differentiation method previously 
described in section 2.2.1.1.3.  Briefly, 35,000 cells were suspended in 20µl droplets from 
the top of non-adherent tissue culture plates.  After 2 days these droplets were washed off Chapter 2 
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the top of these plates into new non-adherent tissue culture plates.  EBs were taken for 
PCR and flow cytometry analysis when necessary. 
 
2.2.8 Statistical  analysis 
 
Where the data could be assumed to be normally distributed, a 2 tailed unpaired t-test was 
applied to determine statistical significance.  The Wilcoxon Mann Whitney, a non 
parametric statistical test, was applied to rest of the data.  The null hypothesis was that 
the treatment caused no difference. 
 
The statistics software package SPSS Version 13.0 was used to perform the calculations.  
If P<0.05 then the result was judged to be significant.   
 
 
For the real time PCR data the logarithmic values had to be converted to real values by 
raising 2 to the power of the ∆∆Ct value before statistical analysis was performed. 
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Chapter 3  The effect of BMP4 on haematopoietic 
stem cells 
 
3.1 Introduction 
 
In these experiments the role of BMP4 in three different culture systems was explored: 
ES cells as a model of yolk sac haematopoiesis, foetal liver cells and bone marrow cells.  
The main aim of these experiments was to discover whether BMP4 had an effect on the 
expression of Runx1, Scl, Gata2 and Lmo2.  Evidence from experiments in the ES cell 
system has suggested BMP4 up regulates the expression of these genes as already 
described in Section 1.5.6.   
 
Serum is commonly used as a source of essential survival factors in cell culture. Foetal 
liver and bone marrow ex vivo culture systems had to be developed which would allow 
the survival of these cells in serum free conditions.  Previous papers have already 
described serum free conditions for the differentiation of CCE ES cells (Adelman, 
Chattopadhyay, & Bieker 2002).    
 
In taking samples for analysis the same time points were used across the different culture 
systems to determine if there were any similarities in the way the cells responded to 
BMP4.  Samples were analysed by quantitative reverse transcription PCR for the Chapter 3 
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expression of Runx1,  Scl,  Gata2 and Lmo2 and by flow cytometry for cell surface 
markers.   
 
A common panel of antibodies was used for flow cytometry across all of the culture 
systems to establish any similarities in the response to BMP4.  A stem cell panel of 
antibodies including CD34, Sca-1, Flk-1 and C-kit was used.  These antigens are all 
known to be expressed on stem cells (see Section 1.1.3.2) with the exception of Flk-1 
which is a marker for the haemangioblast (see Section 1.5.3.2).  In the ES cell system 
BMP4 has been shown to increase the number of Flk-1 expressing cells (Park et al. 
2004).  In addition to attempting to verify this result, one of the aims of these experiments 
was to detect whether BMP4 up regulated Flk-1 expression in the developmentally more 
mature cells of the foetal liver and bone marrow. 
 
In addition a differentiation panel was used to detect the presence of blood lineage 
markers including: CD45, Ter119, CD11b and CD19 (see Figure 1.2B).  CD45 is a pan-
haematopoietic marker (Hermiston, Xu, & Weiss 2003), Ter119 is an erythroid marker 
(Kina et al. 2000), CD11b is a myeloid marker (Springer et al. 1979) and CD19 is a 
lymphoid marker (Krop et al. 1996).  This panel was used to detect differentiation of 
haematopoietic progenitors resulting from the presence of BMP4. 
 
In the foetal liver and bone marrow systems methylcellulose colony assays were also 
performed to determine the number and type of progenitors present in culture.   
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Thus intracellular changes in gene expression could be correlated with changes in the 
type of cells present based on cell surface markers and colony analysis.  The experimental 
approach is summarised in Figure 3.1.1. 
 
Embryonic
Stem cells
Foetal Liver
Bone Marrow
Negative Control:
Serum Free culture
Serum Free Culture
+ Growth Factor
Positive Control:
Serum culture
Flow Cytometry
PCR
CFU-Assay
 
Figure 3.1.1 Experimental protocol in ES cell, foetal liver and bone marrow experiments  
Cells were cultured in serum-free conditions (minimal growth conditions), with recombinant BMP4 or in 
the presence of foetal calf serum (maximal growth conditions).  Analysis was carried out for changes in cell 
surface markers (flow cytometry), transcription factor expression (PCR) and haematopoietic output (CFU 
assay).   
 
 
 
3.2   Embryonic Stem Cell Differentiation to Haematopoietic 
cells: The effect of BMP4 
 
 
Many different types of murine ES cell line have been derived. For the purposes of these 
experiments a CCE embryonic stem cell line was used.  This cell line is derived from the 
inbred 129/Sv mouse strain.  These cells have previously been shown to differentiate into 
haematopoietic cells (Keller et al. 1993). 
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ES cells are known to differentiate to haematopoietic cells in the presence of 15% foetal 
calf serum (Keller et al. 1993).  However serum contains variable amounts of factors and 
many other ill defined substances.  These uncontrolled influences would have masked or 
at least complicated the analysis of a single growth factor (Johansson & Wiles 1995).  For 
this reason ES cells were differentiated in serum replacement (SR) media which contains 
a minimal defined set of growth factors necessary to support the growth and survival of 
these cells.  In order to determine the effects of BMP4, cells were differentiated in SR 
media with BMP4.  Cells were differentiated in serum in addition as a positive control. 
 
When ES cells are plated in EB differentiation medium they coalesce to form embryoid 
bodies.  Within these embryoid bodies many different types of cells differentiate 
mimicking the processes that take place within the embryo.  ES cells were differentiated 
in hanging drops suspended from the top of a petri dish (see Figure 3.2.1).  Each 20 µL 
droplet contains 35000 ES cells and gives rise to a single embryoid body.  Because each 
droplet contains the same number of cells there is greater consistency in the size of the 
embryoid bodies.  Consistency in the size of the embryoid body aims to ensure greater 
consistency in the developmental stage between embryoid bodies and ultimately greater 
consistency in the results overall.   
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Figure 3.2.1 Embryoid body differentiation  
Droplets on the top of the Petri dish contain 35,000 cells each.  One embryoid body forms per droplet.  This 
method aims to ensure greater consistency in the size of EBs that are formed and results overall. 
 
 
Johansson and Wiles (1995) have tested BMP4 at concentrations between 0.1 and 
10ng/ml for its ability to increase mesoderm and haematopoietic gene expression in CCE 
ES cells.    Park et al. (2004) used BMP4 at 5ng/ml on R1 ES cells and found this was 
optimal for generation of Flk-1 and SCL expressing cells.  Lugus et al. (2007) using R1 
ES cells have also found this to be the optimal concentration of BMP4 for haematopoietic 
differentiation.  Given this previous data I decided to use BMP4 at 5ng/ml.   
 
Haematopoietic colony forming cells (CFCs) can only be detected from day 4 after 
differentiation in 15% serum.  The frequency of CFCs increases up to day 6 when they 
comprise between 0.5 and 1% of the total EB population (Keller et al. 1993).  For this 
reason samples were taken for analysis at day 0, day 3 and day 6.  Sampling at these time 
points also allowed comparison of results obtained with the bone marrow and foetal liver 
cultures.   Chapter 3 
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Cell samples were harvested as described in section 2.2.1.1 and then counted using trypan 
blue to check cell viability.  Cell viability was 80-95% at all time points and under all 
conditions.   
 
3.2.1 PCR  Results 
 
3.2.1.1 Reasons for using Real Time PCR 
 
In reverse transcription PCR, mRNA is converted to cDNA by reverse transcriptase.   
Traditionally the quantity of mRNA can then be quantified by semi-quantitative PCR.   In 
this process primers are chosen to amplify a specific sequence from the cDNA.  PCR 
conditions, in particular, cycle number must then be determined such that a comparison 
can be made in the amount of DNA amplified from different samples at the end of the 
reaction.   
 
In real time PCR in addition to the primers detecting a target sequence there is a 
fluorogenic probe.  This probe has a 5’ fluorescent dye and a quencher dye on the 3’ end.  
While the probe is intact the quencher dye reduces the fluorescence emitted by the 
reporter dye.  If the target sequence is present the probe anneals downstream of one of the 
primers and is cleaved by the 5’ nuclease activity of Taq DNA polymerase as the primer 
is extended.  The cleavage of the probe separates the reporter dye from the quencher dye 
increasing the fluorescence of the reporter dye.  This cleavage also removes the probe Chapter 3 
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from the target strand such that primer extension can continue to the end of the template 
strand.  With each cycle there is an increase in the amount of amplicon present and thus 
the intensity of fluorescence.   
 
In real time PCR the fluorescence is measured and recorded at the end of each cycle.  At 
the end of the PCR reaction a threshold is set at which point the PCR reactions were in 
the exponential phase and from this the cycle threshold or Ct is determined for each 
reaction.  In these experiments relative quantification was used to determine the changes 
in gene expression.  Thus in a given sample, gene expression was determined relative to 
the level of expression in the day 0 sample.   
 
An endogenous control, in this case GAPDH, is used to normalize for differences in the 
amount of cDNA that is loaded into the reaction.  Endogenous expression levels must be 
the same in all samples so that any differences between samples are only due to changes 
in the expression level of the gene under investigation.   
 
Real time PCR has several advantages when compared with semi-quantitative PCR.   
Firstly because the level of amplicon is recorded at the end of each cycle this allows 
relative quantification to be carried out easily without the need for optimization 
experiments.  Furthermore real time PCR is far more sensitive in that it can detect down 
to a 2 fold change in gene expression compared to agarose quantification which can only 
detect down to a 10 fold change.  Gene expression values also control for the amount of Chapter 3 
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cDNA added to the reaction so that these quantities only reflect the levels of expression 
of the gene of interest. 
 
3.2.1.2 Gene expression changes relative to day 0 
 
In these experiments Runx1, Scl, Gata2 and Lmo2 expression was analysed at day 0, day 
3 and day 6.  Gapdh was used as an internal standard.  Gapdh has been tested as an 
internal standard in differentiating ES cells and was found to remain relatively constant in 
comparison with HPRT and β-tubulin (Murphy & Polak 2002).  
 
Data from 3 independent experiments is shown in Figure 3.2.2 and in the PCR tables in 
Appendix 1.  The raw PCR data for experiment ES5 is also in Appendix 1.  The data 
showed variability however some general trends were observed. 
 
There were no statistically significant changes in Runx1, Scl, Gata2 and Lmo2 expression 
although the expression of each of these genes were generally at higher levels at day 3 
and day 6 relative to day 0 under all culture conditions (see Appendix 1).    
 
In experiment ES2 there were quite dramatic increases in Lmo2 expression at day 6.  
Because these changes were present in all conditions it was not thought to be anomalous.  
ES cells are known to differentiate haphazardly and it is possible that in this experiment 
the cells were more predisposed to expanding an Lmo2 expressing population of cells.  
Lmo2 is expressed in cells of the erythroid and megakaryocytic lineage (Warren et al. Chapter 3 
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1994).  This increase in expression may have reflected an expansion of this population 
however further analysis is required to prove this. 
 
3.2.1.3 Gene expression changes dependent on culture condition 
 
There were no differences between the serum replacement and BMP4 culture conditions.  
The lack of any clear difference between the BMP4 treated sample and the serum 
replacement samples was in contrast to previous evidence from experiments performed in 
ES cells suggesting that BMP4 is involved in up regulating the expression of these genes.   
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Figure 3.2.2 ES differentiation PCR results   
Runx1, Scl, Gata2 and Lmo2 expression in EBs at day 0, day 3 and day 6.  EBs were cultured in serum 
replacement (SR), with BMP4 and with serum (FCS).  These logarithmic graphs show expression values 
standardised against a Gapdh control and are relative to Day 0.  Results are from 3 independent 
experiments.  The horizontal bars represent the mean and the standard error of the data set. 
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3.2.1.4 Flow Cytometry 
 
Flow cytometry offers a rapid method for analysing the cell surface markers expressed on 
cells within a particular sample.  Using different antibodies it is possible to perform 
analysis for the presence of multiple cell surface markers at one time.  In addition flow 
cytometry can detect the size and granularity of cells using the forward scatter and side 
scatter characteristics of a cell.  Different blood lineages can be distinguished using this 
method.  Furthermore dead cells can be gated out of the analysis.  For these reasons flow 
cytometry was the method of choice for analysing the expression of cell surface markers 
in these experiments. 
 
EB cells were dissociated and labelled with a stem cell and differentiation panel of 
antibodies as described in section 2.2.2.1 at day 0, day 3 and day 6.  The stem cell panel 
consisted of antibodies to CD34, Sca-1, Flk-1 and C-kit.  The differentiation panel of 
antibodies consisted of antibodies to CD45, Ter119, CD11b and CD19.  Data from 5 
independent experiments is presented in the flow cytometry results tables in Appendix 1.     
 
3.2.1.5 Stem Cell Markers 
 
Figure 3.2.3 shows data from the stem cell marker analysis experiments and Figure 3.2.4 
shows flow cytometry plots from a representative experiment (ES5). 
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Under serum replacement conditions at day 6 there was an increase in Flk-1 positive cells 
(P<0.05) when compared with day 0 levels.  Overall however the trends were similar 
between serum replacement and BMP4 conditions.  There was no statistically significant 
difference in stem cell marker expression between serum replacement and BMP4 
conditions.  This was surprising as BMP4 is well documented to cause an increase in the 
expression of Flk-1 expressing cells (Park et al. 2004). 
 
Under serum conditions at day 6 there was an increase in Flk-1 expressing cells (P<0.05) 
relative to day 0.   
 
The percentage of CD34 expressing cells was higher at day 6 (P<0.05) under serum 
conditions compared with serum replacement conditions.  Flk-1 expressing cells were 
also higher at day 6 under serum conditions relative to serum replacement conditions 
(P<0.05).  This most likely reflected the composition of factors in the serum promoting 
the differentiation of Flk-1 and CD34 positive populations.   
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Figure 3.2.3 Flow cytometry analysis of stem cell surface markers  
Stem cell markers: CD34, Sca-1 Flk-1 and C-kit expressed on EB cells at day 0 and after 3 and 6 days of 
culture with serum replacement media (SR), with BMP4 and with serum (FCS).  Data is from 5 
independent experiments.  The horizontal bars represent the mean and the standard error of the data set.  P 
values are shown where significant changes have occurred relative to day 0. 
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Figure 3.2.4 Representative stem cell panel flow cytometry plots  
These plots from experiment ES5 show changes in stem cell markers for BMP4 culture conditions only at 
day 3.  Day 0 data is included for comparison.  Numbers indicate the percentage of cells in each quadrant.  
ES5 was chosen as a representative experiment as it best illustrated the general pattern of results. 
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3.2.1.6 Differentiation Markers 
 
Figure 3.2.5 shows data from the differentiation marker analysis experiments and Figure 
3.2.6 shows flow cytometry plots from a representative experiment (ES5). 
 
Generally there were low levels of CD45, Ter119, CD11b and CD19 expressing cells 
under all conditions at Day 3 and Day 6.  The low levels of differentiation were as 
expected given that haematopoietic differentiation only commences between day 3 and 6 
(Park et al. 2004). 
 
There were no statistically significant difference in differentiation marker expression 
between the serum replacement and BMP4 conditions.  There was therefore no evidence 
for BMP4 promoting differentiation to any of the blood lineages.   
 
Under serum conditions there was an increase in CD11b expressing cells at day 6 relative 
to day 0 (P<0.05).  Serum conditions may promote myeloid differentiation.  
 
Results from experiment ES5 at day 3 showed dramatically elevated CD19 positive cells 
under all conditions despite day 0 levels being similar to the other experiments.  This 
once again is probably due to the haphazard differentiation of ES cells in this case 
promoting a CD19 positive cell population.   Chapter 3 
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Figure 3.2.5 Flow cytometry analysis of differentiation markers 
Differentiation markers: CD45, Ter119, CD11b and CD19 expressed on EB cells at day 0 and after 3 and 6 
days of culture with serum replacement media (SR), with BMP4 and with serum (FCS).  Data is from 5 
independent experiments.  The horizontal bars represent the mean and the standard error of the data set.  P 
values are shown where significant changes have occurred relative to day 0. 
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Figure 3.2.6 Representative differentiation panel flow cytometry plots 
These plots from experiment ES5 show changes in differentiation markers for BMP4 culture conditions 
only at day 3.  Day 0 data is included for comparison.  Numbers indicate the percentage of cells in each 
quadrant.  ES5 was chosen as a representative experiment as it best illustrated the general pattern of results. 
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3.2.2 Discussion  of  ES  differentiation results 
 
These initial experiments in the ES cell system were aimed at identifying trends that 
might be worth further investigation in both gene expression data and cell surface marker 
analysis resulting from the addition of BMP4.     
 
Despite previous data, these experiments did not provide any evidence that BMP4 has a 
role in increasing the number of Flk-1 expressing cells or in the up regulation of the 
expression of Runx1, Scl, Lmo2 and Gata2.  This may have been due to the concentration 
of BMP4 used in the experiments.  The concentration of 5ng/ml was chosen as this was 
the concentration that had been used in previous experiments for optimal haematopoietic 
differentiation (Park et al. 2004;Lugus et al. 2007).  However these papers used R1 ES 
cells and it is possible that CCE ES cells respond to different concentrations of BMP4.   
 
Another potential reason for the absence of any changes with the addition of BMP4 may 
have been the endogenous production of BMP4 by ES cells during differentiation.  
 
In these experiments the data suggested that serum provided optimal conditions for 
haematopoietic differentiation.  The increase in CD34 and Flk-1 positive cell populations 
was greatest under serum conditions.  There was also an increase in CD11b expressing 
cells at day 6 under serum conditions. 
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Overall there were few markers for differentiated cells even at day 6.  This is as expected 
as haematopoietic differentiation only begins between day 3 and day 6 (Park et al. 2004).   
 
In both the gene expression and flow cytometry analysis inconsistent and dramatic results 
were produced in individual experiments.  Lmo2 expression in experiment ES2 and CD19 
in experiment ES5 were dramatically increased over all culture conditions in contrast to 
the results achieved in the other experiments.  This demonstrates the variability of ES cell 
differentiation and probably reflects the disorganisation of the developmental processes 
which are occurring in the embryoid bodies.     
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3.3  Foetal liver haematopoietic stem cells:  the effect of BMP4 
 
Little is known about the haematopoietic environment of the foetal liver except that there 
is a large expansion of HSCs in the murine foetal liver between 12-15dpc.   
Myelosupportive stromal cell lines have been derived from the foetal liver.  However the 
molecular basis of HSC expansion in the foetal liver has yet to be identified.   
 
These experiments sought to investigate whether BMP4 might play a role in the foetal 
liver environment.  For this purpose foetal livers were obtained from 14.5dpc CD1 mouse 
embryos.  Cells were then dissociated and grown in culture for a period of 3 days.   
 
Culture conditions for growing foetal liver cells were optimised in serum and serum free 
conditions.  In order to investigate the effect of BMP4 it was essential to develop serum 
free conditions in which a defined set of growth and survival factors could be added.  In 
these primary cultures it proved difficult to develop serum free conditions which would 
allow sufficient survival after 3 days.  In RPMI medium there was significant cell death 
and insufficient cells remained for analysis.  However the use of CellGro medium with β-
mercaptoethanol improved viability (data not shown).  CellGro medium is a proprietary 
mixture based on DMEM with smaller amounts of RPMI and McCoys 5A medium 
containing minimal protein so as to facilitate serum free survival and experiments to 
determine the effects of added growth factors.   
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Cells were cultured serum free, with serum (10% FCS) and with BMP4 (10ng/ml) as 
described in Section 2.1.3.  The concentration of 10ng/ml was chosen as this is within the 
range of concentrations used in studies of haematopoietic development in murine systems 
(Johansson & Wiles 1995).  In experiments FL5 and FL6 BMP receptor culture 
conditions were added.   BMP receptor was added at a concentration of 200ng/ml to 
antagonise the effects of BMP4.  This concentration of BMP receptor has previously been 
shown to block the colony forming potential of CD34/c-kit
highcells derived from the 
AGM region (Marshall et al. 2007).   
 
Samples were taken at 0 and 3 days for PCR, flow cytometry and methylcellulose assays.  
As before the aim was to analyse whether there were any affects on gene expression and 
how this correlated with cell types present measured by cell surface marker analysis in 
flow cytometry and colony forming potential in methylcellulose assays.   
 
After 3 days there was some cell death under serum free and BMP4 culture conditions 
with cell viability at 60%.  Cells grown under serum conditions however had 80-90% 
viability.  3x10
6 cells were plated out at day 0 and under serum conditions there were 
similar cell numbers at day 3 but under BMP4 and serum free conditions there was on 
average 1.2x10
6 live cells at day 3. 
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3.3.1 PCR  results 
 
The expression of Runx1, Scl, Gata2 and Lmo2 was analysed.  Gapdh was used as an 
internal standard.  Gapdh has previously been used in foetal liver real time gene 
expression studies as an internal standard (Jochheim et al. 2004). 
 
Data from 4 independent experiments is shown in Figure 3.3.1 and in the PCR tables in 
Appendix 1.   
 
Under BMP4 conditions compared with day 0 values Runx1,  Scl, Gata2 and Lmo2 
expression remained at a similar level at day 3.  Also under serum free conditions the 
expression of Runx1,  Scl, Gata2 and  Lmo2  did not significantly change at day 3 
compared with day 0.  There were no significant differences between gene expression in 
day 3 serum free and BMP4 samples. 
 
The pattern of gene expression under serum conditions after 3 days was similar to that 
under serum free conditions.  There were no significant differences between day 3 serum 
and serum free samples. 
 
The BMP receptor experiments showed at day 3 when compared with the BMP4 
experiments a reduction in Runx1, Scl, Gata2 and Lmo2 expression (see Foetal liver PCR 
tables in Appendix 1).  The reduction in gene expression was below the levels of even the Chapter 3 
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serum free conditions in experiment FL5 indicating that BMP4 may be produced by the 
cells.  However further experiments are needed to clarify these results. 
 
The pattern of changes was similar in serum free, BMP4 and serum conditions.  This 
indicated that neither the addition of BMP4 nor the addition of serum changed the genetic 
response of these cells to being placed in culture.   
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Figure 3.3.1 Foetal liver PCR results  
Runx1, Scl, Gata2 and Lmo2 expression in unsorted foetal liver cells after 3 days in culture serum free (SF), 
with BMP4, with BMP receptor (BMPR) and in foetal calf serum (FCS).  These logarithmic graphs show 
expression values relative to Day 0. Results are from 4 independent experiments.  The horizontal bars 
represent the mean and the standard error of the data set.  P values are shown where significant changes 
have occurred relative to day 0. 
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3.3.2 Flow  Cytometry   
Data from 6 experiments is presented in the flow cytometry results tables in Appendix 1.   
 
3.3.2.1 Stem Cell Markers 
Figure 3.3.2 shows data from the stem cell marker analysis experiments and Figure 3.3.3 
shows flow cytometry plots from a representative experiment (FL5). 
 
The pattern of change in stem cell marker expression was the same regardless of culture 
conditions.   
 
At day 3 under BMP4 conditions there were similar levels of CD34, Sca-1, Flk-1 and C-
kit expressing cells relative to day 0.  Under serum free conditions there was an increase 
in Sca-1 expressing cells at day 3 relative to day 0 (P<0.05) although there were no 
statistically significant differences in stem cell marker expression between serum 
replacement and BMP4.    
 
There were no significant increases in stem cell marker levels under serum conditions at 
day 3 relative to day 0.  There were also no differences in comparison with the other 
culture conditions.      
 
Also the addition of BMP receptor did not make any notable differences to stem cell 
marker expression at day 3 compared with the other culture conditions (see Foetal liver 
flow cytometry tables in Appendix 1). Chapter 3 
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The similarities observed in stem cell marker expression after 3 days in serum free, 
BMP4 and serum culture conditions suggests that the stem cells had the same response to 
being placed in culture regardless of culture condition.   
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Figure 3.3.2 Flow cytometry analysis of stem cell markers  
Stem cell markers CD34, Sca-1, C-kit and Flk expressed on unsorted foetal liver cells at day 0 and after 3 
days of culture without serum (SF), with BMP4, with BMP receptor (BMPR) and with serum (FCS).  
Results are from 6 independent experiments.  The horizontal bars represent the mean and the standard error 
of the data set.  P values are shown where significant changes have occurred relative to day 0. 
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Figure 3.3.3 Representative stem cell panel flow cytometry plots 
Flow cytometry plots from experiment FL5 showing changes in stem cell markers for BMP4 culture 
conditions only at day 3.  Day 0 data is included for comparison.  Numbers indicate the percentage of cells 
in each quadrant.  FL5 was chosen as a representative experiment as it best illustrated the general pattern of 
results. Chapter 3 
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3.3.2.2 Differentiation Markers 
 
Figure 3.3.4 shows data from the differentiation marker analysis experiments and Figure 
3.3.5 shows flow cytometry plots from a representative experiment (FL5). 
 
There were no significant changes in the levels of CD45, Ter119 and CD19 after 3 days 
relative to day 0 under any of the culture conditions.  However there were significant 
increases in CD11b expressing cells relative to day 0 under serum free and serum 
conditions (P<0.05).  Increases in CD11b expressing cells suggest that myeloid 
differentiation may be occurring.   
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Figure 3.3.4 Flow cytometry analysis of differentiation markers 
Differentiation markers: CD45, Ter119, CD11b and CD19  expressed on unsorted foetal liver cells at day 0 
and after 3 days of culture without serum (SF), with BMP4, with BMP receptor (BMPR) and with serum 
(FCS).  Results are from 6 independent experiments.  The horizontal bars represent the mean and the 
standard error of the data set.  P values are shown where significant changes have occurred relative to day 
0. 
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Figure 3.3.5 Representative differentiation panel flow cytometry plots 
Flow cytometry plots from experiment FL5 showing changes in differentiation markers for BMP4 culture 
conditions only at day 3.  Day 0 data is included for comparison.  Numbers indicate the percentage of cells 
in each quadrant.  FL5 was chosen as a representative experiment as it best illustrated the general pattern of 
results. 
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3.3.3  Colony Forming Unit Assays 
 
Methylcellulose colony assays as described in Section 1.1.3.2.1 can be used to determine 
the number of multipotent and lineage restricted progenitors present in a sample.  In this 
experiment samples were taken at day 0 and after culturing cells for 3 days in serum free, 
BMP4, BMP receptor and serum culture conditions.  These cell samples were then placed 
in methylcellulose culture as described in Section 2.2.3.1.  After 14 days visible colonies 
were counted and classified based on the mature cells present within the colony.   
 
Colonies only formed consistently at day 3 from serum cultured samples (see Figure 3.3.6 
and Table 3.3.1).  At day 3 there were fewer colonies than at day 0.  This suggests both 
serum free and BMP4 culture conditions either did not support the survival of progenitors 
or had caused differentiation of progenitors. 
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Figure 3.3.6 Methylcellulose colony assay results   
Bar chart illustrating total number of haematopoietic colonies from samples of 1500 cells taken at Day 0 
and after 3 days in culture serum free, with BMP4 and in foetal calf serum.  Methylcellulose cultures were 
incubated for 2 weeks.   Chapter 3 
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FL3  Total No. of colonies  GM colonies  M Colonies 
Day 0  6 2 4 
Day 3 SF  0 0 0 
Day 3 BMP4  3 3 0 
Day 3 FCS  1 1 0 
 
FL5  Total No. of colonies  GM colonies  M Colonies 
Day 0  11 11 0 
Day 3 SF  0 0 0 
Day 3 BMP4  0 0 0 
Day 3 BMPR  0 0 0 
Day 3 FCS  4 4 0 
 
FL6  Total No. of colonies  GM colonies  M Colonies 
Day 0  9 9 0 
Day 3 SF  0 0 0 
Day 3 BMP4  0 0 0 
Day 3 BMPR  0 0 0 
Day 3 FCS  1 1 0 
 
Table 3.3.1 Methylcellulose assay tables 
Tables show the total number of colonies and the constituent types of haematopoietic colonies obtained 
under each culture condition in 3 independent experiments. GM = Granulocyte macrophage and M = 
Macrophage  
 
3.3.3.1 Cytospins 
 
Cytospins allowed the type of cells e.g. granulocyte-macrophage present in the different 
colonies present to be determined.   
 
Two different types of colony were identified in methylcellulose cultures.  Colonies were 
identified by morphology as granulocyte macrophage colonies or macrophage colonies 
(Figure 3.3.7).  Samples of the two types of colony were taken to confirm their identity.  
A cytospin was performed after which cells were stained using May Grumwald Giemsa 
stain as described in Section 2.2.3.3.  Under a light microscope the cells were examined Chapter 3 
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(Figure 3.3.7).  The granulocyte macrophage colonies were found to contain immature 
macrophages and granulocytes whilst the macrophage colony contained more mature 
macrophages.   
A B
CD
E F
 
 
Figure 3.3.7 Colony micrographs and Cytospin Analysis   
Micrographs showing granulocyte macrophage colonies (A and B) and the mature macrophage colony (C 
and D) obtained in methylcellulose cultures.  Micrographs are at x4 (A and C) and x10  (B and D) 
magnification.  Micrographs E and F (x20 magnification) show cells stained using May Grumwald Giemsa.  
stain from granulocyte-macrophage colonies (E) and mature macrophage colonies (F). 
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3.3.4 Discussion 
The results in both gene expression and flow cytometry experiments showed the same 
pattern of change in serum free, BMP4 and serum conditions.  The changes in gene 
expression and cell surface markers therefore reflect the response of the cells to culture ex 
vivo.   
 
Cell death particularly under BMP4 and serum free conditions was high.  Haematopoietic 
progenitors may either have died or have differentiated after 3 days and this is reflected in 
the results of the methylcellulose assays.  If further experiments were to be performed in 
this system it would be necessary to further improve cell survival under serum free 
conditions.   
 
There was variability in the results.  This may reflect cell death and variations in the 
initial population.   
 
There was some evidence suggesting that BMP receptor culture conditions reduced 
expression of Runx1, Scl, Gata2 and Lmo2.  These results suggest that the cells were 
producing BMP4 and BMP4 may have a role in inducing these genes.  Future 
experiments should titrate the effects of BMP receptor to verify these results. 
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3.4  Bone Marrow Haematopoietic Stem Cells: The effect of 
BMP4 
 
 
The aim of these experiments was to investigate the effect of BMP4 on mouse bone 
marrow derived HSCs.  Previous research has investigated the role of BMP4 on mouse 
bone marrow derived haematopoietic progenitors.  However the results of these 
experiments were conflicting. One experiment suggested BMP4 caused an increase in 
erythroid colony forming potential whilst the other experiment provided evidence 
contradicting this (Fuchs et al. 2002;Maguer-Satta et al. 2003).  In human bone marrow 
derived HSC culture, BMP4 is said to increase HSC survival and engraftment of NOD-
SCID mice (Bhatia et al. 1999).  These experiments sought to characterise the effects of 
BMP4 and investigate whether these effects are mediated by an up regulation of the 
developmentally important genes: Runx1, Scl, Gata2 and Lmo2.   
 
Bone marrow was collected from the femurs of CD1 mice.  It was necessary to find 
serum free conditions which maintained adequate survival.  Initially RPMI medium was 
used however the viability of cells after 3 days was insufficient.  The use of CellGro 
medium with β-mercaptoethanol improved viability.   
 
The experimental set up was the same as with the foetal liver cells.  Briefly, cells were 
cultured serum free, with BMP4 and with serum (10% FCS).  BMP4 was added at 
10ng/ml as this is within the range of concentrations used in studies of haematopoietic Chapter 3 
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development in murine systems (Johansson & Wiles 1995).  In experiments BM6 and 
BM7 a BMP receptor culture condition was added.  BMP receptor was added at 
200ng/ml.  This concentration was the same as used in the foetal liver studies. 
 
Although there was 90% viability at day 0, there was between 40-50% viability at day 3 
in BMP4 and serum free cultured samples.  However in serum cultured samples the 
viability at day 3 was 70-80%.  In order to increase cell survival TPO and IGF1 growth 
factors were added into serum free and BMP4 culture conditions.  As a result cell 
viability after 3 days of culture increased to between 70-80% in BMP4 and serum free 
cultured samples.  The cell numbers at day 3 were similar to those at day 0. 
 
Samples were taken for analysis by PCR, flow cytometry and colony forming potential at 
day 0 and day 3. 
 
3.4.1 PCR  Results 
Real time PCR was carried out to determine expression of Runx1, Scl, Gata2 and Lmo2.  
Gapdh was used as an internal standard.  Gapdh has previously been used as an internal 
standard in bone marrow real time gene expression studies (Gallagher et al. 2003).  Data 
from 3 independent experiments is shown in Figure 3.4.1 and the PCR tables in Appendix 
1.   
 
Under serum free conditions after 3 days there were no significant changes in Runx1, Scl 
Gata2 or Lmo2 expression.  Similarly under BMP4, BMP receptor and serum conditions Chapter 3 
 
  131
there were no significant changes in Runx1, Scl, Gata2 or Lmo2 expression.  There were 
no statistically significant differences between culture conditions.  The genetic response 
of cells was therefore the same regardless of culture condition. 
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Figure 3.4.1 Bone Marrow PCR results  
Runx1, Scl, Gata2 and Lmo2 expression in unsorted bone marrow cells after 3 days in culture serum free 
(SF), with BMP4, with BMP receptor (BMPR) and in foetal calf serum (FCS).  These logarithmic graphs 
show expression values relative to day 0. Data shown is from 3 independent experiments.  The horizontal 
bars represent the mean and the standard error of the data set.  P values are shown where significant 
changes have occurred relative to day 0. 
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3.4.2 Flow  Cytometry 
 
Data from 3 experiments is presented in the flow cytometry results tables in Appendix 1.   
 
3.4.2.1 Stem Cell Markers 
 
Figure 3.4.2 shows results for the stem cell marker analysis experiments and Figure 3.4.3 
shows flow cytometry plots from a representative experiment (BM6). 
 
Under serum free conditions there were increases after 3 days in Sca-1 expressing cells 
(P<0.05) and C-kit expressing cells (P<0.05).  The levels of CD34 and Flk-1 expressing 
cells however stayed about the same after 3 days. 
 
Under BMP4 conditions the same pattern was seen with increases after 3 days in Sca-1 
expressing cells (P<0.05) and C-kit expressing cells (P<0.05).  However CD34 and Flk-1 
expressing cells were at similar levels to those seen in serum free conditions after 3 days.   
 
There were no significant differences at day 3 between serum replacement and BMP4 
cultured cells.  The increase in Sca-1 and C-kit expressing cells may suggest that there 
was an expansion of the HSC population in response to the serum free conditions.   
 
With the addition of BMP receptor in experiment BM6, a reduction in CD34 and C-kit 
expressing cells occurred at day 3 (see Bone marrow flow cytometry results tables in Chapter 3 
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Appendix 1).  Further experiments are required to see if this result can be repeated.   
However this result may provide an initial indication that BMP4 promotes the expression 
of stem cell markers CD34 and C-kit.  
 
There were no changes seen in stem cell markers after 3 days under serum conditions.  
Levels of CD34, Sca-1, Flk-1 and C-kit all remained at similar levels at day 3 relative to 
day 0.   
 
 Chapter 3 
 
  134
CD34
Day 0
Day 3 SF
Day 3 BMP4
Day 3 BMPR
Day 3 FCS
0
20
40
60
Sca1
Day 0
Day 3 SF
Day 3 BMP4
Day 3 BMPR
Day 3 FCS
0
10
20
30
40
50
Flk-1
Day 0
Day 3 SF
Day 3 BMP4
Day 3 BMPR
Day 3 FCS
0
5
10
15
C-kit
Day 0
Day 3 SF
Day 3 BMP4
Day 3 BMPR
Day 3 FCS
0
20
40
60
80
Sample age and culture condition
%
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
P<0.05
P<0.05
P<0.05
P<0.05
 
Figure 3.4.2 Flow cytometry analysis of stem cell markers  
Stem cell markers: CD34, Sca1, C-kit and Flk-1 expressed on unsorted bone marrow cells at day 0 and after 
3 days of culture serum free (SF), with BMP4, with BMP receptor (BMPR) and with serum (FCS).  Results 
are from 3 independent experiments.  The horizontal bars represent the mean and the standard error of the 
data set.  P values are shown where significant changes have occurred relative to day 0. 
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Figure 3.4.3 Representative stem cell panel flow cytometry plots 
Flow cytometry plots from experiment BM6 showing changes in stem cell markers for BMP4 culture 
conditions only at day 3.  Day 0 data is included for comparison.  Numbers indicate the percentage of cells 
in each quadrant.  BM6 was chosen as a representative experiment as it best illustrated the general pattern 
of results. Chapter 3 
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3.4.2.2 Differentiation Markers 
 
Figure 3.4.4 shows results for the differentiation marker analysis experiments and Figure 
3.4.5 shows the flow cytometry plots from a representative experiment (BM6). 
 
Under serum free, BMP4 and BMP receptor conditions the same pattern of changes in 
differentiation markers was seen.  There was a decrease in Ter119 expressing cells over 3 
days (P<0.05).  Serum free conditions may have been inadequate to support the survival 
of Ter119 expressing cells.  CD45, CD11b and CD19 expressing cells however remained 
at similar levels.   
 
There were no statistical differences between serum free and BMP4 conditions.  BMP4 
therefore did not increase the differentiation of any particular lineage after 3 days in 
culture.   
 
Cells grown under serum conditions had similar levels of CD45, CD11b, Ter119 and 
CD19 expressing cells after 3 days relative to day 0.   
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Figure 3.4.4 Flow cytometric analysis of differentiation markers 
Differentiation markers: CD45, Ter119, CD11b and CD19 on unsorted bone marrow cells at day 0 and after 
3 days of culture serum free (SF), with BMP4, with BMP receptor (BMPR) and with serum (FCS).  Results 
are from 3 independent experiments.  The horizontal bars represent the mean and the standard error of the 
data set.  P values are shown where significant changes have occurred relative to day 0. 
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Figure 3.4.5 Representative differentiation panel flow cytometry plots   
Flow cytometry plots from experiment BM6 showing changes in differentiation markers for BMP4 culture 
conditions only at day 3.  Day 0 data is included for comparison.  Numbers indicate the percentage of cells 
in each quadrant.  BM6 was chosen as a representative experiment as it best illustrated the general pattern 
of results. 
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3.4.3  CFU assays and Cytospins 
3.4.3.1 CFU assays 
 
Samples were taken at day 0 and day 3 from each culture condition and were placed in 
methylcellulose culture as described in Section 2.2.3.1.   
  
There were large increases in colonies under serum free and BMP4 conditions after 3 
days (Figure 3.4.7).  The addition of BMP4 to this mixture from the trends observed in 
experiments BM5 and BM6 did not cause a significant change in the numbers of 
haematopoietic progenitors.  
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Figure 3.4.6 Methylcellulose colony results 
Micrographs illustrating the dense colony formation obtained in methylcellulose cultures from Day 3 
Serum Free and BMP4 samples after 2 weeks incubation.  Micrographs are at x4 (A) and x10 (B) 
magnification.  Bar chart (C) shows total number of haematopoietic colonies from samples of 1500 cells 
taken at Day 0 and after 3 days in culture serum free, with BMP4 and in foetal calf serum.  BMP receptor 
culture conditions were added in BM6. 
 
3.4.3.2 Cytospins  
Two different types of colonies were present in methylcellulose cultures (Figure 3.4.8).  
The majority were identified visually as granulocyte macrophage colonies.  Another type 
of colony was also seen.  To confirm the nature of these two colony types cytospins were Chapter 3 
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performed and the cells were stained with May Grumwald Giemsa stain as described in 
Section 2.2.3.3.  Under a light microscope the cells were examined (Figure 3.4.8).  The 
colonies initially identified as granulocyte macrophage colonies actually contained 
macrophages and earlier cells including myeloblasts and erythroblasts.  The other type of 
colony contained mature macrophages.   
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Figure 3.4.7 Colony micrographs and cytospin analysis  
Micrographs showing granulocyte macrophage colonies (A and B) and the mature macrophage colony (C 
and D) obtained in methylcellulose cultures.  Micrographs are at x4 (A and C) and x10  (B and D) 
magnification.  Micrographs (x20 magnification) showing cells stained using May Grumwald Giemsa stain 
from granulocyte-macrophage colonies (E) and the macrophage colonies (F). Chapter 3 
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3.4.4 Discussion 
 
Similar patterns were seen in PCR and flow cytometry in serum free and BMP4 
conditions.  There was a trend for an increase in Sca-1 and C-kit progenitors above day 0 
levels under serum free and BMP4 conditions.   
 
Further BMP receptor experiments are required to confirm if BMP receptor does reduce 
levels of CD34 and C-kit expressing cells as seen in BM6.  BMP receptor did not show 
any effects in PCR analysis.  This may have been due to the concentration of BMP 
receptor being too low.  A titration of BMP receptor concentrations should be performed.   
 
There was variability in the results probably due to variability in the bone marrow 
obtained which can be seen in the day 0 cell surface markers.  In addition endogenous 
BMP4 produced by these variable populations of cells may have interfered with analysis.  
This may account for the similarities observed in the serum free and BMP4 culture 
conditions.   
 
In experiment BM5 experiment there were large increases in Runx1, Scl, Gata2 and Lmo2 
expression with the addition of BMP4.  One distinguishing feature from flow cytometry 
was a high percentage of CD34 expressing cells in the initial population (20%).   Clearly 
in this experiment a BMP4 responsive population was collected which was not present in 
the other repeat experiments.  This illustrates the difficulty in drawing conclusions caused 
by the variability in the initial cell population.   Chapter 3 
 
  143
3.5  Investigating the effect of BMP4 on a CD34 C-kit sorted 
bone marrow derived haematopoietic cell population 
 
The viability of bone marrow cells remained high after 3 days with the addition of IGF1 
and TPO. However there were concerns that the inconsistent initial population collected 
was causing variability in results.  In order to resolve this, a specific cell population was 
sorted from collected bone marrow.    The CD34 C-kit positive population was chosen as 
results from previous BMP receptor experiments had indicated that this population might 
be responsive to BMP4.   
 
Bone marrow was collected from CD1 mice and then sorted for CD34 C-kit positive cells 
(Figure 3.5.1).  The CD34 positive cells were also collected.  In each experiment 
approximately 800,000 CD34 C-kit positive cells were collected and 500,000 CD34 
positive cells were collected.  These cells, along with S17 stromal cells which were 
included as a control, were then cultured in serum free conditions (with TPO and IGF1), 
with BMP4 (10ng/ml) and with BMP receptor (200ng/ml).   
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CD34 C-kit +ve
CD34+ve
 
Figure 3.5.1 Cell sorting of adult murine bone marrow 
FACS plot shows the populations of CD34 +ve and CD34 C-kit +ve cells that were sorted from adult 
murine bone marrow.   
 
Cells were collected for analysis after 3 days by flow cytometry for CD34 C-kit positive 
cells and by PCR for Gata2 expression only.  This was because experiment BM5 had 
previously indicated that BMP4 may up regulate Gata2 expression.   
 
Cell survival was poor (Table 3.5.1).  Unsorted bone marrow cells may contain cell 
populations that secrete growth factors and provide cell-cell interactions that support the 
survival of haematopoietic cells.  The absence of these populations may have caused the 
increased levels of cell death. 
 
At day 3 in 
CD34
+C-kit
+ cells 
Number of live 
cells 
 
Viability at day 3 
 
Experiment 1  4.0x10
5 69% 
Experiment 2  3.7x10
5 67% 
Experiment 3  4.8x10
5 72% 
 
Table 3.5.1 Cell survival table Cell survival at day 3 in CD34 C-kit positive cells in all 3 experiments. 
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In CD34 C-kit positive sorted cells there was a large reduction in CD34 C-kit expressing 
cells to between 20-30% of initial levels after 3 days (P<0.05, Figure 3.5.2 and Table 
3.5.2).  This occurred under all culture conditions.  However the CD34 sorted cells, 
which were at day 0 CD34 C-kit negative, showed an increase in CD34 C-kit positive 
cells of between 20-30% to similar levels to that occurring in the CD34 C-kit positive 
cultured cells.  This pattern of change occurred regardless of culture condition.   
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Figure 3.5.2 Effect of BMP4 on a CD34 C-kit expressing cells in sorted populations 
CD34 +ve, CD34 C-kit +ve and S17 stromal cells were sorted and cultured.  Graph shows the percentage of 
CD34 C-kit positive cells in each population after 3 days of culture under serum free, BMP4 and BMP 
receptor conditions.  Data represents the average data from 3 experiments.  Error bars represent the 
standard error.   * indicates significant change in percentage of CD34 Ckit +ve cells relative to day 0 at 
P<0.05.   At day 0 there was 100% CD34 C-kit +ve cells in the CD34+ C-kit population and 0% CD34 C-
kit +ve cells in the CD34 population. 
0 0 0 30.41 19.52 20.81 22.21 31.32 19.34 AV
0.09 0.26 0.08 0.02 0.03 0.01 P
0 0 0 23.5 1.92 14.71 26.03 36.49 31.67 EXP 3
0 0 0 50.06 43.73 33.77 23.98 34.1 10.51 EXP 2
0 0 0 17.68 12.9 13.94 16.62 23.37 15.83 EXP 1
BMPR BMP4 SF BMPR BMP4 SF BMPR BMP4 SF
S17 CD34+ CD34 Ckit+
 
Table 3.5.2  Effect of BMP4 on a CD34 C-kit expressing cells in sorted populations 
Table shows the data for each experiment and the overall average.  P values indicate statistical change 
relative to day 0.   Chapter 3 
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Gata2 expression was dramatically reduced after 3 days in the CD34 C-kit positive 
population across all culture conditions (P<0.05, Figure 3.5.3 and Table 3.5.3).  A smaller 
reduction in Gata2 expression occurred in CD34 population but this again occurred under 
all culture conditions.   
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Figure 3.5.3 Effect of BMP4 on Gata2 expression in sorted bone marrow populations  
This is a logarithmic graph showing fold change in Gata2 expression after 3 days in each sorted population.  
Data represents the average data from 3 experiments.  Error bars represent the standard error.  * indicates 
results significant at P<0.05.  
 
0 0 0 0.14 0.40 0.28 0.10 0.09 0.06 AV
0.01 0.21 0.08 0.08 0.001 0.001 P
0 0 0 0.13 0.12 0.11 0.08 0.08 0.05 EXP 3
0 0 0 0 0.02 0.03 0.08 0.05 0.01 EXP 2
0 0 0 0.3 1.05 0.71 0.13 0.13 0.12 EXP 1
BMPR BMP4 SF BMPR BMP4 SF BMPR BMP4 SF
S17 CD34 CD34 ckit
 
Table 3.5.3 Effect of BMP4 on Gata2 expression in sorted bone marrow populations  
Table shows the data for each experiment and the overall average.  P values indicate statistical change 
relative to day 0.   
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The general pattern of change in CD34 C-kit positive cells and Gata2 expression seems 
to reflect the response of cells to being placed in culture.  Because cell survival was poor 
it is not possible to conclude whether BMP4 had any role to play in expanding a CD34 C-
kit positive population or in up regulating Gata2 expression.   
 
 
 
 
3.6  Comparison of ES cell, Foetal Liver and Bone Marrow 
derived haematopoietic populations  
 
A comparison of the haematopoietic populations derived from ES cells was made based 
on the PCR and flow cytometry data that was collected.   
 
3.6.1 Gene  Expression 
 
Runx1, Scl, Gata2 and Lmo2 have all been shown to be essential to the development of 
the haematopoietic system.  However there is little data on the relevance of these genes to 
the more mature haematopoietic populations of the foetal liver and bone marrow.  Data 
from conditional gene targeting of Scl (Mikkola et al. 2003) and Runx1 (Ichikawa et al. 
2004) suggests that these genes are dispensable for adult haematopoietic function.   
 
Previous experiments have shown that haematopoietic populations are formed in ES cells 
at day 6 under serum conditions.  PCR data for day 0 bone marrow and foetal liver 
populations were therefore standardised against the haematopoietic population from ES Chapter 3 
 
  148
cells at day 6 under serum conditions.  The level of gene expression was then compared 
(Figure 3.6.1).   
 
The expression of Scl and Lmo2 was at dramatically higher levels in both the foetal liver 
and bone marrow populations than in ES cells (P<0.05).  Furthermore Runx1 expression 
was also at higher levels in foetal liver and bone marrow populations than in ES cells 
(P<0.05).  Gata2 expression was however similar in all 3 populations.   
 
The levels of expression of Runx1, Scl, Gata2 and Lmo2 were similar in both the foetal 
liver and bone marrow populations.   
 
Although a major role for these genes has been demonstrated in early development 
clearly they are expressed in the case of Scl, Lmo2 and Runx1 at higher levels in more 
mature populations.  It seems likely therefore that these genes continue to have an 
important function at later stages of development and in the adult. 
 
SCL and LMO2 are postulated to act in a complex with GATA factors in early 
development.  The expression of both Scl and Lmo2 at similarly high levels may suggest 
that these genes continue to act in a complex at later developmental stages and in the 
adult.   Chapter 3 
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Figure 3.6.1 Gene expression comparison  
A comparison of Runx1, Scl, Gata2 and Lmo2 gene expression in ES cells differentiated to day 6 in serum 
and day 0 cells from 14.5 dpc foetal livers and adult bone marrow.  The results represent the average of the 
data collected.  * indicates a statistically significant difference in gene expression relative to that in the ES 
cell population at P<0.05. 
 
 
3.6.2 Stem  Cell  Markers 
 
Bone marrow and foetal liver flow cytometry data show some differences in the initial 
populations (Figure 3.6.2).  There were more Sca-1 positive cells in bone marrow than in 
foetal liver (P<0.05).  However there were higher levels of C-kit expressing cells in the 
foetal liver (P<0.05).   
 
ES cells after 6 days of differentiation in serum expresses C-kit at higher levels than in 
the bone marrow (P<0.05). 
 
These stem cell markers have been shown to mark the haematopoietic stem cell (see 
section 1.1) and it is known that at different developmental stages these markers are Chapter 3 
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expressed at different levels.  This may correlate with whether they are mostly quiescent 
as would be expected in the bone marrow or self renewing as would be expected in the 
foetal liver.  It might therefore be hypothesised that the higher levels of C-kit expression 
found on foetal liver cells reflects HSC expansion and higher levels of Sca-1 found on 
bone marrow cells reflects HSC quiescence.   
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Figure 3.6.2 Stem cell surface marker comparison  
A comparison of cells expressing stem cell markers in ES cells differentiated to day 6 in serum and day 0 
cells from 14.5 dpc foetal livers and bone marrow.  The results represent the average of the data collected.  
Statistically significant differences at P<0.05 are marked with *.   C-kit is expressed at higher levels in ES 
cells after 6 days of differentiation and foetal liver cells than in the bone marrow.  Sca-1 is expressed at 
higher levels in the bone marrow relative to the foetal liver. 
 
3.6.3 Differentiation  Markers 
 
There were much higher levels of Ter119 expressing cells in the foetal liver than in the 
bone marrow (P<0.05, Figure 3.6.3).  There were lower levels of CD11b expressing cells 
at day 0 in the foetal liver compared with the bone marrow (P<0.05).  CD19 cells were 
present at higher levels at day 0 in bone marrow compared with foetal liver (P<0.05).   Chapter 3 
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These differences in the presence of differentiated cells at day 0 may reflect that in the 
foetal liver environment haematopoietic stem cells are more prone to erythroid 
differentiation compared with the bone marrow environment where the environment 
favours myeloid and lymphoid differentiation.  This may reflect differing priorities in the 
foetus where oxygenation is higher priority compared to the adult where defence 
becomes more important.   
 
There were much lower levels of differentiated cells in the ES cells which was not 
surprising at this early developmental stage. 
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Figure 3.6.3 Differentiation surface marker comparison  
A comparison of cells expressing differentiation markers in ES cells differentiated to day 6 in serum and 
day 0 cells from 14.5 dpc foetal livers and bone marrow.  The results represent the average of the data 
collected.  Statistically significant differences at P<0.05 are marked with *.  There were more Ter119 cells 
in the foetal liver than in the bone marrow.  There were more CD11b and CD19 cells in the bone marrow 
than in the foetal liver. 
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3.6.4 Discussion 
 
Conditional gene targeting studies show that in adult Scl deletion mutants there is 
impaired erythroid and megakaryocytic differentiation (Mikkola et al. 2003) and in adult 
Runx1 deletion mutant there is impaired megakaryocytic maturation and T and B 
lymphocyte differentiation (Ichikawa et al. 2004).  The differences observed in the 
expression of these genes may therefore reflect the presence of more differentiated cells.  
Compared to the levels of differentiated cells at day 6 in ES cells, there were much higher 
levels of differentiated cells in the foetal liver and bone marrow.  However between the 
foetal liver and bone marrow the patterns and levels of gene expression were very similar 
not reflecting differences in the types of differentiated cells present in the two 
populations.   
 
These results may alternatively reflect higher levels of Runx1, Scl and Lmo2 expression 
in the HSCs of these more mature populations.  The reason few effects were seen on adult 
haematopoietic function in conditional gene mutants of Runx1 and Scl maybe because 
other proteins with overlapping function can take over.   
 
 
 
 Chapter 3 
 
  153
3.7  Cell cycle analysis of C-kit positive and Sca-1 positive bone 
marrow cells 
 
Day 0 analysis showed that foetal liver cells expressed C-kit at higher levels than in the 
bone marrow. Sca-1 however was expressed at higher levels in the bone marrow than in 
the foetal liver.  Given that the foetal liver environment is one of haematopoietic 
expansion (Lessard, Faubert, & Sauvageau 1994;Takeuchi et al. 2002) it was 
hypothesised that C-kit was expressed at higher levels on dividing cells.  In the bone 
marrow most bone marrow HSCs are known to be quiescent (Szilvassy et al. 1990) and 
so it was hypothesised that Sca-1 was expressed on quiescent cells.   
 
In order to investigate this fresh bone marrow isolated from CD1 mice was stained for 
Sca-1 and C-kit.  These cells were then stained with PI and the cell cycle status of the 
Sca-1 and C-kit single positive cells was analysed.   
 
PI fluoresces on binding double stranded DNA.  The DNA content of cells can therefore 
be determined. Thus quiescent cells and cells entering the cycle (G0/G1 phase) can be 
distinguished from cells preparing for cell division (in S phase) which will have a greater 
DNA content.  Furthermore cells about to undergo or undergoing mitosis (G2/M phase) 
can be distinguished as they contain double the normal quantity of DNA. 
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The C-kit population was found to have higher levels of both cells in S phase (P<0.01) 
and G2/M phase (P<0.01, see Figure 3.7.1).  The Sca-1 population however had higher 
levels of cells G0/G1 phase (P<0.01).   
 
Despite these clear differences there were still a large number of C-kit positive cells that 
were in G0/G1 phase.  It would be interesting to analyse whether these cells are preparing 
for cell division. 
 
Experiments by Till and McCulloch made it possible to identify HSCs based on the 
expression of C-kit, Sca-1 and lineage negative cell surface markers (Worton, 
McCulloch, & Till 1969;van Bekkum et al. 1979).  This experiment supports the 
hypothesis that C-kit and Sca-1 expression is an indicator of cell cycle status.  C-kit is 
present on dividing cells whereas Sca-1 is present on quiescent cells.   
 
Previous data has found embryonic HSCs express low levels of Sca-1 (de Bruijn et al. 
2002) and high levels of C-kit (Sanchez et al. 1996).  In these experiments ES cells at day 
6 of differentiation and foetal liver cells at 14.5 dpc were both found to contain a high 
level of C-kit cells relative to that seen in bone marrow.  In the light of these findings this 
reflects the high level of cell division that is taking place at these early developmental 
stages.  Sca-1 levels were higher in the bone marrow than in the foetal liver.   This 
reflects the comparative quiescence of the bone marrow cells. 
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Figure 3.7.1 Cell cycle analysis in bone marrow C-kit and Sca-1 populations   
A: The percentage of cells in G1/0, S and G2/M phase of the cell cycle in Sca1 and C-kit populations.  
Results are based on the average of 6 experiments.  Error bars represent the standard error.  Statistically 
significant results when comparing Sca1 and C-kit populations are marked with *.  B:  Results from a 
representative experiment showing the gating of Sca-1 and C-kit populations.  Propidium Iodide staining 
for cell cycle analysis is shown for each population.   
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3.8  General Discussion  
 
In these initial experiments much time was spent developing serum free cultures that 
contained minimal added growth factors.  Following this, optimisation of the methods 
used for sample analysis was necessary.  In the end several interesting observations were 
made from these experiments. 
 
3.8.1 Comparison  of  Haematopoietic Populations 
 
The simultaneous use of ES cells, foetal liver cells and bone marrow cells gave rise to an 
opportunity to compare haematopoietic populations at different developmental stages.   
Runx1, Scl and Lmo2 which have critical roles in development were all found to have 
much higher levels of expression in the more mature populations of the foetal liver and 
bone marrow.  This probably provides the best indication from the data obtained that 
these genes do play an important role in haematopoiesis at later developmental stages.   
A comparison of stem cell markers found that there were higher levels of C-kit positive 
cells in the foetal liver and higher levels of Sca-1 positive cells in the bone marrow.  
Further investigation found that this correlated to cell cycle status with C-kit expressed on 
dividing cells and Sca-1 expressed on quiescent cells.  This result sheds light on the role 
of these cell surface markers which since the first discovery of HSCs have been used to 
separate and identify them.   
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3.8.2  The effect of BMP4 
 
The main aim of these experiments was to investigate the effect of BMP4 on 
haematopoietic populations at 3 stages of haematopoietic development.  
 
In ES cell differentiation there was no evidence of BMP4 specific effects on the 
expression of Runx1, Scl, Gata2 and Lmo2 or any of the stem cell and differentiation 
markers studied.  Given previous evidence indicating that BMP4 might play a role in the 
expression of these genes it may have been that the concentration of BMP4 was not 
optimal to produce these effects.    
 
In foetal liver experiments there was no evidence of any BMP4 specific effects in PCR, 
flow cytometry and colony assays.  There was a significant level of cell death in serum 
free conditions.  The inadequate survival of cells may have been the reason that no effect 
was seen with the addition of BMP4.  Further optimisation of serum free conditions 
therefore was needed.  There was some evidence that BMP receptor did reduce the 
expression of all four genes studied.  This may reflect that the foetal liver cells 
themselves were secreting BMP4.   
 
In bone marrow experiments cell survival with the addition of TPO and IGF1 was much 
improved.   Despite this there was still inconsistency in results which was thought to 
result from the variability of the initial population. One BMP receptor experiment showed 
a CD34 C-kit positive population might be BMP4 responsive.  Based on this, in order to Chapter 3 
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reduce variability, experiments were conducted on a CD34 C-kit population that was 
sorted from the bone marrow.  However cell survival was poor and no BMP4 specific 
effects were observed. 
 
3.8.3 The  next  step 
 
In the case of foetal liver cultures further optimisation of serum free conditions to 
improve cell survival was required in order that meaningful experiments could be 
conducted into the effects of BMP4.  However even if this was achieved there were 
concerns about the variability in the initial populations and the problems this caused in 
conducting meaningful repeat experiments.  One solution to this problem was to sort cell 
populations.  Despite good cell survival in the unsorted bone marrow cultures, the culture 
of sorted populations proved significantly more difficult.   
 
In order to continue experiments on bone marrow and foetal liver it would have been 
necessary to sort populations and then optimise culture conditions to allow cell survival.  
Given the results from experiments that had been carried out, there was no clear evidence 
of a population in either foetal liver or bone marrow that was BMP4 responsive.   
 
However data from other studies had begun to provide evidence demonstrating a role for 
BMP4 in haematopoietic development.   Furthermore it was known that the genes Runx1, 
Scl, Gata2 and Lmo2 had roles critical to haematopoietic development.  It was therefore Chapter 3 
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decided to focus future experiments on whether BMP4 plays a role in up regulating these 
genes in early development using the ES cell differentiation model.   
   
 
 
 
 
 
 
 
 
 
 
 
  
160 
Chapter  4  Titration of BMP4 in ES cell 
haematopoietic differentiation 
 
4.1   Introduction 
 
Results from initial experiments in ES cells had shown no clear evidence of a BMP4 
specific effect in either the PCR or flow cytometry studies that had been carried out. This 
was despite data from previous studies showing that BMP4 up regulated Flk-1 and in 
combination with VEGF also up regulated SCL expression (Park et al. 2004).  This may 
have been due to the concentration not being optimal to produce these effects.  In order to 
find the optimal concentration a titration of the effects of BMP4 on Runx1, Scl, Gata2 
and Lmo2 was performed.   
 
In foetal liver experiments there was also no effect observed with the addition of BMP4.  
However with the addition of BMP receptor there was a reduction in the expression of all 
four genes studied.  This implied that foetal liver cells were secreting BMP4.  In order to 
allow comparison of serum free and BMP4 conditions it is necessary that serum free 
conditions are BMP4 free.  There were concerns that ES cells, which are known to 
produce BMP4 as a mesoderm patterning factor, might also secrete BMP4.  In order to 
address this, experiments were conducted to analyse the gene expression of BMP4 in ES 
cells. Chapter 4 
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In my initial ES cell experiments there had been some variability in results.  This may 
have reflected normal variations in the developmental processes that take place in ES 
cells.  However before carrying out further studies it was important to validate the 
experimental system in order to ensure that ES cells were in an undifferentiated state.  In 
ES cell culture a small percentage of ES cells differentiate but over time this level can 
accumulate.  This is why it is essential that ES cells used in haematopoietic 
differentiation are at a low passage number.  The second purpose of validation was to 
ensure that these ES cells were capable of haematopoietic differentiation.  Different ES 
cell lines are well known to have preferences in their differentiation potential.  Some ES 
cell lines will be more prone to haematopoietic differentiation than others.  This has been 
demonstrated in a recently published study using human ES cells (Chang et al. 2008).   
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4.2  Validation of ES cell culture 
 
These experiments were aimed at ensuring that the ES cell line used was suitable for use 
in future experiments which would analyse the effects of BMP4 on haematopoietic 
differentiation.  ES cells were first analysed in culture for the expression of markers 
associated with the undifferentiated phenotype.  Then the capacity of these cells to 
differentiate into haematopoietic cells was analysed using PCR and CFU assays. 
 
4.2.1 Alkaline phosphatase and SSEA-1 staining of undifferentiated 
ES cells 
Mouse ES cells can be maintained in the undifferentiated state for extensive periods in 
the presence of leukaemia inhibitory factor (LIF).  Upon removal of LIF mouse ES cells 
differentiate to produce cells of the three germ layers: endoderm, mesoderm and 
ectoderm (Evans & Kaufman 1981).  However it is normal in culture even in the presence 
of LIF that a few ES cell colonies show signs of differentiation.  It was therefore 
necessary to ensure that a sufficient level (at least 90%) of ES cell colonies were kept in 
an undifferentiated state.   
 
Alkaline phosphatase is expressed at high levels by undifferentiated ES cells (Pease et al. 
1990).   A substrate, naphthol phosphate, was used to detect the presence of alkaline 
phosphatase.  The precipitation of fast red chromogen at enzymatic sites resulted in Chapter 4 
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red/pink staining.  Colonies with high levels of alkaline phosphatase activity were visible 
as seen in Figure 4.1A.  99% of colonies expressed high levels of alkaline phosphatase. 
 
Stage-specific embryonic antigen 1 (SSEA-1) is a carbohydrate antigen that is expressed 
at the late cleavage stages of murine embryonic development (Solter & Knowles 1978).   
This antigen is strongly expressed by undifferentiated mouse ES cells.  An antibody 
directed at mouse SSEA-1 antigen conjugated to FITC visible using a fluorescent 
microscope was used to stain ES cells.  The expression of SSEA-1 on ES cell colonies 
can be seen in Figure 4.1B.   
 
A B
 
Figure 4.1 Alkaline phosphatase and SSEA-1 staining of ES cell colonies   
Cells were cultured to high confluency and then fixed and stained for alkaline phosphatase (A) and SSEA1 
(B) expression.  In A the high level of alkaline phosphatase expression is in contrast to the background 
SNH stromal cell feeder layer (magnification 4x).  B shows a single ES cell colony.  SSEA-1 expression 
was visualised using a fluorescent microscope (magnification 10x). 
 
 
4.2.2  QPCR analysis of Nanog, Oct4 and Sox2 expression 
Several transcription factors have been implicated in pluripotency however the best 
characterised is Oct4.  When Oct4 is deleted in vivo cells failed to adopt a pluripotent Chapter 4 
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identity and instead differentiated to trophectoderm (Nichols et al. 1998).  Similarly when 
Oct4 was deleted in ES cells the cells differentiated to trophectoderm (Niwa, Miyazaki, & 
Smith 2000).   Oct4 acts on DNA in conjunction with Sox2 (Pevny & Lovell-Badge 
1997).  Sox2 knockout ES cells differentiate to trophectoderm and do not have a 
pluripotent phenotype (Li et al. 2007).  Nanog a homeodomain protein maintains ES cell 
self renewal.  Gene deletion of Nanog results in cell differentiation to primitive endoderm 
(Chambers et al. 2003).   
 
Thus Oct4, Sox2 and Nanog are crucial to ES cell identity.  The expression of these genes 
were analysed in ES cells using quantitative PCR.  These three genes were all found to be 
expressed (see Figure 4.2) confirming that these ES cells were pluripotent and in an 
undifferentiated state. 
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Figure 4.2 Nanog, Oct4 and Sox2 gene expression in undifferentiated ES cells  
These logarithmic quantitative PCR plots show the amount of amplified PCR product plotted against the 
cycle number.  In this RT-PCR the detection of PCR product represents the detection of mRNA and thus 
gene expression.  Nanog, Oct4 and Sox2 gene expression was detected in these ES cells.  The three lines in 
each plot represent the results of the triplicate repeats. 
 
4.2.3 Flk-1  expression 
Flk-1 is expressed on BL-CFCs which give rise to both endothelial and haematopoietic 
cells.  These colonies arise between day 2.5 and day 3.5 of differentiation.  Cells 
expressing Flk-1 represent the earliest progenitors of the haematopoietic system.   
Previous work by Park et al. using R1 ES cells has shown that under serum 
differentiation conditions Flk-1 expression occurs at day 2 of differentiation peaking at 
day 4 and then reduces again after this (Park et al. 2004).  This change in expression 
represents the transient appearance of the haemangioblast.   Chapter 4 
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In order to investigate whether there was the transient appearance of a Flk-1 expressing 
population within differentiation cultures, real time PCR was carried out to determine 
Flk-1 expression at time points day 0, 2, 4 and 6 as had been previously used by Park et 
al.  Flk-1 primers were successfully tested on the mouse endothelial cell line SVEC 
which had previously been shown to express Flk-1 (Walter-Yohrling et al. 2004).   
 
Results showed a four fold increase in Flk-1 expression at day 2 (P<0.05) before a 
reduction in Flk-1 expression levels at day 4 and day 6 (see Figures 4.3B and 4.3C).  
These results show the transient appearance of a Flk-1 expressing population as has 
previously been described.  The Flk-1 expressing population peaked earlier in 
comparison with previous data at day 2 rather than day 4.  However different ES cell 
lines may exhibit different patterns of differentiation.  Since an R1 ES cell line was used 
previously and a CCE ES cell line was used in this experiment, this may explain the 
difference in results.  These results overall confirm that a transient increase in Flk-1 
expression consistent with the appearance of a haemangioblast population occurs. 
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Figure 4.3 Flk-1 expression in differentiating ES cells  
A shows logarithmic quantitative PCR plot showing the detection of Flk-1 expression on the control cell 
line SVEC.  B shows the fold change in Flk-1 expression relative to day 0 at each time point.  This is a 
logarithmic graph and the results shown represent the average of 3 experiments.  A transient increase in 
Flk-1 expression can be seen at day 2.  Error bars represent the standard error.  C shows a table of the 
results obtained in each experiment.   
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4.2.4  Colony forming unit assays and F480 colony analysis 
 
Methylcellulose assays are used to quantify the numbers of multipotent and lineage 
restricted progenitors in culture.  In these experiments a sample of cells was taken from 
differentiation cultures after 6 days in the presence of serum.  These cells were plated in 
methylcellulose medium with added cytokines (see Section 2.2.3.2) so as to allow the 
survival and maturation of progenitors.  There are several variations of ES 
methylcellulose mixtures that have been used previously that allow colony formation, 
some of which use ingredients not readily available.  Several rounds of optimisation were 
required in order to develop a media that would reliably allow colony formation.   
 
After one week plates were analysed for the presence of haematopoietic colonies.   
Haematopoietic colonies were observed and pictures were taken (Figure 4.4).   
Granulocyte-macrophage, macrophage and erythroid-myeloid mixed colonies were 
present.  This experiment provided visual evidence of the presence of haematopoietic 
cells in samples taken from differentiation cultures.   Chapter 4 
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A B
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Figure 4.4 Colony forming potential of ES cells after 6 days of differentiation  
Cells from day 6 EB differentiation cultures were plated in methylcellulose and after a further 7 days 
pictures were taken of colonies obtained.  Granulocyte macrophage colonies (A and B), mature macrophage 
colonies (C) and mixed erythro-myeloid colonies (D) were observed.  Micrographs were taken at x4 
magnification. 
 
Haematopoietic colonies which resembled macrophage colonies were harvested and 
further analysed for expression of the F4/80 cell surface marker.  F4/80 is a 160kDa cell 
surface glycoprotein that is a member of the EGF TM7 family of proteins.  F4/80 has 
been identified as a marker for mature mouse macrophages (Austyn & Gordon 1981).  
Harvested cells were fixed and stained with anti-mouse F4/80 antibody.  A secondary 
antibody was then applied with peroxidase activity.  Cells taken from macrophage 
colonies were found to express F4/80 (see Figure 4.5). 
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Figure 4.5 F4/80 staining of macrophage colony cells  
Micrographs A and B show cells expressing the macrophage marker F4/80.  Cells were stained with an 
anti-mouse F4/80 antibody and then a secondary antibody with peroxidase activity was applied. The 
addition of peroxidase substrate caused cells expressing F4/80 to become brown in colour.  
 
4.2.5 Discussion 
ES cells expressed high levels of alkaline phosphatase and SSEA-1 antigen consistent 
with an undifferentiated phenotype.  Furthermore gene expression data showed that Oct4, 
Sox2 and Nanog which are markers of a pluripotent phenotype were also expressed.  This 
data therefore confirms that these ES cells were both undifferentiated and pluripotent. 
 
The ability of these ES cells to differentiate to haematopoietic cells was also analysed.  
Flk-1 expression marks the haemangioblast which is the earliest progenitor of the 
haematopoietic system.  A transient increase in Flk-1 expression occurred at day 2 which 
is consistent with the appearance of a haemangioblast population.   
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In previous experiments flow cytometry analysis for the expression of differentiation 
markers was performed.  Cells expressing Ter119 and CD11b corresponding to erythroid 
and myeloid differentiation were found after 6 days of differentiation.  In these 
experiments methylcellulose assays found visual evidence of erythroid and myeloid 
colonies.  The presence of mature macrophages in macrophage colonies was confirmed 
by F4/80 staining.  Thus these ES cells were shown to be capable of haematopoietic 
differentiation.   
 
4.3 BMP4 and BMP receptor expression in differentiating ES 
cells 
 
There were concerns about BMP4 being secreted by differentiating cells in the ‘negative 
control’ serum free differentiation conditions.   This endogenous BMP4 would make it 
difficult to detect the effect, if any, of BMP4 added into the culture medium.  In order to 
address these concerns RT-PCR analysis was carried out for the expression of Bmp4.   
 
BMP4 can only produce a cellular response if cell surface receptor is expressed.  BMP 
receptor has two components: ALK3 and BMPR2.  BMP4 binds BMPR2 and then ALK3 
is recruited resulting in the activation of intracellular kinase activity that activates the 
Smad signaling pathway (Larsson & Karlsson 2005).  Thus both component receptors 
must be expressed for BMP4 signaling to take place.  RT-PCR was therefore also carried 
out to detect the expression of Alk3 and Bmpr2.   Chapter 4 
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Primer sequences to Bmp4, Alk3 and Bmpr2 were taken from previous papers (Pesce, 
Gioia, & De Felici 2002;Peretto et al. 2004).  A BLAST search was done to ensure that 
the primers were specific to Bmp4, Alk3 and Bmpr2.  Primers were also checked to ensure 
that they were designed to cross intron-exon boundaries and therefore would not detect 
genomic DNA contamination.   
 
The murine stromal cell line ST2 had previously been shown to express Bmp4, Alk3 and 
Bmpr2 (Otsuka et al. 1999).  Primers were therefore tested on the ST2 cell line to confirm 
their ability to detect BMP4 and BMP receptor expression (see Figure 4.6).  
 
To analyse Bmp4, Alk3 and Bmpr2 expression ES cells were differentiated under serum 
replacement conditions and samples taken at day 0, 2, 4 and 6 for RT-PCR analysis.  Hprt 
which is a housekeeping gene was used as a control for the reverse transcription reaction.     
 
At all time points cells expressed both components of BMP receptor: Alk3 and Bmpr2 
(see Figure 4.6).  The cells therefore had the capacity to detect the presence of BMP4 
added into the culture medium.  In addition Bmp4 was expressed by the cells at all time 
points (see Figure 4.6).  The endogenous expression of BMP4 meant that further 
experiments needed to take into account that the serum replacement ‘negative control’ 
could not be assumed to be BMP4 free.  This endogenous expression of BMP4 may also 
have explained why previous experiments had yielded few differences between the 
BMP4 treated samples and ‘negative control’ serum free samples.   Chapter 4 
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Figure 4.6 RT-PCR analysis of the expression of Alk3, Bmpr2 and Bmp4 in the ST2 control cell line 
and in EB differentiation cultures at days 0, 2, 4 and 6.   
Differentiation was under serum free conditions.  Hprt is a housekeeping gene and was included as a 
control for the reverse transcription reaction.  Water controls were included as a control for contamination.  
The size of PCR products were as follows: Hprt- 324 base pairs (bp), Alk3 - 626bp, Bmpr2 – 460bp and 
Bmp4 – 468bp.  Bmp4 and both components of the BMP receptor were detected at all time points. 
 
 
4.4 BMP4  titration 
Other published work had shown a difference in untreated and BMP4 treated samples 
despite any endogenous BMP4 expression that may have been present.  Work done by 
Park et al. showed that BMP4 had a role in the up-regulation of SCL in combination with 
VEGF in R1 ES cells (Park et al. 2004).  However in my previous experiments there was 
no clear evidence of a BMP4 specific role in the regulation of Runx1, Scl, Gata2 or 
Lmo2.  It was possible that an effect wasn’t observed because the concentration of BMP4 Chapter 4 
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was not optimal to change the expression of these genes.  In order to determine whether a 
different concentration of bmp4 might more optimally induce haematopoietic gene 
expression a BMP4 titration was carried out. 
 
Concentrations of BMP4 between 2 and 25ng/ml had been used with different types of 
ES cells in other work (Bhatia et al. 1999;Park et al. 2004).  Therefore in these 
experiments ES cells were differentiated in serum replacement medium containing 0, 5, 
10 and 25ng/ml BMP4 and samples were taken at day 0, 2, 4 and 6.  Samples were 
analysed by quantitative RT-PCR for Runx1,  Scl,  Gata2 and Lmo2 expression.  The 
experimental method has been summarised in figure 4.7. 
Day 0
Day 2 
Day 4
Day 6
4 culture conditions:
‘untreated control’
BMP4 0ng/ml
BMP4 5ng/ml
BMP4 10ng/ml
BMP4 25ng/ml
Quantitative RT-PCR:
Runx1, Scl, Gata2, Lmo2
EB
differentiation
 
 
Figure 4.7 Experimental protocol used in BMP4 titration experiments. 
 
4.4.1  Analysis of Data 
In previous experiments fold change in gene expression was calculated relative to day 0.  
This data is useful to determine the direction of change in gene expression relative to day 
0.  Since the expression levels of the haematopoietic genes at day 0 would be expected to Chapter 4 
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be low only an increase in expression above day 0 levels indicates that haematopoietic 
development is taking place. 
 
Previous variability in gene expression data came about because in each experiment gene 
expression increased to a different level relative to day 0.  With this variability it is 
difficult to make conclusions about the effect of BMP4.  In order to control for this, gene 
expression values were calculated relative to the age matched untreated control.   
 
Data was therefore analysed relative to day 0 to determine whether any increase in 
haematopoietic gene expression had taken place indicating haematopoietic development.  
Also gene expression relative to the age-matched untreated control was calculated to 
determine the effect of BMP4. 
 
 
4.4.2  Effects of BMP4 concentration on gene expression 
 
Tables showing the data for each experiment are in Appendix 2. 
 
Runx1 expression increased at day 2 in serum free conditions above day 0 levels (P<0.05, 
Figure 4.8).  Although the general trend across all culture conditions was for an increase 
in Runx1 expression at day 2.   
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At day 4 BMP4 reduced Runx1 expression at 5ng/ml relative to the untreated control 
(P<0.05).  At the other concentrations BMP4 did not produce any notable changes in 
Runx1 expression compared with the untreated control. 
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Figure 4.8  Graphs showing the fold difference in gene expression relative to: (A) day 0 and (B) the 
untreated age matched control for Runx1.   
Samples were taken at day 2, 4 and 6 and were differentiated with BMP4 at concentrations of 0, 5, 10 and 
25ng/ml.  Gene expression values represent the average achieved over 5 experiments.  The error bars show 
standard error.  * indicates statistically significant results at P<0.05. 
 
There were no statistically significant changes in Scl expression at any of the time points 
relative to day 0 (Figure 4.9).  There were however higher levels overall of Scl expression 
at day 4 relative to day 0. 
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At day 6 BMP4 at 10ng/ml increased Scl expression relative to the untreated control 
(P<0.05).   
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Figure 4.9  Graphs showing the fold difference in gene expression relative to: (A) day 0 and (B) the 
untreated age matched control for Scl.   
Samples were taken at day 2, 4 and 6 and were differentiated with BMP4 at concentrations of 0, 5, 10 and 
25ng/ml.  Gene expression values represent the average achieved over 5 experiments.  The error bars show 
standard error.  * indicates statistically significant results at P<0.05. 
 
There were no statistically significant changes in Gata2 expression at any of the time 
points but there was a definite trend for higher levels of Gata2 expression at day 4 
relative to day 0 (Figure 4.10).   
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At day 4 with 10ng/ml and 25ng/ml BMP4 there was an increase in Gata2 expression 
relative to the untreated control (at 10ng/ml P<0.05 and 25ng/ml P<0.05).  This increase 
in expression was striking particularly in experiments 2 and 3. 
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Figure 4.10  Graphs showing the fold difference in gene expression relative to: (A) day 0 and (B) the 
untreated age matched control for Gata2.   
Samples were taken at day 2, 4 and 6 and were differentiated with BMP4 at concentrations of 0, 5, 10 and 
25ng/ml.  Gene expression values represent the average achieved over 5 experiments.  The error bars show 
standard error.  * indicates statistically significant results at P<0.05. 
 
There were no statistically significant changes in Lmo2 expression at any time points 
(Figure 4.11).  There was however an average increase in Lmo2 expression at all time 
points.   Chapter 4 
 
  179
 
At day 6 there was evidence of a concentration dependent increase in Scl, Lmo2 and 
Gata2 gene expression relative to the untreated control.  Although these increases were 
not statistically significant it is possible that if higher concentrations of BMP4 are used 
larger statistically significant increases in gene expression might occur. 
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Figure 4.11 Graphs showing the fold difference in gene expression relative to: (A) day 0 and (B) the 
untreated age matched control for Lmo2.   
Samples were taken at day 2, 4 and 6 and were differentiated with BMP4 at concentrations of 0, 5, 10 and 
25ng/ml.  Gene expression values represent the average achieved over 5 experiments.  The error bars show 
standard error.  * indicates statistically significant results at P<0.05. 
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4.4.3 Discussion  of  BMP4 titration data: 
The data was still variable.  Although in some experiments there were large increases in 
the expression of one gene there were large increases in other genes in other experiments.  
This variability probably reflects the chaotic nature of the developmental processes that 
are occurring as the ES cells differentiate due to the artificial environment in which they 
are differentiating.  Therefore the data was analysed with reference to the average 
changes in gene expression and the statistical significance of the results.   
  
The most prominent result was an increase in Gata2 expression at day 4 with the addition 
of BMP4 at 10 and 25ng/ml.  This increase in Gata2 expression was above day 0 levels.  
This data therefore supports work previously done by Lugus et al. which showed that 
Gata2 was a direct target of BMP4 in R1 ES cells (Lugus et al. 2007).   
 
It is possible given the apparent concentration dependence of average gene expression 
changes at day 6 in Scl, Gata2 and Lmo2 that higher concentrations would have produced 
larger changes in gene expression.   
 
This data further suggests BMP4 maintains rather than up regulates Scl expression at 
10ng/ml at day 6.  Furthermore BMP4 actually reduced Runx1 expression at 5ng/ml at 
day 4.  These results differ from data obtained in previous work.  However Park et al. and 
Pearson  et al. used combinations of growth factors and this may account for the 
difference in results.  Specifically in the experiments performed by Park et al. VEGF in 
combination with BMP4 produced an increase in SCL expressing cells.  In Pearson et al.  Chapter 4 
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BMP4 was used in combination with Activin A, basic fibroblast growth factor and VEGF 
to produce increases in Runx1, Scl and Lmo2 expression.  These are therefore the first 
experiments to describe the effects of BMP4 alone on the expression of Runx1, Scl, 
Gata2 and Lmo2.   
 
 
4.5  BMP receptor titration 
 
The expression of BMP4 in the ‘negative control’ serum free samples posed several 
problems to investigating the role of BMP4 in haematopoietic development in ES cells.  
Firstly calculations of gene expression relative to untreated control assumed that the 
untreated control was BMP4 free.  Therefore accurate calculations as to the change in 
gene expression resulting from the addition of BMP4 could not be carried out.  The 
second problem was that there was an unknown quantity of BMP4 secretion in each 
experiment which could have been adding to the variability of results.   
 
Previous experiments in the foetal liver and bone marrow had used soluble BMP receptor 
to antagonize the action of BMP4.  An experiment was therefore carried out to determine 
if soluble BMP receptor would reduce haematopoietic gene expression.  Previous 
experiments in human ES cells had used BMP receptor at concentrations of 250ng/ml 
(Kennedy et al. 2007).  BMP receptor was added at concentrations of 0, 25, 100 and 
250ng/ml. 
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Samples were taken at day 0, 2, 4 and 6 and analysed by quantitative RT-PCR.  Gene 
expression values were calculated relative to day 0 and relative to the age matched 
untreated control.  The experimental method is summarized in Figure 4.12. 
 
Day 0
Day 2 
Day 4
Day 6
4 culture conditions:
‘untreated control’
BMP receptor 0ng/ml
BMP receptor 25ng/ml
BMP receptor 100ng/ml
BMP receptor 250ng/ml
Quantitative RT-PCR:
Runx1, Scl, Gata2, Lmo2
EB
differentiation
 
Figure 4.12 The experimental protocol used in BMP receptor titration experiments. 
 
 
Tables showing the data for each experiment are in Appendix 1. 
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Although not statistically significant Runx1 expression was highest at day 2 (Figure 
4.13).  At all BMP receptor concentrations there was no effect on Runx1 expression.   
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Figure 4.13 Graphs showing the fold difference in gene expression relative to: (A) day 0 and (B) the 
untreated age matched control for Runx1.  
Samples were taken at day 2, 4 and 6 and were differentiated in the presence of soluble BMP receptor at 
concentrations of 0, 25, 100 and 250ng/ml.  Gene expression values represent the average achieved over 4 
experiments.  The error bars show standard error.   
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Scl expression was at its highest at day 2 but did not increase significantly above day 0 
levels (Figure 4.14).  There was no change in Scl expression at any concentration of BMP 
receptor at any of the time points.   
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Figure 4.14 Graphs showing the fold difference in gene expression relative to: (A) day 0 and (B) the 
untreated age matched control for Scl.  
Samples were taken at day 2, 4 and 6 and were differentiated in the presence of soluble BMP receptor at 
concentrations of 0, 25, 100 and 250ng/ml.  Gene expression values represent the average achieved over 4 
experiments.  The error bars show standard error.   
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At day 2 Gata2 expression was at its highest relative to day 0 (Figure 4.15).  There was 
no change in Gata2 expression at any concentration of BMP receptor at any of the time 
points.   
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Figure 4.15 Graphs showing the fold difference in gene expression relative to: (A) day 0 and (B) the 
untreated age matched control for Gata2.  
Samples were taken at day 2, 4 and 6 and were differentiated in the presence of soluble BMP receptor at 
concentrations of 0, 25, 100 and 250ng/ml.  Gene expression values represent the average achieved over 4 
experiments.  The error bars show standard error.   
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Lmo2 expression was at its highest at day 2 relative to day 0 levels (Figure 4.16).  Lmo2 
expression then reduced at days 4 and 6 to day 0 levels.  BMP receptor did not change 
Lmo2 expression at any concentration at any of the time points. 
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Figure 4.16 Graphs showing the fold difference in gene expression relative to: (A) day 0 and (B) the 
untreated age matched control for Lmo2.  
Samples were taken at day 2, 4 and 6 and were differentiated in the presence of soluble BMP receptor at 
concentrations of 0, 25, 100 and 250ng/ml.  Gene expression values represent the average achieved over 4 
experiments.  The error bars show standard error.   
 
4.5.1 Discussion 
The addition of BMP receptor had been expected to result in a reduction in Runx1, Scl, 
Gata2 and Lmo2 gene expression.  However no reduction in gene expression occurred.  
This may be because the concentration of BMP receptor used was inadequate to Chapter 4 
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sufficiently antagonize the action of BMP4 so as to achieve a reduction in gene 
expression.   
 
4.6 General  discussion 
ES cell differentiation experiments in chapter 3 produced variable results and did not 
show any effect for BMP4 in haematopoietic differentiation despite results showing 
otherwise in other published work (Park et al. 2004;Pearson et al. 2008).  In order to 
address these issues the ES cell system was tested to ensure that: 1) the cells had an 
undifferentiated and pluripotent phenotype and 2) the cells could differentiate into 
haematopoietic cells.  Cells were found to express SSEA-1 and high levels of alkaline 
phosphatase consistent with an undifferentiated phenotype.  Cells expressed Oct4, Sox2 
and  Nanog consistent with a pluripotent phenotype.  The transient expression of the 
haemangioblast marker Flk-1, the demonstration of methylcellulose haematopoietic 
colony formation combined with differentiation cell surface marker data from previous 
experiments proved that these cells were capable of haematopoietic differentiation. 
 
In previous foetal liver experiments there was evidence of secretion of BMP4 by cells in 
culture.  BMP4 is a mesoderm patterning factor and therefore is secreted during 
development.  It was therefore a concern that BMP4 was being secreted in ‘negative 
control’ serum free conditions.  The expression of BMP4 and the two components of the 
BMP receptor: Alk3 and Bmpr2 were analysed.  At all time points: Day 0, 2, 4 and 6 there 
was expression of both Bmp4 and the two components of the BMP receptor.   
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Nevertheless other published work had indicated that BMP4 had a role in haematopoietic 
differentiation despite the endogenous expression of BMP4 by differentiating cells.  With 
this in mind a BMP4 titration was carried out to find out whether other concentrations of 
BMP4 might produce changes in the expression of Runx1, Scl, Lmo2 and Gata2.   A 
significant increase in Gata2 expression occurred with the addition of BMP4.   This result 
is in agreement with work done by Lugus et al. which has produced similar findings 
(Lugus et al. 2007).    
 
However there continued to be variability in the results from these experiments.  This was 
probably in part due to the chaotic nature of the differentiation processes occurring in 
EBs.  This may also have resulted from the variable expression of BMP4 by 
differentiating cells.  A BMP receptor titration was carried out.  However the 
concentration of BMP receptor may have been inadequate and no effects were seen on 
gene expression.   
 
The general pattern of gene expression was similar in both the BMP4 and BMP receptor 
titration results.  There were increases in Runx1, Gata2 and Lmo2 expression at day 2.  
The expression of Scl increased in the BMP4 experiments at day 4 whereas in the BMP 
receptor experiments there were smaller increases only at day 2.  The early expression of 
Runx1 in combination with Gata2 and Lmo2 probably indicates that Runx1 has some role 
in the formation of the haemangioblast cells and primitive haematopoiesis.  This would 
concur with data from Lacaud et al. that found a reduction in BL-CFCs and fewer Chapter 4 
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primitive erythroid cells produced from Runx1 deletion mutant ES cells (Lacaud et al. 
2002).  
 
The secretion of BMP4 by serum free samples may have been variable between repeat 
experiments.  In addition calculations comparing BMP4 treated samples to serum free 
samples assumed that serum free samples were BMP4 free.  Thus the secretion of BMP4 
by differentiating cells posed a major hurdle to further investigation of the role of BMP4 
in haematopoietic development.   
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Chapter 5  Knockdown  of  Bmp4 expression to 
investigate haematopoietic differentiation of ES cells 
 
5.1 Introduction 
 
In order to resolve the issues caused by the secretion of BMP4 by differentiating ES cells 
attempts were made to use short hairpin RNA (shRNA) to knock down BMP4 
expression.  The aim of these experiments was to provide a BMP4 free experimental 
system in which the effect of added BMP4 could be determined.   
 
Homologous recombination could be used to knock down gene expression completely by 
generating a null mutation of the gene.  This method has previously been used by 
Winnier et al. to produce BMP4 deletion mutant mice.  Most embryos developed only to 
the egg cylinder stage showing little or no mesoderm differentiation.  There was an 
absence of the expression of the mesodermal marker Brachyury.  Embryos died between 
6.5 and 9.5 dpc, too early for study of the effects of BMP4 on haematopoietic 
development (Winnier et al. 1995).  These experiments were aimed at taking these results 
further by effectively rescuing the null phenotype in differentiating ES cells.   
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5.1.1  RNAi – triggering the pathway using siRNA versus shRNA 
In recent years RNA interference (RNAi) has been developed as a technique for gene 
silencing.  Experiments originally performed in C. elegans have shown that double 
stranded RNA (dsRNA) can be used to specifically and efficiently inhibit gene 
expression by causing the degradation of mRNAs with sequences homologous to that of 
the dsRNA  (Fire et al. 1998).    This occurs via a two step mechanism (Figure 5.1).  First 
dsRNA is cleaved to 21-25 nucleotide small interfering RNAs (siRNAs) by Dicer 
enzymes, part of the RNase III ribonuclease family.  The siRNAs are then unwound and 
incorporated into a multicomponent nuclease known as RNA induced silencing complex 
(RISC) which recognises and destroys mRNAs with homologous sequences (Hannon 
2002).   Chapter 5 
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dsRNA
shRNA
siRNA
DICER
RISC
Figure 5.1 The RNAi pathway  
dsRNA and shRNA is processed into 21 nucleotide fragments by the enzyme dicer.  These fragments are 
bound by the RISC and unwound.  mRNAs with homologous sequences are then recruited to the RISC and 
destroyed (adapted from Hannon et al. 2002). 
 
Most mammalian cells have a potent antiviral response that is triggered by the presence 
of dsRNA mediated by dsRNA activated protein kinase (PKR).  The ultimate outcome of 
this response is cell death via apoptosis.  It was therefore a welcome surprise that dsRNA 
could be introduced to a range of cells inducing sequence specific silencing without 
producing a generalised cellular response (Paddison, Caudy, & Hannon 2002).  However 
restriction of RNAi to these particular cell culture systems would have severely limited 
the usefulness of this technology. 
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Tuschl and colleagues were the first to demonstrate that short RNAs designed to mimic 
the products of Dicer could trigger RNA interference (Tuschl et al. 1999).  These siRNAs 
enter the silencing pathway without triggering PKR dependent cellular changes.  This has 
led to the use of chemically synthesised siRNAs to induce gene silencing in a wide range 
of human and mouse cell lines (Caplen et al. 2001).  However the major disadvantage of 
siRNA is that the effects are transient.   
 
Although the original purpose of the RNAi pathway was thought to be as a cellular 
defence mechanism against viruses, endogenous triggers of RNAi pathways have been 
described more recently.  This was initially discovered due to the similarities in 
phenotype of Dicer deletion mutants and Let-7 deletion mutants.  The Let-7 gene encodes 
a small highly conserved RNA species that regulates the expression of endogenous genes 
in worm development.  The active RNA species is initially transcribed as a 70 nucleotide 
precursor and then is processed into a 21 nucleotide form by Dicer (Reinhart et al. 
2000;Grishok et al. 2001).  The Let-7 gene has been discovered as founding member of a 
large group of small RNAs known as miRNAs thought to be involved in the post 
transcriptional regulation of gene expression (Lagos-Quintana et al. 2001).  This 
mechanism has been exploited to induce sequence specific gene silencing.  These short 
hairpin RNAs (shRNAs) can be cloned into a plasmid and synthesised from a RNA 
polymerase III promoter to induce long term stable suppression of a target gene 
(Paddison et al. 2002).   
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The aim of these experiments was to use plasmids expressing shRNA to knockdown 
Bmp4 expression in differentiating ES cells so as to create a BMP4 free experimental 
system. 
 
5.1.2  pLKO.1 plasmid  
A set of five plasmids containing different shRNA sequences to knockdown BMP4 
expression were obtained from Sigma Aldrich.  The shRNA sequences were designed 
using Sigma’s proprietary algorithm that scores potential sequences for efficient 
knockdown and sequence specificity to minimise off target effects.  The shRNA 
sequences were designed to produce a hairpin structure consisting of a 20-21 base pair 
stem and a 6 base loop that would be recognised and cleaved by Dicer upon expression 
via a U6 RNA polymerase III promoter in the host cell.  The resulting siRNA duplex 
could then incorporate into the RISC to suppress BMP4 expression.  The plasmid 
contained an ampicillin resistance marker to allow for plasmid propagation in E. coli and 
a puromycin resistance marker for stable selection in mammalian cells.  The expression 
of puromycin resistance was driven by a PGK promoter. 
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Figure 5.2 Features of the pLKO.1 puro plasmid   
This plasmid contains a U6 promoter to drive shRNA expression, a puromycin resistance gene (puroR) 
driven by a human PGK promoter (hPGK) and an ampicillin resistance (ampR).  The pUC origin (pUC ori) 
is an origin of replication allowing propagation of the plasmid in E. coli.  The F1 origin (f1 ori) allows 
single stranded DNA synthesis.  The 5’LTR, 3’LTR, RRE and Ψ signal are all features taken from 
lentiviruses explained in section 5.3.  The diagram illustrates the structure of a short hairpin RNA.  This 
diagram is adapted from the Sigma Aldrich website. 
 
 
5.2  Transfection of ES cells 
 
DNA can be delivered to cells using viral and non-viral methods.  Viral methods are 
more time consuming and costly than non viral methods. shRNA expressing plasmids 
were therefore delivered to ES cells by transfection using a non viral method.   
Transfection can be achieved by electroporation and lipofection.  A comparison of 
electroporation and lipofection in ES cells showed that lipofection achieved a 5.8 fold 
higher transfection efficiency than electroporation (Ma et al. 2004).  Lipofection was 
therefore used in preference to electroporation. 
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5.2.1 Lipofection 
Lipid molecules can be used to mediate gene delivery in a process known as lipofection.  
When lipids are mixed with DNA the lipids form spheres called liposomes with DNA 
trapped in the aqueous centre.  When added to cells cultured in vitro these liposomes fuse 
with cell membranes and are taken up into cells via endocytosis.  The use of lipid 
molecules with a positively charged head linked to a hydrophobic tail allows the 
formation of lipoplexes when mixed with DNA.  The positive charge of lipoplexes allows 
more efficient binding to negatively charged cell membranes.  Once taken up into cells by 
endocytosis there would normally be fusion of the vesicle contents with lysosomes and 
the degradation of DNA contained within.  However the inclusion of the molecule 
dioleoylethanolamine (DOPE) allows entrapped DNA to escape the endosomes.  The 
DNA can then go to the nucleus of the cell where it can use the transcriptional machinery 
of the cell (Kobayashi et al. 2005).   
 
Ma  et al. transfected murine ES cells with an enhanced green fluorescence protein 
(eGFP) expression plasmid by lipofection and quantified transfection efficiency.  They 
found that 5.75% of cells expressed GFP two days after transfection.  They went on to 
generate knock in mice using stably transfected cells.  Thus lipofection can be used to 
stably transfect ES cells.   
 
Lipofection of shRNA expressing plasmids has been tested using a GFP reporter system 
in murine ES cells (Tang et al. 2004).  The reagent lipofectin was used to transfect ES 
cells.  Transfection efficiency was around 15%.  Cells were harvested two hours after Chapter 5 
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transfection and GFP expressing cells quantified.  Knockdown of GFP expression was 
achieved.  The transfected ES cells showed no difference in morphology or growth rate 
compared with untransfected ES cells.   
 
However there are few papers where successful lipofection of ES cells has been carried 
out.  The generation of stably transfected ES cells and knock in mice by Ma et al. shows 
that ES cells can maintain the phenotype brought about by the expression plasmid 
through differentiation.  This however has not previously been shown with shRNA 
plasmids in the context of lipofection.  Furthermore Tang et al. only quantified 
knockdown after 2 hours.  In order to study haematopoietic differentiation it was 
necessary to induce knockdown over 6 days. 
 
5.2.2 Lipofection  of  ES  cells with pEFGP-N1 
The first step was to analyse whether transfection in ES cells would be efficient enough 
to allow its use for the delivery of shRNA expression plasmids in future experiments.   In 
order to achieve this ES cells were transfected with the pEGFP-N1 plasmid which 
expresses GFP (Figure 5.3A). 
 
The pEGFP-N1 plasmid was amplified in E. coli bacterial culture and in order to test 
plasmid integrity a restriction digest was performed using NdeI and NotI (Figure 5.3B). 
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Figure 5.3 pEGFP-N1 plasmid  
A shows the features of the pEGFP-N1 plasmid (4.7kb).  eGFP expression is driven by a CMV promoter.  
The plasmid also carries a kanamycin resistance gene.  Plasmid integrity was checked after bacterial 
propagation by restriction digest with NotI and NdeI as shown in B.  This double restriction resulted in the 
formation of 3 fragments: 3.5kb and 1.2kb in size.   
 
Lipofectamine has previously been used to transfect GFP expression plasmids into 
murine ES cells (Ma et al. 2004).  Cells were transfected by adding 1.6µg of plasmid 
DNA to 4µl of lipofectamine 2000 on 200,000 cells.  For comparison cells were treated 
with lipofectamine alone, DNA alone and untreated.  The transfection efficiency was 
determined by flow cytometry at days 2, 4 and 6 of differentiation.  The percentage of 
GFP expressing cells and the expression of GFP per cell was quantified at each time 
point.  The experimental protocol is summarised in Figure 5.4.   
 
Future experiments using shRNA expression plasmids would seek to suppress expression 
of BMP4 over 6 days of differentiation, it was therefore important to quantify 
transfection efficiency over this period.  
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ES cells differentiated 
under 4 culture 
conditions:
• SR medium alone
• Lipofectamine alone
• Transfection with 
pEGFP-N1
• pEGFP-N1 alone
Flow cytometry 
for GFP 
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Day 0
Day 2 
Day 4
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Figure 5.4 Experimental protocol used in testing the transfection efficiency of ES cells.   
 
Three repeat experiments were carried out.  At days 2, 4 and 6 GFP expression was 
visualised in differentiating EBs using fluorescent microscopy.  As can be seen in Figure 
5.5 transfected EBs at day 2 and 4 could be seen to brightly express GFP however at day 
6 no GFP expression could be seen. 
DAY 2
DAY 4
DAY 6
x10
 
Figure 5.5 GFP expression in transfected ES cells  
Micrographs of EBs taken at days 2, 4 and 6 after transfection with a light microscope (left) and with a 
fluorescent microscope to detect GFP expression (right) at 10x magnification.   Chapter 5 
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Flow cytometry revealed that in transfected day 2 EBs 44.7% of cells expressed GFP 
(Figure 5.6).  This was a significantly higher percentage than in the untreated cells 
(P<0.05).  However the percentage of GFP expressing cells dropped back to 9.6% at day 
4 and 6.2% at day 6.  These levels were not significantly different compared with 
untreated cells at the same time points. 
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Figure 5.6 Lipofection of ES cells with pEGFP-N1 – GFP expression 
The percentage of GFP positive cells as detected by flow cytometry at day 2, 4 and 6 when untreated, with 
treated with lipofectamine alone, with plasmid DNA alone and when transfected.  Results are the average 
of 3 experiments.  Error bars indicate the standard error. * indicates results significant at P<0.05. 
 
The mean fluorescence intensity measures the amount of GFP expression per cell 
providing another measure of plasmid uptake.  Although the mean fluorescence intensity 
was on average higher at day 2 this increase was not statistically significant when 
compared with untreated cells (Figure 5.7). Chapter 5 
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Figure 5.7 Lipofection of ES cells with pEGFP-N1 – Mean Fluorescence Intensity 
The mean fluorescence intensity at day 2, 4 and 6 when untreated, with treated with lipofectamine alone, 
with plasmid DNA alone and when transfected.  Results are the average of 3 experiments.  Error bars 
indicate the standard error. * indicates results significant at P<0.05. 
 
These results showed that it was possible to achieve transfection of ES cells using 
lipofection.  The transfection efficiency of 44.7% at day 2 was higher than recorded in 
previous experiments.  This may be due to the cells being transfected at the onset of 
differentiation compared to previous studies which have transfected undifferentiated 
cells.  The effect however was transient with the percentage of GFP expressing cells 
being comparable with that in the untreated control at day 4 and day 6. 
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5.2.3  Lipofection of ES cells with pLKO.1 shRNA plasmids 
Given the success of transfection using the pEGFP-N1 plasmid further experiments were 
carried out to determine the kinetics of knockdown using the set of five shRNA 
expressing plasmids obtained from Sigma.  Although the shRNA sequences in these 
plasmids were predicted to knockdown Bmp4 this can only be determined by testing.  
Therefore the aim of these experiments was to determine which shRNA sequence 
produced the highest knockdown of Bmp4 expression.  This plasmid would then be used 
in subsequent ES cell differentiation experiments. 
 
The murine stromal cell line ST2 was previously used to test Bmp4 primers as it is known 
to express Bmp4 (see Section 4.3).  In these experiments the SNH cell line was used to 
assay Bmp4 knockdown with each of the five plasmids.  Therefore SNH cells underwent 
lipofection with each of the five plasmids and then were cultured for 6 days.  An 
untreated control was cultured for comparison.  A further control group of cells was 
treated with lipofectamine alone to check that the transfection reagent was not affecting 
cell behaviour.  Also a control pLKO.1 plasmid with no shRNA sequence was 
transfected.  This was to ensure that the plasmid alone was not altering cell behaviour. 
 
Samples were taken for analysis at day 0, 2, 4 and 6.  This was to determine knockdown 
at each of the time points that would be analysed in future experiments.  Samples were 
analysed by RT-PCR for Bmp4 expression.  The experimental protocol is summarised in 
Figure 5.8.   
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Figure 5.8 The experimental protocol used in testing shRNA expressed from pLKO.1 plasmids on 
ST2 cells   
 
The knockdown of Bmp4 was initially determined using semi-quantitative PCR.  Bmp4 
primers had already been tested and used in previous experiments (see Section 4.3).   
Furthermore at this point the main aim was to choose the plasmid which would produce 
the best knockdown.  Thus precise quantification was unnecessary.  
 
The quantity of expression was estimated by computer analysis based on the brightness of 
the band visualised on the gel.  As can be seen in Figure 5.9 there were no differences in 
band intensity using any of the sequences at any of the time points.  This may have been 
due to saturation of the PCR.  That is to say the amount of amplified product appeared the 
same because the PCR reaction had not been stopped during the exponential phase of the 
reaction.  In order to optimise this it would have been necessary to conduct further 
experiments to determine the number of cycles necessary for the PCR to be in the 
exponential phase.  This would have been time consuming.  It was therefore decided that 
real time PCR was a faster and superior technique for determining Bmp4 knockdown. 
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DAY 0 DAY 2
DAY 4 DAY 6
 
Figure 5.9 Testing shRNA expressed from pLKO.1 plasmids on ST2 cells using RT-PCR 
The expression of Bmp4 and the housekeeping gene Hprt at Day 0, 2, 4 and 6 in ST2 cells was determined 
by semi-quantitative PCR.  Lane 1 shows expression in untreated cells.  Lanes 2-6 show expression in cells 
treated with each of the 5 shRNA plasmids. Lane 7 shows expression in cells treated with pLKO.1 plasmid 
with no shRNA sequence.  Lane 8 shows expression in cells treated with lipofectamine alone and Lane 9 
shows expression in the water control.   
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Bmp4 knockdown was calculated relative to the untreated control.  Results are shown in 
Figure 5.10.  Overall Bmp4 knockdown begun at day 2 and was at its maximum at day 4.  
The knockdown in expression was transient and by day 6 there was no reduction in Bmp4 
expression.  Plasmids 2 and 4 produced the greatest knockdown at day 4 (P<0.05).   
However there was also a reduction in Bmp4 expression in both the plasmid without 
shRNA control and transfection reagent alone control (P<0.05).  In order to determine 
whether this was an anomaly or a genuine result the experiment was repeated.  Chapter 5 
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Figure 5.10 Testing shRNA expressed from pLKO.1 plasmids on ST2 cells using real time PCR – 
Experiment 1 
Logarithmic graphs showing fold change in Bmp4 expression relative to the untreated control in ST2 cells 
in cells treated with each of the 5 shRNA plasmids, in cells treated with pLKO.1 plasmid with no shRNA 
sequence, in cells treated with lipofectamine (TF) alone and in the water control.  Results are the average of 
3 experiments.  Error bars indicate the standard error.  * indicates change in BMP4 expression relative to 
the untreated control at P<0.05. Chapter 5 
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In the second experiment (Figure 5.11) overall the highest level of knockdown was 
achieved at day 2.  The level of knockdown reduced from these levels at day 4 and day 6.  
Plasmid 4 produced the highest level of knockdown at day 2 and plasmid 2 produced the 
highest level of knockdown at day 4 (P<0.05).  There was again knockdown of Bmp4 
expression in the transfection reagent alone control at day 2 (P<0.05).  However there 
wasn’t a reduction in Bmp4 expression in the plasmid without shRNA control as well.   Chapter 5 
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Figure 5.11Testing shRNA expressed from pLKO.1 plasmids on ST2 cells using real time PCR – 
Experiment 2 
The experiment was repeated to confirm whether initial results showing knockdown with transfection 
reagent alone was accurate.  These logarithmic graphs show fold change in Bmp4 expression relative to the 
untreated control in ST2 cells in cells treated with each of the 5 shRNA plasmids, in cells treated with 
pLKO.1 plasmid with no shRNA sequence, in cells treated with lipofectamine (TF) alone and in the water 
control.  Results are the average of 3 experiments.  Error bars indicate the standard error.  * indicates 
change in BMP4 expression relative to the untreated control at P<0.05. Chapter 5 
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In both experiments plasmid 2 induced the highest level of knockdown at day 4.   
However these results also indicated that the transfection reagent was changing the 
behaviour of the cells causing a reduction in Bmp4 expression.  It was a concern that ES 
cells might be even more sensitive to the transfection reagent.  It was therefore necessary 
to either use a different transfection reagent or method of DNA delivery in further 
knockdown experiments.    
 
This result in addition to previous work that suggested that high toxicity was caused by 
lipid based transfection reagents in ES cells led to a decision not to pursue the use of 
other transfection reagents for plasmid delivery (Ma et al. 2004;Kobayashi et al. 2005).   
 
 
 
5.3  Development of Lentiviruses expressing shRNA for 
knockdown of BMP4 
 
Lentiviral vectors are derived from the human immunodeficiency virus, HIV-1.  HIV-1 is 
a retrovirus and has an RNA genome that is replicated via a DNA intermediate.  In the 
host cell, reverse transcriptase is used to create the DNA intermediate that can then be 
integrated into the host genome using integrase.  HIV-1 alternates between two forms: the 
provirus and the virion.  The provirus describes the double stranded DNA that has 
integrated into the host genome.  Viral RNA and proteins are produced from the provirus 
using the host’s transcription and translation apparatus.  Assembled viruses then bud off 
from the host’s cell membrane as virions capable of infecting other cells.   Chapter 5 
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Lentiviral vectors have several characteristics that make them excellent mediators of 
DNA delivery (Kobayashi et al. 2005).  Firstly they have been shown to be capable of 
infecting many different types of cells including dividing and non-dividing cells.  They 
generally exhibit low cytotoxicity.  Also they integrate their genetic material into host 
chromosomes with high efficiency resulting in stable expression of transgenes (Naldini et 
al. 1996). 
 
Lentiviral vectors in comparison to other types of retroviral vectors are less susceptible to 
silencing in ES cells (Ellis 2005).  ES cells genetically modified with retroviruses shut 
down expression of integrated transgenes.  The mechanisms are thought to include DNA 
methylation, histone deacetylation and binding of negative trans-acting factors to 
integrated transgenes (Chilton & Le Doux 2008).     
 
Several papers have now been published in which lentiviruses have been used to achieve 
stable expression of lentiviral transgenes in murine ES cells.  Pfeifer et al.  have achieved 
stable transgene expression in undifferentiated murine ES cells.  The transgene 
expression was maintained during EB differentiation and also in vivo.  EB differentiation 
was studied for a period of 8 days and occurred normally.  ES cells carrying the transgene 
were used to generate transgenic mice successfully (Pfeifer et al. 2002).  Kosaka et al.  
have also shown that lentiviruses are capable of efficient gene delivery in undifferentiated 
murine ES cells.  They add that there was no transduction associated cytotoxicity 
(Kosaka et al. 2004).  Hamaguchi et al. have transduced murine ES cells with GFP using 
a lentiviral vector and shown that GFP was expressed through to day 6 in EB Chapter 5 
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differentiation.  Haematopoietic colonies derived from these EBs also expressed GFP.  
Thus lentiviruses are capable of mediating gene delivery in ES cells.  Furthermore stable 
transgene expression can be maintained in EB differentiation and EB derived 
haematopoietic cells.   
 
Liu et al. have used lentiviral vectors expressing shRNA targeting Sox17 expression to 
investigate cardiac muscle formation in differentiating murine ES cells.  The knockdown 
of  Sox17 expression lasted for 12 days of differentiation (Liu et al. 2007).  This 
experiment provides proof of principle for the use of shRNA expressing lentiviral vectors 
to knockdown gene expression in differentiating murine ES cells. 
 
The pLKO.1 plasmids obtained from Sigma had features allowing the generation of 
lentiviral particles (see Figure 5.2).  Within the plasmid there was a 5’ long terminal 
repeat (LTR), a 3’LTR, Ψ encapsidation signal, central polypurine tract and Rev response 
element all of which are lentiviral features.  The 5’LTR acts as a promoter of viral 
transcription by RNA polymerase II.  Although the 3’LTR has the same sequence 
arrangement as the 5’LTR it does not normally act as a promoter instead it is involved in 
transcription termination and polyadenylation.  Each LTR has a U3, R and U5 region.  In 
this vector the U3 region of the 3’LTR had been engineered with a 400 base pair deletion.  
Because in reverse transcription the U3 region of the 3’LTR is used as a template to 
generate the U3 regions of the 3’ and 5’LTR, modifications in 3’LTR are copied to the 
5’LTR.  These vectors are therefore self-inactivating in that once they integrate they are 
incapable of synthesising vector transcripts and rely on internal promoter activity.  These Chapter 5 
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self inactivating (SIN) vectors are replication incompetent.  The SIN mutation also 
alleviates concerns regarding cellular non-specific gene activation caused by promoter 
insertional mutagenesis.    
 
Other features included the Ψ encapsidation signal which normally ensures only full 
length transcripts are packaged into virions.  The central polypurine tract is thought to be 
involved in the nuclear import of lentiviral DNA.  The Rev response element normally 
binds Rev to allow nuclear export of viral RNA.   
 
Thus in order to prepare competent virus it was necessary to transfect these plasmids into 
a packaging cell line. 
 
5.3.1  Cloning GFP-WPRE into pKLO.1 
In order to facilitate easier virus titring and analysis of transduction efficiency, green 
fluorescent protein and the woodchuck hepatitis virus post-transcriptional regulatory 
element (GFP-WPRE) was cloned into plasmid 2 (Figure 5.12).  The shRNA sequence 
from plasmid 2 had induced the highest level of knockdown compared with other 
plasmids in the previous transfection experiments and so was chosen for use in further 
experiments.  By cloning GFP-WPRE into the lentiviral construct virus titring and 
transduction efficiency could be determined quickly and easily by analysing the 
percentage of GFP expressing cells using flow cytometry.   
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hPGK puro
hPGK GFP-WPRE
A
 
Figure 5.12 Cloning strategy  
Puromycin resistance gene was excised and a GFP-WPRE fragment from the SEW plasmid was cloned in. 
 
WPRE acts to increase transgene expression in this case GFP.  It is thought to act at a 
post-transcriptional level however the exact mechanism is not known (Zufferey et al. 
1999).   
 
A restriction digest was performed to excise GFP-WPRE, a 1.4 kilobase (kb) fragment 
from the SEW plasmid using BamHI and EcoRI.  The SEW plasmid was chosen only 
because it contained the GFP-WPRE fragment and any plasmid containing this fragment 
could have been used.  Also the puromycin resistance gene a 679 base pair (bp) fragment 
was excised from the pLKO.1 plasmid using the same enzymes, BamHI and EcoRI.  The 
6.3kb pLKO.1 backbone and 1.4kb GFP-WPRE fragments were resolved by gel 
electrophoresis.  These bands were cut out of the gel and the DNA gel extracted (Figure 
5.13).   Chapter 5 
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6.3kb pLKO backbone
1.4kb GFP-WPRE fragment
0.7kb puro fragment
 
Figure 5.13 SEW and pLKO.1 restriction digest  
Restriction digest of SEW and pLKO.1 puro plasmids with BamHI and KpnI in order to obtain pLKO.1 
backbone and GFP-WPRE insert (highlighted fragments).  The puro fragment was removed from the 
pLKO.1 plasmid.   
 
The pLKO.1 backbone was then phosphatase treated in order to remove phosphates group 
that can allow vectors that have been single digested to religate without taking up the 
GFP-WPRE insert.  The aim was to reduce background colonies following 
transformation. 
 
The phosphatase treated pLKO.1 backbone and GFP-WPRE fragment was then ligated.  
After overnight incubation competent bacteria were transformed by heat shock and then 
were cultured on plates selective for ampicillin resistant bacteria.   
 
In order to confirm that resulting colonies contained pLKO.1-GFP-WPRE, plasmid DNA 
from six colonies was expanded by miniprep and then a series of restriction digests were 
performed.  This included a single restriction digest with HindIII and also a double digest 
with  BamHI  and  KpnI (Figure 5.14).  This confirmed that GFP-WPRE had been 
successfully ligated into pLKO.1. 
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Figure 5.14 Restriction digests to test cloning 
Following ligation and transformation, bacteria were cultured on ampicillin plates.  6 colonies were picked 
for restriction digest analysis to confirm successful insertion of GFP-WPRE into pLKO.1.  Restriction 
digests used HindIII and BamHI with KpnI.  Plasmid diagrams indicate sites at which enzymes cut the 
plasmid.  Expected fragment sizes are indicated at the side of the gel. Chapter 5 
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5.3.2  Generating lentivirus  
 
Lentiviral particles carry a coat protein that affects the ability of the virus to infect certain 
cell types.  This viral coat is known as the pseudotype of the lentivirus.  Previous 
experiments have used lentivirus vector pseudotyped with vesicular stomatitis virus G 
protein (VSV-G) to efficiently transduce murine ES cells (Hamaguchi et al. 2000).  Thus 
VSV-G pseudotyped lentivirus was generated in these experiments. 
 
In order to produce lentiviral particles the pLKO.1-GFP-WPRE plasmid was transfected 
into the human 293T packaging cell line along with the pMDG2 plasmid which expresses 
the VSV-G viral coat protein and the p8.74 plasmid that expresses the Gag and Pol 
proteins necessary for functional lentivirus production.  Two days after transfection, the 
supernatant was harvested.  The virus was then concentrated by ultracentrifugation and 
frozen down for future use.   
 
A pLKO.1-GFP-WPRE plasmid carrying a ‘scrambled’ sequence (kindly donated by J. 
Metelo, Institute of Child Health) was also used to generate lentivirus.  The ‘scrambled’ 
sequence consisted of 4 base pairs mismatched to any known mouse gene.  The purpose 
of this plasmid was for use as a control in future experiments.  This enabled testing of 
whether lentivirus alone could change the expression of BMP4 and cell behaviour in 
general.  
 Chapter 5 
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The 293T cell line was observed to express GFP using a fluorescent microscope two days 
after transfection for both the pLKO.1-GFP-WPRE shRNA (Figure 5.15A).  This 
provided confirmation of successful ligation of the GFP-WPRE fragments. 
 
To determine the virus titre, 293T cells were transduced with a 5 fold dilution series of 
virus.  The transduction efficiency was then measured by analysing the percentage of 
GFP expressing cells using flow cytometry.  The dilution at which 5-15% of cells were 
transduced was determined (Figure 5.15B).  The virus titre was then calculated by 
dividing the number of transduced cells in this well by the volume of virus used to 
transduce them.  The titre for shRNA lentivirus was calculated as 2.8 x 10
8 and for 
scramble sequence lentivirus 4.325x10
8 virus particles per millilitre. 
 Chapter 5 
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Figure 5.15 Generating shRNA and scramble sequence lentivirus  
A shows GFP expressing 293T cells following transfection with shRNA GFP-WPRE pLKO.1 plasmid.  B 
shows virus titre data for both the shRNA and scramble sequence lentiviruses.  Virus titre was determined 
by transducing lentivirus with a 5 fold dilution series.  The virus titre was calculated using the dilution at 
which 5-15% of cells were transduced. 
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5.3.3  Testing lentiviral shRNA in ST2 cells 
Initial experiments were aimed at determining the ability of shRNA expressing 
lentiviruses to transduce cells and to knockdown Bmp4 expression.  The control scramble 
sequence lentivirus was included in experiments to determine whether the lentivirus alone 
would cause a reduction of Bmp4 expression that might be indicative of non-specific 
cellular effects caused by the introduction of lentivirus. 
 
ST2 cells, cells previously shown to express Bmp4, were seeded into a 24 well plate.  The 
following day these cells were transduced with virus at a range of multiplicity of 
infection’s (MOIs): 0, 0.16, 0.8, 4, 20 and 100.  The MOI is defined as the number of 
lentiviral particles per cell introduced to the culture.   
 
After 2 and 4 days samples were taken for analysis by flow cytometry to determine the 
percentage of GFP positive cells and therefore the transduction efficiency.  Also samples 
were taken for quantitative RT-PCR so that the knockdown of BMP4 could be quantified.  
The experimental protocol is summarised in Figure 5.16.  3 repeat experiments were 
carried out. 
 
• Untransduced cells
• Transduced cells with 
shRNA sequence  
• Transduced cells with 
scramble sequence
MOIs: 0, 0.16, 0.8, 
4, 20,100
Day 0
Day 2
Day 4
• Flow cytometry for GFP 
expression
• RT PCR for Bmp4 expression
Sample Analysis
 
Figure 5.16 Experimental protocol for testing shRNA lentivirus 
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At day 2 GFP expression was visualised using a fluorescent microscope and was 
observed in both the shRNA and scramble treated ST2 cells (Figure 5.17A).  Flow 
cytometry demonstrated that at day 2 an MOI of 4 and above was sufficient to produce a 
significant increase in GFP expressing cells above the level of untransduced cells with 
both the scramble and shRNA lentiviruses (P<0.05, Figure 5.17B).  At day 4 the levels of 
transduced cells remained similar compared to day 2 levels.  However an MOI of 0.8 and 
above was sufficient to produce an increase in GFP expressing cells above the level of 
untransduced cells with both scramble and shRNA sequences (P<0.05). Chapter 5 
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Figure 5.17 Testing shRNA lentivirus on ST2 cells – Transduction efficiency 
A shows micrographs (10x magnification) obtained using a fluorescent microscope showing ST2 cells 
transduced with both shRNA and scramble sequence lentivirus (MOI 20) at day 2.  B shows transduction 
efficiency measured as the percentage of cells expressing GFP.  Cells were transduced with shRNA and 
scramble sequence lentiviruses at MOIs of 0, 0.16, 0.8, 4, 20 and 100.  Results shown are the average of 3 
experiments.  Error bars represent the standard error.  * indicates significant change at P<0.05 relative to 
untransduced cells. Chapter 5 
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Bmp4 expression analysis revealed that Bmp4 knockdown was increased at higher MOIs.  
However at higher MOIs there was also Bmp4 knockdown with the scramble sequence 
lentivirus (Figures 5.18 and Table 5.1).  At day 2 an MOI of 20 produced significant 
knockdown only with the shRNA lentivirus (P<0.05) but at an MOI of 100 there was 
significant knockdown with both the shRNA and scramble lentiviruses (P<0.05).  At day 
4 an MOI of 0.8 was sufficient to produce a significant knockdown with the addition of 
shRNA lentivirus (P<0.05).  However significant knockdown occurred in both the 
shRNA and scramble treated cells at MOIs of 4 and above (P<0.05).   
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Figure 5.18 Testing shRNA lentivirus on ST2 cells – Bmp4 expression   
Logarithmic graphs showing fold change in Bmp4 expression relative to the untreated control at day 2 and 
day 4.  Cells were transduced with shRNA and scramble sequence lentiviruses at MOIs of 0, 0.16, 0.8, 4, 
20 and 100.  Results shown are the average of 3 experiments.  Error bars represent the standard error.  * 
indicates results significant at P<0.05 relative to untreated cells.   Chapter 5 
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shRNA results
Scramble results
0.13 0.28 0.55 1.28 1.03 1 Average
0.12 0.24 0.90 1.46 0.73 1 Exp 3
0.18 0.21 0.25 1.30 1.45 1 Exp 2
0.09 0.39 0.50 1.09 0.92 1 Exp 1
100 20 4 0.8 0.16 0 DAY 2
0.14 0.67 2.03 1.08 1.29 1 Average
0.13 0.54 1.04 0.70 0.53 1 Exp 3
0.23 0.91 0.82 0.83 1.33 1 Exp 2
0.06 0.56 4.24 1.70 2.02 1 Exp 1
100 20 4 0.8 0.16 0 DAY 2
0.09 0.26 0.28 0.45 0.59 1 Average
0.05 0.19 0.20 0.36 0.37 1 Exp 3
0.04 0.18 0.32 0.60 0.82 1 Exp 2
0.18 0.41 0.33 0.38 0.59 1 Exp 1
100 20 4 0.8 0.16 0 DAY 4
0.09 0.43 0.53 0.74 1.11 1 Average
0.08 0.50 0.42 0.65 0.55 1 Exp 3
0.08 0.52 0.53 0.68 0.85 1 Exp 2
0.11 0.27 0.66 0.89 1.94 1 Exp 1
100 20 4 0.8 0.16 0 DAY 4
 
 
Table 5.1 Bmp4 expression tables  
Fold change in Bmp4 expression relative to the untreated control at day 2 and day 4.  Cells were transduced 
with shRNA and scramble sequence lentiviruses at MOIs of 0, 0.16, 0.8, 4, 20 and 100.  Results shown are 
from 3 experiments.  P values indicate the statistical significance of results relative to untreated cells. 
 
These experiments showed that both shRNA and scramble sequence lentiviruses were 
capable of transducing cells and achieving knockdown of BMP4 expression.  With higher 
MOIs there was a greater level of transduction and knockdown.  However knockdown in 
scramble treated cells occurred at higher MOIs.  This may indicate toxicity caused by the 
introduction of lentivirus.  Thus in ES experiments it would be important to use an MOI 
which would achieve optimal knockdown with the lowest toxicity. Chapter 5 
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5.3.4  Testing lentiviral shRNA in ES cells 
The next step was to determine the optimal MOI at which to transduce ES cells with 
shRNA lentivirus.  ES cells were also transduced with lentivirus expressing scramble 
sequence to assess non specific effects caused by the introduction of lentivirus.   
 
In ES cell differentiation a large range of tissue types is generated.  This is likely to 
involve large scale changes in gene expression which could have affected the expression 
of the shRNA.  It was therefore important to assess over time whether there were any 
changes in transduction efficiency or Bmp4 knockdown.   
 
ES cells were transduced and differentiated on the same day.   Samples were taken at day 
2 and day 4 of differentiation.  Samples were analysed by flow cytometry for the 
percentage of GFP expressing cells and by quantitative RT-PCR for Bmp4 knockdown.  
The experimental protocol was as shown in Figure 5.16. 
 
At day 2 GFP expression was visualised using a fluorescent microscope for EBs 
transduced using both the scramble and shRNA lentiviruses (Figure 5.19). Chapter 5 
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+shRNA virus +Scramble virus
 
Figure 5.19 Micrographs of EBs at day 2 of differentiation obtained using light microscope (top) and 
fluorescent microscope (bottom) at 10x magnification (MOI 20).   
 
At day 2 a higher MOI correlated with an increase in the percentage of GFP expressing 
cells (Figure 5.20).  The shRNA lentivirus at an MOI of 0.8 produced a significant 
increase in GFP expressing cells relative to untransduced cells (P<0.05).  At an MOI of 4 
both the shRNA and scramble sequence lentivirus produced an increase in GFP 
expressing cells relative to untransduced cells (P<0.05).   
 
At day 4 the pattern was similar with an MOI 0.8 producing a significant increase in GFP 
expressing cells only with shRNA transduced cells relative to untransduced cells 
(P<0.05).  However at an MOI of 4 both the shRNA and scramble sequence lentivirus 
produced an increase in GFP expressing cells relative to untransduced cells (P<0.05).  A 
higher MOI correlated with an increase in GFP expressing cells.  However at an MOI of 
100 there was a suspicious decrease in GFP expressing cells which may have reflected 
cell death caused by uptake of the virus.  At such a high MOI it is possible that multiple 
copies of the virus are taken up by each cell overloading the cell causing cell death. Chapter 5 
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Figure 5.20 Testing shRNA lentivirus on ES cells –  Transduction efficiency 
Transduction efficiencies measured as percentage of GFP positive cells at day 2 and day 4.  Cells were 
transduced at MOIs of 0, 0.16, 0.8, 4, 20 and 100 using shRNA and scramble sequence lentivirus before 
differentiation.   Graph show average values obtained in 3 experiments.  Error bars are the standard error.  * 
indicates significant results at P<0.05 relative to the untransduced cells. 
 
At day 2 at MOIs of 20 and 100 there was a significant reduction in Bmp4 expression 
with shRNA lentivirus (P<0.05, Figure 5.21 and Table 5.2).  However there was no 
significant change in Bmp4 expression with scramble sequence lentivirus at any of the Chapter 5 
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MOIs used.  At day 4 there was significant Bmp4 knockdown with shRNA lentivirus at 
MOIs of 4 and 100 (P<0.05).  It was surprising that an MOI of 20 did not produce 
significant knockdown.  However this was probably as a result of the larger range of 
expression values in the three experiments conducted at this MOI.  Scramble sequence 
shRNA only produced significant knockdown of Bmp4 expression at an MOI of 100. 
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Figure 5.21 Testing shRNA lentivirus on ES cells –  Bmp4 expression 
Fold change in Bmp4 expression relative to the untreated control at day 2 and day 4.  Logarithmic graph 
shows average values obtained in 3 experiments.  Error bars are the standard error.  * indicates significant 
results at P<0.05 relative to the untreated control. 
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shRNA results
Scramble results
0.11 0.39 0.59 0.97 0.86 1 Average
0.08 0.28 0.41 1.15 0.77 1 Exp 3
0.07 0.40 0.52 0.79 0.82 1 Exp 2
0.17 0.51 0.84 0.99 0.98 1 Exp 1
100 20 4 0.8 0.16 0 DAY 2
0.50 1.03 1.31 1.39 1.22 1 Average
0.46 1.04 1.31 1.28 0.80 1 Exp 3
0.89 1.50 1.31 1.39 1.58 1 Exp 2
0.14 0.54 1.30 1.51 1.27 1 Exp 1
100 20 4 0.8 0.16 0 DAY 2
0.13 0.41 0.43 0.93 0.51 1 Average
0.08 0.28 0.41 1.15 0.77 1 Exp 3
0.07 0.76 0.23 1.26 0.39 1 Exp 2
0.24 0.18 0.64 0.38 0.37 1 Exp 1
100 20 4 0.8 0.16 0 DAY 4
0.62 0.71 1.00 0.84 0.63 1 Average
0.46 1.04 1.31 1.28 0.80 1 Exp 3
0.74 0.80 0.90 0.60 0.64 1 Exp 2
0.65 0.30 0.79 0.65 0.45 1 Exp 1
100 20 4 0.8 0.16 0 DAY 4
 
Table 5.2 Bmp4 expression tables  
Fold change in Bmp4 expression relative to the untreated control at day 2 and day 4.  Cells were transduced 
with shRNA and scramble sequence lentiviruses at MOIs of 0, 0.16, 0.8, 4, 20 and 100.  Results shown are 
from 3 experiments.  P values indicate the statistical significance of results relative to the untreated control. 
 
In order to determine if the shRNA lentivirus caused cytotoxicity, ES cells were 
transduced at the same range of MOIs and differentiated to day 4 at which point cells 
were stained with Annexin V and Propidium Iodide to assess cell death (Figure 5.22).  
Annexin V staining identifies apoptotic cells and staining with both propidium iodide and 
annexin V identifies necrotic cells.  There were significant increases in cell death in 
particular apoptotic cells at MOIs of 20 and 100 (P<0.05).  This was probably caused by 
the uptake of multiple lentivirus particles overloading the cells causing cell death.   Chapter 5 
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Figure 5.22 Cell death in transduced ES cells 
Necrosis and apoptosis at each MOI with the addition of shRNA lentivirus at day 4. Graph shows average 
values obtained in 3 experiments.  Error bars are the standard error.  * indicates significant results at 
P<0.05. 
 
The conclusion from these experiments was that an MOI of 4 would produce the highest 
knockdown of Bmp4 with the lowest cytotoxicity.  This MOI was therefore used in 
following experiments.  The average knockdown over 3 experiments at day 2 was 41% 
and at day 4 was 57%.  There would therefore be some limited expression of Bmp4 in 
further experiments however this would be at much lower level.     
 
Given that further haematopoietic differentiation experiments would continue through to 
day 6, knockdown of Bmp4 expression at an MOI of 4 was assayed at day 6 as well 
(figure 5.9F).  There was an average reduction of Bmp4 expression by 54% with shRNA 
treated cells in line with the reduction of Bmp4 expression at day 4. 
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Figure 5.23 Testing shRNA lentivirus on ES cells –  Day 6 Bmp4 expression  
A shows logarithmic graph showing fold change in Bmp4 expression relative to the untreated control at day 
6.  Graph shows average values obtained in 3 experiments. Error bars are the standard error.  * indicates 
significant results at P<0.05 relative to the untreated control.  B shows values obtained in each experiment.   
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5.4   The effects of lentiviral shRNA mediated BMP4 knockdown 
on the haematopoietic differentiation of ES cells 
 
 
In these experiments shRNA was used to knockdown the expression of Bmp4.  This 
would provide a Bmp4 free culture condition so that the effects of added BMP4 could be 
determined.  The primary aim of these experiments was to determine whether BMP4 
caused a change in the expression on the haematopoietic stem cell genes Runx1, Scl, 
Gata2 and Lmo2.   
 
The expression of Bmp4 is important to the undifferentiated phenotype as it blocks neural 
differentiation through the induction of Id genes (Ying et al. 2003).  The knockdown of 
Bmp4 expression may therefore have fundamentally affected the undifferentiated ES cell 
phenotype.  For this reason Bmp4 knockdown was only induced at the start of 
differentiation in ES cells.  Data from shRNA testing experiments showed that induction 
of Bmp4 knockdown occurred from day 2 which is when haematopoietic differentiation 
begins.  This was sufficient for the purpose of assessing the effect of BMP4 in 
haematopoietic differentiation.   
 
Thus ES cells were differentiated for 6 days in serum free culture, with shRNA lentivirus, 
with shRNA lentivirus plus BMP4 (25ng/ml) and with scramble sequence lentivirus.   
BMP4 was added at 25ng/ml because in previous experiments there was evidence that 
this concentration caused an increase in Scl, Gata2 and Lmo2 expression (see Section Chapter 5 
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4.4.2).  ES cells were transduced with scramble sequence lentivirus to detect any non-
specific cellular effects caused by uptake of the lentivirus.  The experimental protocol is 
summarised in Figure 5.24. 
 
• Serum Free (SF) culture
‘Untreated cells’
• SF + shRNA (MOI 4)
• SF + shRNA + BMP4
•S F  +  S c r a m b l e   
Day 0
Day 2
Day 4
• RT PCR for Runx1,
Scl, Gata2 and Lmo2
expression
• Flow cytometry for stem 
cell markers: CD34, Sca-1,
Flk-1, C-kit
Day 6
Culture conditions Sample Analysis
 
Figure 5.24 Experimental protocol for determining the effects of BMP4 in ES cell haematopoietic 
differentiation. 
 
5.4.1 Quantitative  PCR  analysis 
Samples were taken for quantitative PCR analysis of Runx1,  Scl,  Gata2 and Lmo2 
expression at days 0, 2, 4 and 6.  The experiment was repeated 5 times.  Tables showing 
the results obtained in each experiment are in Appendix 3.  Results were interpreted 
relative to day 0 to determine whether positive changes reflecting haematopoietic 
differentiation were occurring and relative to the untreated control to determine the effect 
of added BMP4 as described in Section 4.4.1.   
 
At day 2 and day 4 under all culture conditions Runx1 expression stayed at day 0 levels 
(Figure 5.25A).  However at day 6 there was a reduction in Runx1 expression in serum 
free culture conditions, with shRNA and with scramble lentiviruses (P<0.05).  However 
with the addition of BMP4 to shRNA treated cells Runx1 expression was maintained at 
day 0 levels (P=0.138). Chapter 5 
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The most striking change in Runx1 expression relative to the untreated control was at day 
6 (Figure 5.25B).   There was an increase in Runx1 expression relative to the untreated 
control with added BMP4 (P<0.05).  Taking the expression relative to day 0 and the 
expression relative to the untreated control into account, at day 6 BMP4 maintained 
Runx1 expression at day 0 levels. 
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Figure 5.25 QPCR analysis – Runx1 
Graphs show fold change in Runx1 expression.  Gene expression has been calculated relative to: (A) day 0 
and (B) the untreated control.  Cells were differentiated under serum free conditions, with shRNA, with 
shRNA plus BMP4 and with scramble lentivirus.  Samples were taken at day 0, 2, 4 and 6.  The results 
shown are the average of 5 experiments.  The error bars indicate standard error.  * indicates results 
significant at P<0.05. 
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At day 2 and day 4 there was no change in Scl expression relative to day 0 (Figure 
5.26A).  At day 6 there was a reduction in Scl expression relative to day 0 in serum free 
culture, with the addition of shRNA and scramble sequence lentiviruses (P<0.05).   
However there was an increase in Scl expression above day 0 levels with the addition of 
BMP4 (P<0.05).   
 
Relative to the untreated control Scl expression did not change at day 2 or day 4 (Figure 
5.26B).  At day 6, Scl expression increased dramatically relative to the untreated control 
with the addition of BMP4 (P<0.05).  Under all other culture conditions at day 6, Scl 
expression was at similar levels to the untreated control.  Putting all the data together, this 
indicates that at day 6 BMP4 increased Scl expression.   
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Figure 5.26 QPCR analysis – Scl 
Graphs show fold change in Scl expression.  Gene expression has been calculated relative to: (A) day 0 and 
(B) the untreated control.  Cells were differentiated under serum free conditions, with shRNA, with shRNA 
plus BMP4 and with scramble lentivirus.  Samples were taken at day 0, 2, 4 and 6.  The results shown are 
the average of 5 experiments.  The error bars indicate standard error.  * indicates results significant at 
P<0.05. 
 
Gata2 expression reduced below day 0 levels at days 2, 4 and 6 (P<0.05, Figure 5.27A).  
The only exception to this was at day 6 where the addition of BMP4 caused the 
maintenance of Gata2 expression at day 0 levels (P=0.893).   
 
Relative to the untreated control Gata2 expression levels were similar at day 2 and at day 
4 under all culture conditions (Figure 5.27B).  At day 6 Gata2 expression stayed the same 
with the addition of shRNA lentivirus but reduced with the addition of scramble 
lentivirus (P<0.05) relative to the untreated control.  With the addition of BMP4 however Chapter 5 
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there was an increase in Gata2 expression levels relative to the untreated control at day 6.  
This data indicates that BMP4 maintains Gata2 expression at day 0 levels. 
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Figure 5.27 QPCR analysis – Gata2 
Graphs show fold change in Gata2 expression.  Gene expression has been calculated relative to: (A) day 0 
and (B) the untreated control.  Cells were differentiated under serum free conditions, with shRNA, with 
shRNA plus BMP4 and with scramble lentivirus.  Samples were taken at day 0, 2, 4 and 6.  The results 
shown are the average of 5 experiments.  The error bars indicate standard error.  * indicates results 
significant at P<0.05. 
 
Overall Lmo2 expression levels stayed at similar levels at day 2 relative to day 0 (Figure 
5.28A).  There was a general increase in Lmo2 expression levels at day 4.  Then at day 6 
there was a reduction back to day 0 levels.  There was an increase in Lmo2 expression at 
day 6 under serum free conditions and with the addition of BMP4 relative to day 0 
(P<0.05). Chapter 5 
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Relative to the untreated control Lmo2 expression was at reduced levels with the addition 
of BMP4 at day 4 (P<0.05, Figure 5.28B).  However at day 6 there was a striking 
increase in Lmo2 expression relative to the untreated control with the addition of BMP4 
(P<0.05).  Under all other conditions Lmo2 expression levels were similar to the 
untreated control at day 6.  This data together indicates that at day 6 BMP4 increases 
Lmo2 expression.   
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Figure 5.28 QPCR analysis – Lmo2 
Graphs show fold change in Lmo2 expression.  Gene expression has been calculated relative to: (A) day 0 
and (B) the untreated control.  Cells were differentiated under serum free conditions, with shRNA, with 
shRNA plus BMP4 and with scramble lentivirus.  Samples were taken at day 0, 2, 4 and 6.  The results 
shown are the average of 5 experiments.  The error bars indicate standard error.  * indicates results 
significant at P<0.05. 
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The most striking effects of BMP4 were seen at day 6.  These results showed that at day 6 
BMP4 maintained Runx1 and Gata2 expression at day 0 levels.  However BMP4 
increased the expression of Scl and Lmo2 expression above day 0 levels.   
 
5.4.2 Flow  cytometry 
Samples were taken at day 6 to determine if the changes seen in gene expression at this 
time point correlated with changes in stem cell surface markers.  Cells cultured in serum 
free conditions, with shRNA, with shRNA plus BMP4 and with scramble sequence 
lentivirus were stained with the same stem cell panel of antibodies as used in initial 
experiments (see Section 3.2.2.1).  This included antibodies to detect CD34, Sca-1, Flk-1 
and C-kit.  Results shown in Figure 5.29A show the average results from 4 experiments 
and in Figure 5.29B flow plots from a representative experiment are shown (experiment 
4).  Tables showing the data obtained in each experiment are in Appendix 3.   
 
There was an increase in CD34 expressing cells with the addition of shRNA relative to 
the untreated control (P<0.05).  This was surprising as a reduction in BMP4 would have 
been expected to reduce the number of CD34 expressing cells. 
 
However the addition of BMP4 to shRNA transduced cells caused an increase in C-kit 
expressing cells (P<0.05).  There was also a trend for an increase in Flk-1 expression 
with the addition of BMP4 which did not reach statistical significance. Chapter 5 
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Figure 5.29 Stem cell marker analysis  
A ES cells were differentiated to day 6 under serum free conditions, with shRNA, with shRNA plus BMP4 
and with scramble sequence lentivirus.  The cells were stained with a stem cell panel of antibodies: CD34, 
Sca-1, Flk-1 and C-kit.  Results shown are the average of 4 experiments.  The error bars represent the 
standard error.  * indicates results significant at P<0.05.  B shows flow cytometry plots from a 
representative experiment (Experiment 4).  The results from all experiments are tabulated in Appendix 2. Chapter 5 
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5.4.3 Discussion 
This experiment investigated the role of BMP4 in haematopoietic differentiation by 
measuring changes in haematopoietic stem cell gene expression and stem cell surface 
marker expression.  Lentivirus expressing shRNA was used to knockdown Bmp4 
expression so as to reduce the production of BMP4 by cells in serum free culture.  It is 
known that without the expression of BMP4 mesoderm formation is defective (Winnier et 
al. 1995) and thus this experiment aimed to investigate the role of exogenous BMP4 in 
rescuing a knockdown phenotype. 
 
These results have shown that BMP4 maintains Runx1 and Gata2 expression and up 
regulates expression of Scl and Lmo2 at day 6 of differentiation.  Previous experiments 
have suggested that BMP4 combined with VEGF was necessary to increase Scl 
expressing cells (Park et al. 2004).  This experiment shows that BMP4 alone is sufficient 
to up regulate Scl expression.  Pearson et al. have suggested that BMP4 alone is required 
for efficient mesoderm formation but is insufficient for haematopoietic specification 
(Pearson et al. 2008).  In this paper a combination of growth factors including BMP4 
were used to produce increases in Runx1,  Scl and Lmo2 expression.  In the current 
experiment BMP4 alone has been shown to be capable of producing increases in Scl and 
Lmo2 expression.   
 
Previous titration experiments (Section 4.4) had shown that BMP4 caused an increase in 
Gata2 expression levels.  The general trend in the data suggested that there was an 
increase above day 0 levels.  However in this experiment exogenous BMP4 only resulted Chapter 5 
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in the maintenance of Gata2 expression levels at day 0 levels.  It is possible that in the 
titration experiments although up to 25ng/ml of BMP4 was added, the actual 
concentration in the EBs was higher due to the production of BMP4 by the differentiating 
cells.  The use of a higher concentration of BMP4 might therefore increase the expression 
of Gata2 above day 0 levels as seen in previous experiments. 
 
Runx1 and Gata2 expression relative to the untreated control was reduced at day 6 when 
transduced with scramble sequence lentivirus at P<0.05.  However this pattern was not 
seen with the shRNA expressing lentivirus and therefore it seems unlikely that this 
change in gene expression resulted from non-specific cellular effects caused by the 
uptake of the lentivirus. 
 
Flow cytometry analysis showed increases in C-kit expressing cells with the addition of 
BMP4.  However given that C-kit is a marker for haematopoietic stem cells in early 
development (Sanchez et al. 1996), this may represent the expansion of a HSC 
population.  Further analysis of this population is required to prove this. There was a 
trend for an increase in Flk-1 expressing cells in line with previous data that has shown 
the same result in differentiating ES cells (Park et al. 2004).   
 
The timescale of BMP4 dependent increases in haematopoietic gene expression which 
only occurred at day 6 seems slower compared to earlier titration experiments where 
changes were seen at day 2 and day 4.  This may result from slower less efficient 
mesoderm formation resulting from the knockdown of BMP4 expression. Chapter 5 
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There was no observed reduction in gene expression in the shRNA treated cells relative 
to the untreated cells.  The shRNA treated cells are likely to have had low mesoderm 
formation and little if any haematopoietic specification.  This result reveals that the serum 
free ‘untreated’ cells probably also differentiated little without additional stimulus.   
 
 
 
5.5 General  Discussion 
 
Knockdown of Bmp4 expression can be achieved using siRNA.  However the effects are 
only transient.  In order to achieve more sustained knockdown short hairpin RNA which 
also causes knockdown via the RNAi pathway was expressed from a plasmid.   
 
The main challenge of shRNA delivery in ES cells is to achieve knockdown without 
producing non-specific cellular effects or cytotoxicity.  Transfection is generally less 
expensive and less time consuming.  Published literature suggests that it is possible to 
transfect ES cells (Ma et al. 2004).  In order to determine whether this was a feasible 
technique to deliver shRNA plasmids, ES cells were transfected with the pEGFP-N1 
plasmid to determine transfection efficiency.  In comparison with previous studies using 
lipofection, higher transfection efficiency was observed.  At day 2 44.7% of transfected 
ES cells expressed GFP.  This compares with 5.75% in Ma et al. and 15% in Tang et al.  
In both papers different ES cell lines were used (Tang et al. 2004;Ma et al. 2004).  It 
maybe that different ES cell lines have different transfection potentials.   
 Chapter 5 
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Transfection reagents however are known to cause toxicity (Kim et al. 2008).  shRNA 
plasmids were transfected into the control stromal cell line ST2.  The transfection reagent 
alone caused a reduction in Bmp4 expression.  Concerns that this may have resulted from 
cytotoxicity and that this might be an issue in ES cells led to a search for alternatives to 
transfection for shRNA delivery. 
 
The plasmids came with lentivirus components.  The plasmid with the most effective 
shRNA sequence was chosen and lentivirus was generated.  In order to facilitate easier 
virus titering and analysis of transduction efficiency GFP-WPRE was cloned into the 
plasmid.   
 
shRNA expressed from lentivirus has previously been used as a means to investigate the 
function of the transcription factor Sox17 in cardiac muscle differentiation of ES cells 
(Liu et al. 2007).  However it was important to test the ability of the shRNA expressed 
from lentivirus to knockdown Bmp4.  Testing was carried out at a variety of MOIs in ST2 
cells.  Transduction efficiency was high at MOIs of 4 and above.  The shRNA transduced 
cells were shown to produce up to 89% knockdown.  However at higher MOIs the 
scramble sequence lentivirus was shown to cause Bmp4 knockdown.  Since the scramble 
sequence is designed to have no effect on Bmp4 expression this suggested that at higher 
MOIs uptake of the lentivirus was causing cytotoxicity.   
 
Testing of the shRNA expressing lentivirus in ES cells was therefore aimed at finding the 
optimal MOI which would produce the highest level of Bmp4 knockdown with the Chapter 5 
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minimum cytotoxicity.  An MOI of 4 produced 41% knockdown at day 2, 57% 
knockdown at day 4 and 54% at day 6.  Transduction efficiency was high with over 70% 
transduction at day 2 and day 4.  Annexin V, Propidium Iodide staining revealed that 
there was not significant cytotoxicity at day 4 at an MOI of 4.  Higher MOIs however did 
produce significant cytotoxicity. 
 
shRNA at MOI of 4 was therefore used to investigate the role of BMP4 in haematopoietic 
gene expression.  The addition of BMP4 at 25ng/ml led to the up regulation of Scl and 
Lmo2 genes at day 6.  Runx1 and Gata2 expression was maintained at day 0 levels.  
Further flow cytometric analysis of day 6 EBs showed that this correlated with an 
increase in C-kit expressing cells.   
 
These results were far more robust and consistent than in previous experiments.  This 
probably resulted from the absence of uncontrolled endogenous expression of Bmp4.  
Previous work in the area has not taken into account endogenous expression of Bmp4.  
Furthermore previous work has suggested that additional factors are needed to up 
regulate these haematopoietic genes (Park et al. 2004;Pearson et al. 2008).  This 
experiment has therefore clarified the role of BMP4 showing that it produces an up 
regulation of Scl and Lmo2 expression and maintains expression of Runx1 and Gata2.  
This series of experiments illustrates the importance of taking into account endogenous 
expression in determining the effects of growth factors in differentiation in the ES cell 
system.   
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Scl and Lmo2 along with Gata2 have been shown to act in a complex together.  This 
complex has been shown previously to up regulate expression of C-kit in murine adult 
bone marrow (Lecuyer et al. 2002).  Given the results in this experiment it may be that in 
early development BMP4 up regulates the formation of this complex which can then up 
regulate C-kit expression.   
 
Furthermore the Scl-Lmo2-Gata2 complex has been shown to activate Runx1 expression 
in a murine yolk sac cell line (Landry et al. 2008).  BMP4 may also maintain Runx1 
expression through the up regulation of this complex.   
 
Future experiments should investigate whether BMP4 up regulates the formation of this 
complex and whether this is Smad dependent given that BMP4 signaling is thought to 
occur via the Smad pathway (Larsson & Karlsson 2005).   
 
Scl and Lmo2 have similar deletion mutant phenotypes and expression patterns in early 
and adult haematopoietic lineages.  Given the results in this experiment showing that both 
of these genes were up regulated, this data together suggests that these genes may share 
the same transcriptional control mechanisms.   
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Chapter 6  Final Discussion 
 
This work sought to determine the effect of BMP4 on the developing haematopoietic 
populations in ES cell differentiation, the foetal liver and the adult haematopoietic 
populations of the bone marrow.  In doing this several noteworthy observations have 
been made.   
 
BMP4 in haematopoietic development 
 
Since the initial finding that BMP4 is expressed by stromal cells beneath the ventral floor 
of the dorsal aorta in 28 day old human embryos where intra-aortic clusters form 
(Marshall, Kinnon, & Thrasher 2000), several studies have implicated BMP4 in the initial 
stages of haematopoietic development.  Much of this work has been done in vitro using 
ES cell differentiation which is accepted as a model of haematopoietic development 
(Keller et al. 1993).  The accessibility of cellular material makes this model easy to 
manipulate in comparison with any in vivo developmental system.   
 
This work sought to further investigate the role of BMP4 in ES cell haematopoietic 
differentiation by specifically defining the haematopoietic genes that are up regulated in 
response.  Knockout studies have shown that Runx1, Scl, Gata2 and Lmo2 are all critical 
to haematopoietic development.  The deletion mutant phenotype for all of these genes is 
lethal due to the absence of blood development.  At the time of completing this thesis two Chapter 6 
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papers were published further elucidating the roles of Scl and Runx1 in the development 
of definitive haematopoietic cells.  These studies show that haemangioblasts give rise to 
the haemogenic endothelium which then gives rise to definitive haematopoietic cells.   
Furthermore these studies demonstrate that Scl is necessary for the establishment of the 
haemogenic endothelium and Runx1 is critical in the generation of definitive 
haematopoietic cells (Lancrin et al. 2009;Chen et al. 2009). The aim of this study was to 
establish whether BMP4 would up regulate the expression of any of these critical 
haematopoietic genes: Runx1, Scl, Gata2 and Lmo2.   
 
Previous studies have shown that BMP4 in combination with other factors can up 
regulate these genes.  Park et al. have shown that whilst BMP4 alone is sufficient for the 
differentiation of Flk-1 expressing mesoderm, a combination of VEGF and BMP4 
dramatically enhances Scl up regulation (Park et al. 2004).  Pearson et al. have developed 
this work adding that BMP4 in combination with activin A, basic fibroblast growth factor 
and VEGF is required for optimal haematopoietic differentiation (Pearson et al. 2008).  In 
this study they showed that this combination of growth factors could increase Runx1, Scl 
and Lmo2 expression within a 24 hour period.  Lugus et al. have shown that after 2 days 
of differentiation cells treated for 1 hour with BMP4 showed an increase in Gata2 
expression (Lugus et al. 2007).  This was in contrast to results in Pearson et al. in which 
no increase in Gata2 expression was observed.   
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Unlike previous studies which have attempted to produce optimal gene expression and 
haematopoietic differentiation, this work was aimed exclusively at discovering the role 
that BMP4 plays in this process.  
 
There was variability in the results achieved from ES cell haematopoietic differentiation 
experiments.  Despite efforts to make the process as consistent as possible, for example 
using the technique of hanging body differentiation, there was still variability in the 
results obtained.  This made it difficult to draw conclusions about the effects of BMP4.  
This was further complicated by endogenous Bmp4 expression in differentiating ES cells.  
The use of lentiviral shRNA to knockdown Bmp4 expression very much improved the 
consistency of data.  This suggests that in part the variability seen was due to inconsistent 
BMP4 production between experiments.   
 
Attempts are currently being made to differentiate specific tissues from ES cells.  In order 
to do this a clear understanding of the role of specific growth factors in the differentiation 
process is necessary.  It is essential that studies take account of endogenous growth factor 
production.  Otherwise endogenous growth factor production in untreated samples will 
mask the effects seen in treated samples.   
 
In this case lentiviral shRNA was used to knockdown Bmp4 expression.  This provided a 
serum free system in which Bmp4 was not being expressed allowing the effect of added 
BMP4 to be determined.  This experiment revealed that BMP4 increased Scl and Lmo2 Chapter 6 
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expression whilst maintaining levels of Runx1 and Gata2 expression.  Furthermore there 
was an increase in C-kit expressing cells. 
 
In the BMP4 titration experiments there were increases in Gata2 expression above day 0 
levels with the addition of BMP4.  The endogenous BMP4 in addition to the exogenous 
BMP4 may have exceeded the levels present in the shRNA experiments.  If a higher 
concentration of BMP4 was used in the shRNA experiment this may have caused a larger 
increase in Gata2 expression.   
 
BMP4 is thought to produce intracellular changes via the Smad signalling pathway in 
particular Smad1.  Zafonte et al. have generated Smad1 inducible ES cells (Zafonte et al. 
2007).  The activation of Smad1 expression caused an increase in Flk-1, Runx1, Scl and 
Gata2 expression.  This data is in line with the data presented in this study.  However 
Zafonte et al. have presented their quantitative PCR data as relative to an untreated age 
matched control and therefore it is difficult to tell whether these changes represent 
changes above day 0 levels or the maintenance of gene expression at day 0 levels.  This 
illustrates the utility of determining gene expression relative to both day 0 and an age 
matched untreated control.   
 
DNA delivery in ES cells 
 
The need to deliver shRNA to ES cells provided an opportunity to investigate the efficacy 
of different gene delivery techniques in ES cells.  The two methods used were lipofection Chapter 6 
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and lentiviral transduction.  In comparison with previous studies which have used 
lipofection, higher transfection efficiencies were observed in these experiments.  At day 2 
there was 44.7% transfection efficiency as compared to 5.75% in studies by Ma et al. 
(Ma et al. 2004).  This could be due to differences in both the transfection reagent used 
and the ES cell line used.  The major concern with the use of lipofection for delivering 
shRNA plasmids was the potential for cytotoxicity.  Several papers suggest that this is 
significant problem in the transfection of ES cells (Ma et al. 2004;Kobayashi et al. 2005).  
In addition knockdown only lasted to day 4 which was insufficient for these experiments.   
 
Lentiviruses integrate into the genome and therefore can produce long lasting effects.  
Given the gene expression changes presumably are occurring as differentiation proceeds, 
it was a concern that there might be inactivation of the knockdown. However experiments 
showed that shRNA knockdown in transduced cells increased from day 2 to day 4 and 
then remained steady to day 6.  However at high MOIs of 20-100, cytotoxicity was 
significant.  The MOI was therefore optimised to produce a high level of knockdown with 
a low level of cytotoxicity.   
 
Thus lentiviruses are effective vectors with which DNA delivery can be achieved in 
differentiating ES cells especially if long term effects are required.   
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C-kit, Sca-1 and the cell cycle 
 
In initial experiments attempts were made to discover what effect if any BMP4 had on 
haematopoietic populations of the foetal liver and bone marrow.  There was variability in 
results caused by variation in the initial populations detected.  One method of resolving 
this issue was to perform experiments on a sorted population of cells.  A CD34 C-kit 
positive population was sorted from bone marrow.  There were difficulties however with 
maintaining adequate cell survival over the culture period.   
 
These initial experiments brought about an opportunity to compare the gene expression 
and cell surface marker characteristics of haematopoietic cell populations from ES cells, 
foetal liver and bone marrow populations.  These experiments showed that Runx1, Scl 
and Lmo2 which have been shown to be critical in the genesis of HSCs are expressed at 
much higher levels in the foetal liver and bone marrow.  This suggests that these genes 
continue to have an important function in more mature haematopoietic populations.   
Conditional knockout has shown that deletion of Runx1 in the adult impairs 
megakaryocytic differentiation and T and B lymphocyte development (Ichikawa et al. 
2004) and deletion of Scl in the adult impairs erythroid and megakaryocytic 
differentiation (Mikkola et al. 2003).  The increased level of expression of these genes 
may reflect the increased presence of these cells in these more mature haematopoietic 
populations.   
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The cell surface markers C-kit and Sca-1 have been used to identify the HSC since its 
first discovery (Worton, McCulloch, & Till 1969).  In this work analysis of cell surface 
markers revealed a higher level of C-kit expressing cells in ES cell derived and foetal 
liver haematopoietic populations compared with bone marrow.  There was however 
higher levels of Sca-1 expressing cells in the bone marrow compared with the ES cell 
derived and foetal liver populations.  It was therefore hypothesised that C-kit was 
expressed on dividing cells whereas Sca-1 was expressed on quiescent cells.  In order to 
test this, bone marrow cells were stained for C-kit and Sca-1 and the cell cycle status of 
these populations was determined.  These experiments showed that there were much 
higher levels of G2/M and S phase cells in the C-kit population and there were much 
higher levels of G1/0 cells in the Sca-1 positive population.  The expression of these 
markers does therefore appear to be related to cell cycle status. 
 
Scl and Lmo2 
 
SCL and LMO2 show overlapping expression patterns in early haematopoietic sites and 
in adult haematopoietic lineages.  The deletions mutants of Scl and Lmo2 both cause 
similar phenotypes with a complete absence of blood formation and death around 9.5 dpc 
(Warren et al. 1994;Shivdasani, Mayer, & Orkin 1995).  In the shRNA experiments both 
Scl and Lmo2 were up regulated to similar levels above day 0 expression.    Furthermore 
in the comparison of day 0 populations there were increases in both Scl and Lmo2 to 
similar levels in both the foetal liver and bone marrow populations.  This data together 
suggests that Scl and Lmo2 may share the same transcriptional control mechanisms.  Chapter 6 
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Timing of gene expression in ES differentiation 
 
The patterns of gene expression between experiments were too inconsistent to draw any 
overall conclusions as to what the kinetics of gene expression was for each gene.   
However in the shRNA experiment, in which the results were most consistent, at day 6 
when the cells responded to BMP4 increases in gene expression for Runx1, Scl, Gata2 
and Lmo2 occurred together.  The regulation of gene expression between these genes has 
been shown previously to be interconnected.  Pimanda et al. have described a gene 
regulatory network comprising of Gata2, Fli1 and Scl and Landry et al. have provided 
evidence that the SCL-Lmo2-Gata2 complex can transactivate Runx1 expression 
(Pimanda et al. 2007b;Landry et al. 2008).  The increase in expression of all these genes 
at the same time therefore is in line with previous data. 
 
Future work 
 
In order to determine the effect of BMP4 in the foetal liver and bone marrow populations 
it is necessary to sort consistent populations and find appropriate culture conditions so as 
to maintain an adequate level of cell survival.  Furthermore future experiments should 
take into account endogenous BMP4 production.   
 
Future experiments could also investigate the signalling pathways that are activated by 
BMP4.  It is known that there is a close relationship in the control of the expression of 
Runx1, Scl, Gata2 and Lmo2.  Given that the transcriptional control mechanisms of the 4 
genes investigated in this study are so closely related, it is possible that BMP4 only Chapter 6 
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triggers one component which causes the up regulation of the other genes.  In particular 
given the results in the shRNA ES experiments it is possible that BMP4 could directly up 
regulate Scl and Lmo2 triggering indirect up regulation of Runx1 and Gata2.  Future 
experiments could explore this hypothesis.  
 
A recent paper has compared Brachyury
+Flk1
+ populations and Brachyury
+Flk1
- 
populations based on mRNA changes and protein changes (Williamson et al. 2008).   
mRNA changes were measured using microarray and quantitative PCR.  Protein changes 
were analysed by quantitative proteomics.  In this study it was found that 95% of protein 
changes were not associated with mRNA changes and that there was more protein 
changes than mRNA changes.  This illustrates the potential importance of post 
transcriptional regulation in protein expression.  Thus future studies should verify the 
gene expression findings in this study with protein analysis.   
 
BMP4 as a mesoderm patterning factor is involved in the development of many different 
tissue types.  It remains a puzzle as to how this one molecule could have so many 
different effects.  It may be that the effects of BMP4 seem diverse but in fact they are just 
part of a multitude of inputs including cell-cell interactions and other locally produced 
factors that cause a cell to differentiate down a particular pathway.  Recent work in 
Xenopus has shown that exposure to BMP4 even for 20 minutes causes Smad1 
phosphorylation and within half an hour effects are seen on the transcription of 
downstream genes (Simeoni & Gurdon 2007).  Cells are therefore able to quickly respond 
to changes in extracellular BMP4 concentration which is reflected by the steady state Chapter 6 
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Smad1 concentration in the nucleus.  Cells in culture are traditionally exposed to one 
concentration of BMP4 however it maybe that in development as the embryo changes 
shape, cell populations are exposed to different concentrations of BMP4 at different time 
points.    Future work should investigate whether the timing of the addition of BMP4 as 
well as the concentration of BMP4 is important.  
 
There are significant differences between the phenotypes of murine ES cells and human 
ES cells.  Human ES cells are SSEA3 +ve, SSEA4 +ve and SSEA1 –ve.  Murine ES cells 
however are SSEA1 +ve and are both SSEA3 and SSEA4 –ve.  In addition human ES 
cells express two keratin sulphate related antigens, TRA-1-60 and TRA-1-81 (Andrews 
2002).  It is likely that the differentiation processes will be different as well.  For this 
reason it is important that future experiments discover the extent to which the lessons 
learnt in the murine ES cell system in regard to haematopoietic differentiation can be 
extrapolated to the human ES cell system.  In particular it is important to determine 
whether the human homologs of Runx1, Scl, Gata2 and Lmo2 play the same roles in the 
haematopoietic differentiation of human ES cells.   Also future experiments should 
establish whether BMP4 induces the expression of these genes.   
 
Conclusion 
 
In order to use ES cells in the clinic it is essential to understand the environmental and 
genetic triggers that cause differentiation down specific pathways.  This study illustrates 
some of the difficulties that must be overcome in order to understand these pathways and Chapter 6 
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also some potential solutions.  The differentiation of ES cells in EBs mimics the 
processes that occur in developing embryos in many ways except that it is considerably 
more disorganised.  When the aim is to develop one specific type of tissue, the processes 
occurring in EBs which are aimed at developing all the tissues of the body will be in 
direct contradiction.  Thus in order to differentiate a particular type of tissue it may be 
necessary in addition to promoting the differentiation of that particular tissue to also 
inhibit differentiation down other pathways.   
 
In this study where it was only necessary to investigate the role of a particular growth 
factor the first step was to suppress the expression of BMP4 using shRNA.  The effect of 
added BMP4 could then be determined.  Previous ES cell differentiation studies do not 
take into account the endogenous production of growth factors and thus untreated 
controls in experiments may not provide fair comparison by which effects can be 
determined.  This study provides a novel method of establishing the effects of growth 
factors in ES cell differentiation.  
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Appendix 1  
 
ES differentiation - PCR tables 
 
Results are expressed as fold difference in gene expression relative to Day 0.  All results are correct to 2 
decimal places.  SR = Serum Replacement, FCS = Foetal calf serum 
 
Runx1 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES2  1  1.45 2.60 2.63 6.48 7.62  8.98 
ES4  1  3.12 2.67 4.94 3.38 3.16  4.91 
ES5  1  0.13 7.75 9.58 1.58 1.41  3.07 
P    0.446 0.400 0.398 0.363 0.401  0.384 
 
Scl 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES2  1  1.36 0.34 0.52 1.78 2.58  9.96 
ES4  1  2.13 2.24 4.73 0.82 1.13  5.45 
ES5  1  2.13 3.20 5.18 3.32 3.87  3.61 
P    0.099 0.314 0.202 0.347 0.268  0.393 
 
Gata2 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES2  1  1.50 0.55 0.90 1.09 2.05  5.36 
ES4  1  1.75 2.20 8.48 1.90 1.48  8.32 
ES5  1  2.53 2.94 4.22 4.34 4.40  5.11 
P    0.159 0.287 0.396 0.367 0.339  0.301 
 
Lmo2 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES2  1  2.89 1.29 2.47 19.16  15.03  54.82 
ES4  1  1.43 1.38 1.75 2.16 1.63  4.99 
ES5  1  1.92 1.79 1.41 3.15 3.48  1.82 
P    0.206 0.117 0.166 0.423 0.422  0.423 
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ES differentiation - Flow cytometry results 
 
Data is from 5 independent experiments.   Tables show stem cell and differentiation marker data.  Results 
are expressed in the form of percentage of positive cells detected.  ND indicates where an experiment has 
not been done.  All results are correct to 1 decimal place.  P values indicate statistical significance relative 
to day 0 result.   
 
Stem Cell Markers 
 
CD34 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES1 1.4  1.3  ND  2.4  2.4  ND  6.4 
ES3 2.6  6.7  7.7  10.9  3.5  16.1  5.2 
ES4  3.8 ND ND ND 2.3 5.7  11.8 
ES5  6.8  4.1  11.7 15.8 3.2  2.0  11.9 
ES6  27.7 16.4 13.7 31.4 12.0 8.1  24.8 
P     0.465  1.00  0.068  0.225  0.715  0.138 
 
Sca1 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES1 2.0  2.8  ND  1.7  1.1  ND  3.6 
ES3  7.4  31.8 32.3 14.8 8.3  8.5  18.5 
ES4  8.4 ND ND ND 12.4  19.2 20.8 
ES5 7.7  13.1  17.8  9.5  11.2  9.2  11.9 
ES6  18.5 24.9 15.6 16.7 19.1 11.7  18.5 
P    0.068 0.285 0.581 0.176 0.465  0.068 
 
Flk1 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES1 0.7  0.5  ND  0.5  5.2  ND  8.3 
ES3  1.1  27.8 11.0 20.3 2.4  1.7  11.3 
ES4  0.8 ND ND ND 0.9 2.7  23.2 
ES5  0.6  3.1  34.2 16.9 4.4  2.5  10.7 
ES6  0.3 0.2 0.2 0.3 0.5 0.2  0.9 
P    0.465 0.285 0.285 0.043 0.141  0.043 
 
C-kit 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES1 16.3  21.6  ND  3.9  13.8  ND  16.8 
ES3  18.8  9.2 6.3 1.9 15.9  18.9  31.0 
ES4  66.3  ND ND ND 50.4  48.0 57.2 
ES5  40.0 45.4 54.9 35.6 12.0 14.0  40.0 
ES6  0.2 0.3 0.2 0.1 1.2 0.4  1.1 
P    0.715 0.655 0.068 0.080 0.465  0.465 
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Differentiation Markers  
 
CD45 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES1 x x x x x x  X 
ES3  0.2 0.9 1.5 2.5 2.7 2.4  4.1 
ES4 x x x x X  x  X 
ES5 0.8  1.3  1.9  62.5  0.2  0.3  2.1 
ES6  1.1 3.6 2.0 2.9 3.0 3.2  2.7 
 
Ter119 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES1 0.1  0.3  ND  0.3  0 ND  0.4 
ES3  0.7 5.3 1.3 1.5 2.4 1.6  5.1 
ES4  0.1 ND ND ND 1.6 0.5  1.9 
ES5  0.3 5.5 1.7 2.4 0.2 0.3  3.9 
ES6  0.3 1.1 0.1 0.2 0.2 1.0  0.1 
P    0.068 0.285 0.144 0.680 0.109  0.080 
 
CD11b 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES1 0.1  0.5  ND  0.2  0.1  ND  0.5 
ES3 1.8  4.6  15.3  7.7  6.2  9.3  10.0 
ES4  6.8 ND ND ND 25.1  14.4 10.1 
ES5  0.2 0.2 0.1 5.0 0.8 1.8  1.6 
ES6  0.2 2.7 0.8 0.4 2.4 1.8  2.4 
P    0.109 0.285 0.068 0.068 0.066  0.043 
 
CD19 
Day 3  Day 6  Experiment 
Date 
Day 0  
    SR           BMP4         FCS       SR          BMP4          FCS 
ES1 0.9  1.9  ND  1.9  0.8  ND  1.1 
ES3  0.5 1.6 0.7 2.3 1.4 0.7  0.4 
ES4  5.8 ND ND ND 3.7 2.7  6.3 
ES5  1.0  15.8 15.8 33.2 0.8  1.8  1.6 
ES6  0.9 0.4 0.2 0.4 0.4 0.4  0.3 
P    0.144 0.593 0.144 0.345 0.715  0.588 
 
 
 
 
 
 
 Appendix 1 
 
  260
Foetal liver PCR tables 
 
Results are expressed as fold difference in gene expression relative to Day 0.  All results are correct to 2 
decimal places.  P values indicate statistical significance relative to day 0 result.  SR = Serum Replacement, 
FCS = Foetal calf serum.   
 
Runx1 
 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4        BMPR     FCS 
FL3 1 1.14  2.26  ND  2.02 
FL4 1 4.26  2.78  ND  2.53 
FL5 1 7.41  7.13  1.91  8.26 
FL6 1 0.53  4.73  1.51  0.63 
P   0.273  0.068    0.144 
 
Scl 
 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4        BMPR     FCS 
FL3 1 0.10  0.02  ND  0.07 
FL4 1 0.22  0.10  ND  0.07 
FL5 1 1.13  0.64  0.12  1.03 
FL6 1 0.04  0.25  0.05  0.07 
P   0.144  0.068    0.131 
 
Gata 2 
 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4        BMPR     FCS 
FL3 1 1.25  1.00  ND  0.86 
FL4 1 1.31  0.88  ND  1.85 
FL5 1 2.28  1.94  0.39  3.68 
FL6 1 0.13  1.34  0.36  0.26 
P   0.715  0.285    1.00 
 
Lmo2 
 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4        BMPR     FCS 
FL3 1 0.16  0.24  ND  0.11 
FL4 1 0.30  0.18  ND  0.15 
FL5 1 0.60  0.57  0.13  1.11 
FL6 1 0.03  0.26  0.08  0.05 
P   0.068  0.068    0.144 Appendix 1 
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Foetal Liver - Flow cytometry results 
Data is from 6 independent experiments.   Tables show stem cell and differentiation marker data.  Results 
are expressed in the form of percentage of positive cells detected.  ND indicates where an experiment has 
not been done.  All results are correct to 1 decimal place.  P values indicate statistical significance relative 
to day 0 result.  
Stem Cell Markers 
CD34 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR       FCS 
FL1 32.7  8.8  ND  ND  7.9 
FL2 9.5  16.3  ND  ND  2.6 
FL3 5.0  19.6  15.2  ND  2.5 
FL4 8.6  15.8  20.2  ND  7.0 
FL5 12.6  10.7  10.5  13.8  45.4 
FL6 9.7  7.4  36.2  35.4  3.1 
P   0.753  0.144    0.345 
 
Sca1 
Day 3  Experiment 
Date 
Day 0  
    SF          BMP4       BMPR        FCS 
FL1 0.6  74.9  ND  ND  17.1 
FL2 7.7  6.3  ND  ND  1.2 
FL3 3.2  17.2  19.5  ND  7.6 
FL4 1.9  16.8  19.1  ND  14.6 
FL5 2.7  9.9  9.6  12.2  11.2 
FL6 1.3  8.5  11.2  41.7  53.0 
P   0.046  0.068    0.075 
 
Flk 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR        FCS 
FL1 44.4  5.5  ND  ND  2.6 
FL2 ND  ND  ND  ND  ND 
FL3 1.5  17.7  13.3  ND  4.4 
FL4 0.6  8.9  3.0  ND  11.7 
FL5 2.7  8.9  8.1  10.0  6.2 
FL6 0.7  4.3  22.7  38.7  2.4 
P   0.5  0.068    0.5 
 
C kit 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR        FCS 
FL1 ND  ND  ND  ND  ND 
FL2 16.6  23.4  ND  ND  1 
FL3 19.7  8.3  14.4  ND  5.9 
FL4 18.9  3.9  7.1  ND  3.9 
FL5 49.3  7.1  7.1  8.8  13.4 
FL6 38.4  10.7  22.2  38.9  5.4 
P   0.080  0.068    0.043 Appendix 1 
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Differentiation Markers 
 
CD45 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR      FCS 
FL1 41.1  25.1  ND  ND  5.8 
FL2 38.0  25.1  ND  ND  8.1 
FL3 27.6  16.6  23.8  ND  39.8 
FL4 8.6  27.8  93.3  ND  40.0 
FL5 16.2  14.8  17.6  23.0  37.5 
FL6 24.7  26.2  51.2  73.0  45.6 
P   0.6  0.273    0.917 
 
Ter119 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4        BMPR      FCS 
FL1 77.9  92.4  ND  ND  51.6 
FL2 81.3  34.9  ND  ND  74.5 
FL3 75.88  64.64  57.0  ND  40.6 
FL4 52.3  11.1  8.8  ND  13.4 
FL5 55.9  86.0  85.0  81.5  65.1 
FL6 35.4  63.7  30.6  19.4  60.7 
P   0.753  0.465    0.249 
 
CD11b 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR      FCS 
FL1 5.3  84.8  ND  ND  21.9 
FL2 2.9  85.5  ND  ND  90.1 
FL3 5.6  23.5  18.9  ND  38.4 
FL4 5.6  17.1  16.8  ND  4.7 
FL5 0.4  9.4  10.2  13.3  45.6 
FL6 0.8  6.2  35.5  29.5  2.2 
P   0.028  0.068    0.046 
 
CD19 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4        BMPR     FCS 
FL1 ND  ND  ND  ND  ND 
FL2 ND  ND  ND  ND  ND 
FL3 0.84  11.5  4.4  ND  3.5 
FL4 1.7  6.0  2.2  ND  6.6 
FL5 0.8  10.0  13.2  13.1  17.1 
FL6 2.4  16.1  44.8  49.6  9.3 
P   0.068  0.068    0.068 
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Bone marrow PCR tables 
Results are expressed as fold difference in gene expression relative to Day 0.  All results are correct to 2 
decimal places.  P values indicate statistical significance relative to day 0 result.  SR = Serum Replacement, 
FCS = Foetal calf serum.   
 
Runx1 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR       FCS 
BM5 1  9.11  23.37  ND  8.26 
BM6 1  3.79  3.10  3.01  1.79 
BM7 1  2.80  2.50  3.10  0.91 
P   0.163  0.334    0.371 
 
Scl 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR       FCS 
BM5 1  1.47  7.78  ND  1.16 
BM6 1  0.59  0.51  0.47  0.08 
BM7 1  0.30  0.29  0.36  0.07 
P   0.606  0.529    0.260 
 
Gata2 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR       FCS 
BM5 1  27.22  92.63  ND  13.96 
BM6 1  4.97  4.16  4.50  1.06 
BM7 1  6.13  5.22  6.29  0.34 
P   0.245  0.377    0.450 
 
Lmo2 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR       FCS 
BM5 1  3.29  12.79  ND  3.44 
BM6 1  0.93  0.88  0.87  0.36 
BM7 1  0.78  0.69  0.97  0.27 
P   0.498  0.444    0.765 
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Bone marrow - Flow cytometry results 
Data is from 7 independent experiments.   Results are expressed in the form of percentage of positive cells 
detected.  ND indicates where an experiment has not been done.  + denotes addition of TPO and IGF1.  All 
results are correct to 1 decimal place.  P values indicate statistical significance relative to day 0 result.  
 
Stem Cell Markers  
CD34 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR       FCS 
BM5 20.0  47.1  49.4  ND  7.8 
BM6 0.7  41.3  48.0  20.7  49.9 
BM7 0.2  5.1  5.7  4.2  8.2 
P   0.146  0.152    0.494 
Sca1 
Day 3  Experiment 
Date 
Day 0  
    SF          BMP4       BMPR        FCS 
BM5 4.4  20.7  21.9  ND  8.2 
BM6 5.9  39.5  34.6  33.0  28.6 
BM7 4.9  36.5  31.8  31.4  32.6 
P   0.038  0.02    0.131 
Flk 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR        FCS 
BM5 2.5  2.9  2.0  ND  1.0 
BM6 1.9  4.5  4.8  7.7  3.1 
BM7 6.6  7.0  7.3  6.2  14.0 
P   0.262  0.408    0.464 
C kit 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR        FCS 
BM5 10.6  52.1  52.9  ND  21.1 
BM6 13.9  54.1  54.5  13.1  48.2 
BM7 9.3  58.7  58.6  57.0  6.1 
P   0.004  0.004    0.333 
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Differentiation Markers  
 
CD45 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR      FCS 
BM5 55.6  96.4  93.3  ND  81.9 
BM6 66.9  97.4  98.4  98.3  77.7 
BM7 22.9  94.6  96.2  96.5  58.0 
P   0.061  0.068    0.077 
Ter119 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4        BMPR      FCS 
BM5 41.3  3.7  4.3  ND  13.0 
BM6 25.4  3.0  2.6  3.6  24.7 
BM7 39.4  6.6  6.6  5.0  29.0 
P   0.02  0.018    0.246 
CD11b 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4       BMPR      FCS 
BM5 20.4  13.4  16.2  ND  11.0 
BM6 1.9  4.8  5.2  3.3  4.8 
BM7 0.3  5.9  7.0  5.2  5.1 
P   0.908  0.609    0.910 
CD19 
Day 3  Experiment 
Date 
Day 0  
    SF           BMP4        BMPR     FCS 
BM5 3.7  7.2  7.0  ND  4.2 
BM6 13.3  6.8  15.1  9.4  8.6 
BM7 21.2  12.4  12.2  11.4  15.0 
P   0.407  0.769    0.23 
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Raw PCR data  
 
Data is from representative ES cell Real Time PCR experiment (ES5) in Chapter 3.  
 
NTC = Non template control 
 
Sample Name  Detector  CT Average  Delta CT  DD CT 
FOLD 
CHANGE
EB D0  mouse gapdh vic  14.06        
EB D0  mouse gapdh vic  14.1        
EB D0  mouse gapdh vic  14.09 14.08333      
EB D3 FCS  mouse gapdh vic  14.47        
EB D3 FCS  mouse gapdh vic  14.33        
EB D3 FCS  mouse gapdh vic  14.62 14.47333      
EB D3 SR  mouse gapdh vic  18.41        
EB D3 SR  mouse gapdh vic  18.64        
EB D3 SR  mouse gapdh vic  18.78 18.61       
EB D3 BMP4  mouse gapdh vic  17.01        
EB D3 BMP4  mouse gapdh vic  17.11        
EB D3 BMP4  mouse gapdh vic  17.24 17.12       
EB D6 FCS  mouse gapdh vic  15.24  
EB D6 FCS  mouse gapdh vic  15.2  
EB D6 FCS  mouse gapdh vic  15.17 15.20333
EB D6 SR  mouse gapdh vic  15.88  
EB D6 SR  mouse gapdh vic  15.9  
EB D6 SR  mouse gapdh vic  15.98 15.92
EB D6 BMP4  mouse gapdh vic  15.81  
EB D6 BMP4  mouse gapdh vic  15.89  
EB D6 BMP4  mouse gapdh vic  16.14 15.94667
 
EB  D0    Runx  26.59     
EB  D0    Runx  26.47     
EB D0   Runx  26.39 26.48333 12.4  0 1
EB D3 SR   Runx  29.68        
EB D3 SR   Runx  29.95        
EB D3 SR  Runx  29.83 29.82 15.34667  2.946667 0.13
EB D3 BMP4   Runx  28        
EB  D3  BMP4 Runx  28.05     
EB D3 BMP4  Runx  28.12 28.05667 9.446667  -2.95333 7.75
EB  D3  FCS  Runx  26.16     
EB D3 FCS   Runx  26.25        
EB D3 FCS   Runx  26.37 26.26 9.14  -3.26 9.58
EB D6 SR   Runx  26.88        
EB D6 SR   Runx  27.1        
EB D6 SR  Runx  26.84 26.94 11.73667  -0.66333 1.58
EB D6 BMP4   Runx  28.12        
EB D6 BMP4   Runx  27.69        Appendix 1 
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EB D6 BMP4   Runx  27.67 27.82667 11.90667  -0.49333 1.41
EB D6 FCS   Runx  26.76        
EB D6 FCS   Runx  26.62        
EB D6 FCS   Runx  26.8 26.72667 10.78  -1.62 3.07
 
EB D0   Scl  27.93        
EB  D0  Scl  28.06      
EB D0   Scl  27.86 27.95 13.86667  0  1
EB D3 FCS   Scl  26.32        
EB D3 FCS   Scl  25.92        
EB D3 FCS   Scl  25.66 25.96667 11.49333  -2.3733  5.18
EB D3 SR   Scl  31.13        
EB D3 SR   Scl  31.52        
EB D3 SR   Scl  31.5 31.38333 12.77333  -1.0933  2.13
EB D3 BMP   Scl  29.15        
EB D3 BMP   Scl  29.37        
EB D3 BMP   Scl  29.41 29.31 12.19  -1.6767  3.20
EB D6 FCS   Scl  27.2        
EB D6 FCS   Scl  27.14        
EB D6 FCS   Scl  27.31 27.21667 12.01333  -1.8533  3.61
EB D6 SR   Scl  28.11        
EB D6 SR   Scl  28.02        
EB D6 SR   Scl  28.04 28.05667 12.13667  -1.73  3.32
EB D6 BMP   Scl  27.79        
EB D6 BMP   Scl  27.76        
EB D6 BMP   Scl  28.03 27.86 11.91333  -1.9533  3.87
 
EB D0  M gata2  24.26        
EB D0  M gata2  24.46        
EB D0  M gata2  24.39 24.37 10.28667  0  1
EB D3 FCS  M gata2  22.68        
EB D3 FCS  M gata2  22.62        
EB D3 FCS  M gata2  22.75 22.68333 8.21  -2.0767  4.22
EB D3 SR  M gata2  27.45        
EB D3 SR  M gata2  27.63        
EB D3 SR  M gata2  27.6 27.56 8.95  -1.3367  2.53
EB D3 BMP4  M gata2  25.81        
EB D3 BMP4  M gata2  25.93        
EB D3 BMP4  M gata2  25.81 25.85 8.73  -1.5567  2.94
EB D6 FCS  M gata2  23.14        
EB D6 FCS  M gata2  23.11        
EB D6 FCS  M gata2  23.16 23.13667 7.933333  -2.3533  5.11
EB D6 SR  M gata2  24.11        
EB D6 SR  M gata2  24.23        
EB D6 SR  M gata2  23.93 24.09 8.17  -2.1167  4.34
EB D6 BMP  M gata2  24.14        
EB D6 BMP  M gata2  24.02        Appendix 1 
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EB D6 BMP4  M gata2  24.13 24.09667 8.15  -2.1367  4.40
 
EB D0  Lmo2 mouse  28.04        
EB D0  Lmo2 mouse  28.06        
EB D0  Lmo2 mouse  28.15 28.08333 14  0  1
EB D3 FCS  Lmo2 mouse  27.89        
EB D3 FCS  Lmo2 mouse  27.99        
EB D3 FCS  Lmo2 mouse  28.06 27.98 13.50667  -0.4933  1.41
EB D3 SR  Lmo2 mouse  31.58        
EB D3 SR  Lmo2 mouse  31.55        
EB D3 SR  Lmo2 mouse  31.88 31.67 13.06  -0.94  1.92
EB D3 BMP4  Lmo2 mouse  30.28        
EB D3 BMP4  Lmo2 mouse  30.41        
EB D3 BMP4  Lmo2 mouse  30.15 30.28 13.16  -0.84  1.79
EB D6 FCS  Lmo2 mouse  28.32        
EB D6 FCS  Lmo2 mouse  28.33        
D6 FCS  Lmo2 mouse  28.37 28.34 13.13667  -0.8633  1.82
EB D6 SR  Lmo2 mouse  28.49        
EB D6 SR  Lmo2 mouse  28.12        
D6 SR  Lmo2 mouse  28.18 28.26333 12.34333  -1.6567  3.15
EB D6 BMP  Lmo2 mouse  28.14        
EB D6 BMP  Lmo2 mouse  28.16        
D6 BMP  Lmo2 mouse  28.14 28.14667 12.2  -1.8  3.48
 
Runx NTC  Undetermined
Runx NTC  Undetermined
Runx NTC  Undetermined
Scl NTC  Undetermined
Scl NTC  Undetermined
Scl NTC  Undetermined
M gata2  NTC  Undetermined
M gata2  NTC  Undetermined
M gata2  NTC  Undetermined
mouse gapdh vic  NTC  Undetermined
mouse gapdh vic  NTC  Undetermined
mouse gapdh vic  NTC  Undetermined
Lmo2 mouse  NTC  Undetermined
Lmo2 mouse  NTC  Undetermined
Lmo2 mouse  NTC  Undetermined
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Runx1 (BMP4 titration)     Relative to Day 0 
 
  Day 2 
0ng/ml 
Day 2 
5ng/ml 
Day 2 
10ng/ml 
Day 2 
25ng/ml
Exp 1  4.68 2.10 3.60  1.68 
Exp 2  2.17 1.20 1.13  1.21 
Exp 3  1.80 0.32 0.20  0.03 
Exp 4  3.23 3.59 4.52  3.72 
Exp 5  3.01 1.18 2.49  1.91 
Average 2.98  1.68  2.39  1.71 
P 0.04  0.23  0.14  0.14 
  
  Day 6 
0ng/ml 
Day 6 
5ng/ml 
Day 6 
10ng/ml 
Day 6 
25ng/ml
Exp 1  1.78 1.88 2.13  1.56 
Exp 2  0.10 0.13 0.12  0.12 
Exp 3  0.08 0.09 0.09  0.12 
Exp 4  0.52 0.51 0.65  0.69 
Exp 5  0.49 0.37 0.48  0.58 
Average 0.59  0.60  0.69  0.61 
P  0.07 0.07 0.07  0.07 
 
Relative to untreated control 
 
  Day 2 
0ng/ml 
Day 2 
5ng/ml 
Day 2 
10ng/ml 
Day 2 
25ng/ml
Exp 1  1 0.45  0.77  0.36 
Exp 2  1 0.55  0.52  0.56 
Exp 3  1 0.18  0.11  0.01 
Exp 4  1 1.11  1.40  1.15 
Exp 5  1 0.39  0.83  0.63 
Average 1  0.54  0.72  0.54 
P  0.08  0.35  0.08 
 
  Day 6 
0ng/ml 
Day 6 
5ng/ml 
Day 6 
10ng/ml 
Day 6 
25ng/ml
Exp 1  1 1.06  1.20  0.87 
Exp 2  1 1.07  0.99  0.99 
Exp 3  1 0.88  0.88  1.18 
Exp 4  1 0.96  1.25  1.32 
Exp 5  1 0.75  0.98  1.19 
Average 1  0.94  1.06  1.11 
P  0.5  0.69  0.23 
  Day 4
0ng/ml
Day 4
5ng/ml
Day 4 
10ng/ml 
Day 4 
25ng/ml 
Exp 1  1.03 0.50 0.99  0.75 
Exp 2  0.30 0.15 0.15  0.13 
Exp 3  0.14 0.08 0.06  0.03 
Exp 4  0.40 0.32 0.39  X 
Exp 5  0.19 0.13 0.00  0.30 
Average 0.41  0.24  0.32  0.30 
P 0.08  0.04  0.04  0.5 
  Day 4
0ng/ml
Day 4
5ng/ml
Day 4 
10ng/ml 
Day 4 
25ng/ml
Exp 1  1 0.49  0.97  0.73 
Exp 2  1 0.51  0.49  0.45 
Exp 3  1 0.52  0.44  0.18 
Exp 4  1 0.79  0.96  X 
Exp 5  1 0.69  1.60  1.60 
Average1  0.60  0.89  0.74 
P  0.04  0.5  0.72    Appendix  2 
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Scl  (BMP4  titration)        Relative  to  Day  0   
 
  Day 2 
0ng/ml 
Day 2 
5ng/ml 
Day 2 
10ng/ml 
Day 2 
25ng/ml
Exp 1  1.42 1.49 2.80  1.39 
Exp 2  0.59 0.48 0.57  0.93 
Exp 3  0.39 0.11 0.12  0.03 
Exp 4  0.65 1.05 0.65  1.29 
Exp 5  0.31 0.24 0.61  0.91 
Average 0.67  0.67  0.95  0.91 
P  0.23 0.35 0.5  0.89 
 
  Day 6 
0ng/ml 
Day 6 
5ng/ml 
Day 6 
10ng/ml 
Day 6 
25ng/ml
Exp 1  3.21 3.26 4.17  2.41 
Exp 2  0.03 0.05 0.05  0.05 
Exp 3  0.06 0.09 0.09  0.53 
Exp 4  0.34 0.19 0.54  0.71 
Exp 5  0.06 0.06 0.07  0.11 
Average 0.74  0.73  0.98  0.76 
P  0.5 0.5 0.5  0.5 
 
Relative to untreated control 
 
  Day 2 
0ng/ml 
Day 2 
5ng/ml 
Day 2 
10ng/ml 
Day 2 
25ng/ml
Exp 1  1 1.05  1.97  0.98 
Exp 2  1 0.82  0.97  1.58 
Exp 3  1 0.29  0.31  0.07 
Exp 4  1 1.62  1.01  2.00 
Exp 5  1 0.76  1.94  2.90 
Average 1  0.91  1.24  1.51 
P  0.69  0.5  0.23 
  
  Day 6 
0ng/ml 
Day 6 
5ng/ml 
Day 6 
10ng/ml 
Day 6 
25ng/ml
Exp 1  1 1.02  1.30  0.75 
Exp 2  1 1.74  1.99  1.83 
Exp 3  1 1.49  1.48  8.65 
Exp 4  1 0.56  1.59  2.08 
Exp 5  1 0.94  1.07  1.85 
Average 1  1.15  1.48  3.03 
P  0.5  0.04  0.08 
  Day 4
0ng/ml
Day 4
5ng/ml
Day 4 
10ng/ml 
Day 4 
25ng/ml 
Exp 1  1.30 0.94 2.68  1.97 
Exp 2  0.08 0.06 0.08  0.05 
Exp 3  0.09 0.10 0.09  0.10 
Exp 4  10.17 5.25  7.13  X 
Exp 5  0.04 0.03 0.12  0.13 
Average2.34  1.27  2.02  0.56 
P 0.69  0.5  0.69  0.69 
  Day 4
0ng/ml
Day 4
5ng/ml
Day 4 
10ng/ml 
Day 4 
25ng/ml 
Exp 1  1 0.72  2.05  1.51 
Exp 2  1 0.72  0.97  0.63 
Exp 3  1 1.08  1.03  1.10 
Exp 4  1 0.52  0.70  X 
Exp 5  1 0.67  3.07  3.26 
Average1  0.74  1.57  1.62 
P  0.08  0.35  0.14    Appendix  2 
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Gata2  (BMP4  titration)     Relative  to  Day  0 
 
   Day 2 
0ng/ml 
Day 2 
5ng/ml 
Day 2 
10ng/ml 
Day 2 
25ng/ml
Exp 1  4.94 2.78 3.92  2.40 
Exp 2  2.48 1.30 1.19  1.94 
Exp 3  0.92 0.21 0.19  0.05 
Exp 4  2.24 3.35 2.84  3.11 
Exp 5  0.89 0.36 1.35  2.30 
Average 2.29  1.60  1.90  1.96 
P 0.23  0.5  0.23  0.14 
  
   Day 6 
0ng/ml 
Day 6 
5ng/ml 
Day 6 
10ng/ml 
Day 6 
25ng/ml
Exp 1  14.66 7.45  9.13  5.46 
Exp 2  0.03 0.10 0.010 0.09 
Exp 3  0.02 0.06 0.08  0.22 
Exp 4  0.33 0.34 0.69  1.14 
Exp 5  0.19 0.21 0.33  0.62 
Average 3.05  1.63  2.06  1.50 
P 0.5  0.69  0.69  0.69 
 
Relative to untreated control 
 
  Day 2 
0ng/ml 
Day 2 
5ng/ml 
Day 2 
10ng/ml 
Day 2 
25ng/ml
Exp 1  1 0.56  0.79  0.49 
Exp 2  1 0.53  0.48  0.78 
Exp 3  1 0.23  0.20  0.05 
Exp 4  1 1.50  1.27  1.39 
Exp 5  1 0.40  1.51  2.58 
Average 1  0.64  0.85  1.06 
P  0.35  0.89  0.35 
 
  Day 6 
0ng/ml 
Day 6 
5ng/ml 
Day 6 
10ng/ml 
Day 6 
25ng/ml
Exp 1  1 0.51  0.62  0.37 
Exp 2  1 3.01  2.98  2.62 
Exp 3  1 3.05  3.81  10.65 
Exp 4  1 1.02  2.08  3.42 
Exp 5  1 1.15  1.77  3.31 
Average 1  1.75  2.25  4.08 
P  0.69  0.89  0.69 
  Day 4
0ng/ml
Day 4
5ng/ml
Day 4 
10ng/ml 
Day 4 
25ng/ml 
Exp 1  2.85 0.27 5.80  4.58 
Exp 2  0.11 2.82 3.03  2.80 
Exp 3  0.17 22.37  19.38 14.32 
Exp 4  0.45 0.49 0.71  X 
Exp 5  0.15 0.10 0.32  0.40 
Average0.74  5.21  5.85  5.53 
P 0.5  0.69  0.23  0.08 
   Day 4
0ng/ml
Day 4
5ng/ml
Day 4 
10ng/ml 
Day 4 
25ng/ml 
Exp 1  1 0.87  2.04  1.61 
Exp 2  1 27.00  28.84  26.66 
Exp 3  1 127.85110.79  81.86 
Exp 4  1 1.10  1.60  X 
Exp 5  1 0.66  2.14  2.74 
Average1  31.45  29.08  28.22 
P  0.5  0.04  0.04    Appendix  2 
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Lmo2  (BMP4  titration)     Relative  to  Day  0 
 
   Day 2 
0ng/ml 
Day 2 
5ng/ml 
Day 2 
10ng/ml 
Day 2 
25ng/ml
Exp 1  8.11 7.00 8.54  4.70 
Exp 2  0.63 1.47 1.61  1.95 
Exp 3  1.08 0.27 0.31  0.05 
Exp 4  2.35 3.81 2.41  4.28 
Exp 5  0.77 0.66 0.70  0.01 
Average 2.59  2.64  2.71  2.20 
P 0.5  0.35  0.35  0.42 
 
   Day 6 
0ng/ml 
Day 6 
5ng/ml 
Day 6 
10ng/ml 
Day 6 
25ng/ml
Exp 1  15.82 10.08 13.61  9.76 
Exp 2  0.27 0.55 0.63  1.29 
Exp 3  0.27 0.35 0.37  0.67 
Exp 4  1.03 0.83 1.87  4.20 
Exp 5  0.20 0.21 0.23  0.31 
Average 3.52  2.40  3.34  3.25 
P 0.69  0.5  0.69  0.35 
 
Relative to untreated control 
 
   Day 2 
0ng/ml 
Day 2 
5ng/ml 
Day 2 
10ng/ml 
Day 2 
25ng/ml
Exp 1  1 0.86  1.05  0.58 
Exp 2  1 2.31  2.54  3.07 
Exp 3  1 0.25  0.29  0.05 
Exp 4  1 1.63  1.03  1.82 
Exp 5  1 0.85  0.90  0.01 
Average 1  1.18  1.16  1.11 
P  0.69  0.89  0.69 
 
  Day 6 
0ng/ml 
Day 6 
5ng/ml 
Day 6 
10ng/ml 
Day 6 
25ng/ml 
Exp 1  1 0.64  0.86  0.62 
Exp 2  1 2.07  2.38  4.83 
Exp 3  1 1.28  1.35  2.46 
Exp 4  1 0.80  1.81  4.07 
Exp 5  1 1.02  1.12  1.53 
Average 1  1.16  1.51  2.70 
P  0.69  0.14  0.08 
  Day 4
0ng/ml
Day 4
5ng/ml
Day 4 
10ng/ml 
Day 4 
25ng/ml 
Exp 1  5.06 11.03  7.57  4.66 
Exp 2  0.23 0.40 0.48  0.39 
Exp 3  0.19 0.19 0.36  0.50 
Exp 4  11.61 7.52  8.86  X 
Exp 5  0.15 0.10 0.18  0.22 
Average3.45  3.85  3.49  1.44 
P  0.72 0.72 0.72  0.72 
   Day 4
0ng/ml
Day 4
5ng/ml
Day 4 
10ng/ml 
Day 4 
25ng/ml
Exp 1  1 2.18  1.50  0.92 
Exp 2  1 1.75  1.21  0.97 
Exp 3  1 1.00  1.88  2.62 
Exp 4  1 0.648  0.763  X 
Exp 5  1 0.69  1.27  1.50 
Average1  1.25  1.32  1.50 
P  0.5  0.08  0.47    Appendix  2 
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Runx1 (BMP receptor titration)        Relative to Day 0  
 
 
 
 
 
 
 
 
 
 
 
 
Relative to untreated control 
 
  
Day2 
0ng/ml 
Day 2 
25ng/ml 
Day 2 
100ng/ml
Day 2 
250ng/ml
Exp 1  1 0.88  0.86  0.68 
Exp 2  1 0.57  0.55  0.95 
Exp 3  1 0.80  0.88  0.81 
Exp 4  1 0.86  0.99  0.90 
Average 1  0.78  0.82  0.84 
P  0.07  0.07  0.07 
  
 
Day6 
0ng/ml 
Day 6 
25ng/ml 
Day 6 
100ng/ml
Day 6 
250ng/ml
Exp 1  1 0.90  0.74  0.68 
Exp 2  1 0.99  1.58  1.06 
Exp 3  1 0.89  0.81  0.96 
Exp 4  1 0.87  1.10  0.64   
Average 1  0.91  1.06  0.83 
P  0.07  1  0.27 
 
 
 
 
 
Day 2 
0ng/ml 
Day 2 
25ng/ml 
Day 2 
100ng/ml
Day 2 
250ng/ml
Exp 1  2.61 2.54  2.99  1.83 
Exp 2  2.32 1.31  1.27  2.21 
Exp 3  2.45 1.96  2.15  1.98 
Exp 4  5.71 5.01  4.91  3.88 
Average 3.27  2.70  2.83  2.47 
P 0.07  0.07  0.07  0.07 
  
Day 4
0ng/ml
Day 4 
25ng/ml 
Day 4 
100ng/ml 
Day 4 
250ng/ml
Exp 1  0.23 0.20  0.23  0.21 
Exp 2  0.89 0.69  0.78  1.02 
Exp 3  1.61 0.97  X  0.94 
Exp 4  0.84 0.75  0.62  0.57 
Average0.89  0.65  0.54  0.69 
P 0.72  0.07  0.11  0.14 
  
Day 6 
0ng/ml 
Day 6 
25ng/ml 
Day 6 
100ng/ml
Day 6 
250ng/ml
Exp 1  0.74 0.73  X  0.78 
Exp 2  0.44 0.40  0.36  0.42 
Exp 3  0.88 0.92  0.89  0.79 
Exp 4  0.10 0.09  0.11  0.06 
Average 0.54  0.53  0.45  0.51 
P 0.07  0.11  0.07  0.07 
  
Day4 
0ng/ml
Day 4 
25ng/ml 
Day 4 
100ng/ml 
Day 4 
250ng/ml
Exp 1  1 1.05  1.01  0.89 
Exp 2  1 0.97  1.15  0.70 
Exp 3  1 0.77  0.88  1.15 
Exp 4  1 0.60  X  0.59 
Average1  0.85  1.01  0.83 
P  0.27  0.59  0.27    Appendix  2 
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Scl (BMP receptor titration)         Relative to day 0 
 
  
Day 2 
0ng/ml 
Day 2 
25ng/ml 
Day 2 
100ng/ml
Day 2 
250ng/ml
Exp 1  0.64 0.91  1.67  1.21 
Exp 2  1.18 0.94  1.27  1.70 
Exp 3  1.96 0.55  0.61  0.44 
Exp 4  1.71 1.84  3.10  2.02 
Average 1.37  1.06  1.66  1.34 
P 0.27  0.72  0.27  0.27 
 
 
Day 6 
0ng/ml 
Day 6 
25ng/ml 
Day 6 
100ng/ml
Day 6 
250ng/ml
Exp 1  0.28 1.42  0.47  0.32 
Exp 2  0.16 0.18  0.17  0.21 
Exp 3  0.50 0.66  0.73  0.38 
Exp 4   0.37  0.39    0.21  0.22  
Average 0.33  0.66  0.40  0.28 
P 0.07  0.27  0.07  0.07 
 
Relative to untreated control 
 
  
Day2 
0ng/ml 
Day 2 
25ng/ml 
Day 2 
100ng/ml
Day 2 
250ng/ml
Exp 1  1 1.07  1.81  1.18 
Exp 2  1 0.79  1.07  1.44 
Exp 3  1 1.27  1.40  1.01 
Exp 4  1 0.60  0.71  0.71 
Average 1  0.93  1.25  1.08 
P  0.72  0.27  0.47 
  
  
Day6 
0ng/ml 
Day 6 
25ng/ml 
Day 6 
100ng/ml
Day 6 
250ng/ml
Exp 1  1 1.17  0.44  0.72 
Exp 2  1 5.08  1.67  1.15 
Exp 3  1 1.14  1.06  1.28 
Exp 4  1   1.03  0.56   0.59  
Average 1  2.46  1.06  1.05 
P  0.07  1  0.72 
 
 
 
 
 
  
Day 4
0ng/ml
Day 4 
25ng/ml 
Day 4 
100ng/ml 
Day 4 
250ng/ml
Exp 1  0.44 0.25  0.31  0.31 
Exp 2  0.70 0.51  0.76  0.73 
Exp 3  1.17 0.99  X  0.93 
Exp 4  0.69 0.81  0.31  0.50 
Average0.75  0.64  0.46  0.62 
P 0.14  0.07  0.11  0.07 
  
Day4 
0ng/ml
Day 4 
25ng/ml 
Day 4 
100ng/ml 
Day 4 
250ng/ml
Exp 1  1 1.32  1.47  0.76 
Exp 2  1 1.41  2.60  1.89 
Exp 3  1 0.72  1.09  1.04 
Exp 4  1 0.85  X  0.79 
Average1  1.07  1.72  1.12 
P  0.47  0.11  1.00    Appendix  2 
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Gata2 (BMP receptor titration)        Relative to day 0 
 
 
Day 2 
0ng/ml 
Day 2 
25ng/ml 
Day 2 
100ng/ml
Day 2 
250ng/ml
Exp 1  1.96 2.41  1.97  1.80 
Exp 2  3.50 2.52  2.17  3.40 
Exp 3  2.16 2.05  2.34  2.36 
Exp 4  4.10 3.61  4.33  3.40 
Average 2.93  2.65  2.70  2.74 
P 0.07  0.07  0.07  0.07 
 
 
Day 6 
0ng/ml 
Day 6 
25ng/ml 
Day 6 
100ng/ml
Day 6 
250ng/ml
Exp 1  0.80 1.03  1.25  0.92 
Exp 2  0.37 0.40  0.26  0.33 
Exp 3  0.82 1.01  0.90  0.41 
Exp 4  0.08  0.08   0.07   0.05  
Average 0.52  0.63  0.62  0.43 
P 0.07  0.47  0.27  0.07 
 
Relative to untreated control 
 
  
Day2 
0ng/ml 
Day 2 
25ng/ml 
Day 2 
100ng/ml
Day 2 
250ng/ml
Exp 1  1 0.88  1.06  0.83 
Exp 2  1 0.72  0.62  0.97 
Exp 3  1 0.95  1.08  1.09 
Exp 4  1 0.77  0.89  0.85 
Average 1  0.83  0.91  0.93 
P  0.07  0.47  0.27 
  
 
Day6 
0ng/ml 
Day 6 
25ng/ml 
Day 6 
100ng/ml
Day 6 
250ng/ml
Exp 1  1 0.86  0.57  0.44 
Exp 2  1 1.29  1.57  1.14 
Exp 3  1 1.08  0.70  0.91 
Exp 4  1  0.99  0.86   0.61  
Average 1  1.06  0.92  0.77 
P  0.72  0.72  0.27 
 
 
 
 
  
Day 4
0ng/ml
Day 4 
25ng/ml 
Day 4 
100ng/ml 
Day 4 
250ng/ml
Exp 1  0.33 0.25  0.29  0.28 
Exp 2  1.02 0.80  0.97  0.96 
Exp 3  3.74 3.94  X  2.83 
Exp 4  0.71 0.61  0.41  0.31 
Average1.45  1.40  0.56  1.09 
P 1.00  0.72  0.11  0.72 
 
Day4 
0ng/ml
Day 4 
25ng/ml 
Day 4 
100ng/ml 
Day 4 
250ng/ml
Exp 1  1 1.23  1.10  0.50 
Exp 2  1 1.23  1.01  0.92 
Exp 3  1 0.78  0.95  0.94 
Exp 4  1 1.05  X  0.76 
Average1  1.07  1.02  0.78 
P  0.27  0.59  0.07    Appendix  2 
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Lmo2 (BMP receptor titration)       Relative to day 0 
 
  
Day 2 
0ng/ml 
Day 2 
25ng/ml 
Day 2 
100ng/ml
Day 2 
250ng/ml
Exp 1  7.19 9.02  15.85  11.06 
Exp 2  3.62 3.70  4.57  6.09 
Exp 3  3.13 5.30  4.21  3.74 
Exp 4  8.09 8.80  11.37  10.17 
Average 5.51  6.70  9.00  7.77 
P 0.07  0.07  0.07  0.07 
 
 
Day 6 
0ng/ml 
Day 6 
25ng/ml 
Day 6 
100ng/ml
Day 6 
250ng/ml
Exp 1  1.77 2.27  2.45  2.84 
Exp 2  0.56 0.95  0.59  0.59 
Exp 3  3.62 3.50  3.26  1.26 
Exp 4   2.27  2.40  3.39  2.37  
Average 2.06  2.28  2.42  1.77 
P 0.14  0.14  0.14  0.27 
 
Relative to untreated control 
 
  
Day2 
0ng/ml 
Day 2 
25ng/ml 
Day 2 
100ng/ml
Day 2 
250ng/ml
Exp 1  1 1.09  1.40  1.26 
Exp 2  1 1.02  1.26  1.68 
Exp 3  1 1.69  1.34  1.20 
Exp 4  1   X 0.84  0.86 
Average 1  1.27  1.21  1.25 
P  0.11  0.14  0.14 
 
 
Day6 
0ng/ml 
Day 6 
25ng/ml 
Day 6 
100ng/ml
Day 6 
250ng/ml
Exp 1  1 1.53  0.81  0.57 
Exp 2  1 1.28  1.38  1.60 
Exp 3  1 1.69  1.06  1.05 
Exp 4  1  1.06  1.50   1.21  
Average 1  1.39  1.18  1.11 
P  0.07  0.27  0.47 
 
 
  
Day 4
0ng/ml
Day 4 
25ng/ml 
Day 4 
100ng/ml 
Day 4 
250ng/ml
Exp 1  1.64     1.37  1.42 
Exp 2  2.16 1.81  2.04  2.26 
Exp 3  4.62 4.69  X  2.77 
Exp 4  1.45 2.21  1.17  0.82 
Average2.47  2.90  1.53  1.82 
P 0.07  0.11  0.14  0.11 
  
Day4 
0ng/ml
Day 4 
25ng/ml 
Day 4 
100ng/ml 
Day 4 
250ng/ml
Exp 1  1 0.97  0.90  0.35 
Exp 2  1 1.25  2.20  1.54 
Exp 3  1 0.84  0.95  1.05 
Exp 4  1 1.02  X  0.60 
Average1  1.02  1.35  0.88 
P  1.00  1.00  1.00 Appendix 3 
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Runx1 (shRNA experiment)      Relative to Day 0 
 
Values are fold difference in gene expression correct to 2 decimal places.  The statistical 
significance of results is given by the P values. 
 
 
Day 2 
Serum 
free 
Day 2 
shRNA 
Day 2 
shRNA 
+BMP4
Day 2 
Scramble
Exp 1  0.93 1.28 1.24 1.30 
Exp 2  1.40 1.21 1.10 1.06 
Exp 3  0.58 0.72 0.67 0.35 
Exp 4  0.37 0.71 0.41 0.31 
Exp 5  0.15 0.31 0.20 0.15 
Average  0.68 0.85 0.72 0.64 
P 0.225  0.5  0.225  0.225 
 
 
 
Day 4 
Serum 
free 
Day 4 
shRNA 
Day 4 
shRNA 
+BMP4
Day 4 
Scramble
Exp 1  0.32 0.71 0.54 0.37 
Exp 2  3.37 3.46 3.30 2.62 
Exp 3  0.35 0.40 0.30 0.12 
Exp 4  0.28 0.29 0.29 0.26 
Exp 5  0.14 0.36 0.42 0.33 
Average  0.89 1.04 0.97 0.74 
P  0.5 0.5 0.5 0.5 
 
 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  0.69 0.34 1.32 0.56 
Exp 2  0.42 0.30 1.05 0.19 
Exp 3  0.23 0.20 0.95 0.12 
Exp 4  0.20 0.21 1.10 0.20 
Exp 5  0.28 0.20 1.60 0.09 
Average  0.36 0.25 1.20 0.23 
P  0.043 0.043 0.138 0.043 
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Runx1 (shRNA experiment)  Relative to untreated control 
 
 
 
Day 2 
Serum 
free 
Day 2 
shRNA 
Day 2 
shRNA 
+BMP4
Day 2 
Scramble
Exp 1  1  1.37 1.33 1.40 
Exp 2  1  0.87 0.79 0.76 
Exp 3  1  1.25 1.15 0.61 
Exp 4  1  1.93 1.11 0.85 
Exp 5  1  2.10 1.37 0.98 
Average  1  1.50 1.15 0.92 
P   0.08  0.225  0.5 
 
 
Day 4 
Serum 
free 
Day 4 
shRNA 
Day 4 
shRNA 
+BMP4
Day 4 
Scramble
Exp 1  1  2.26 1.71 1.18 
Exp 2  1  1.03 0.98 0.78 
Exp 3  1  1.15 0.86 0.35 
Exp 4  1  1.11 1.04 0.91 
Exp 5  1  2.51 2.98 2.35 
Average  1  1.61 1.51 1.11 
P    0.043 0.345 0.893 
 
 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  1  0.49 1.91 0.80 
Exp 2  1  0.72 2.51 0.44 
Exp 3  1  0.84 4.06 0.51 
Exp 4  1  1.07 5.58 0.99 
Exp 5  1  0.71 5.66 0.33 
Average  1  0.77 3.94 0.61 
P   0.08  0.043  0.043 
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Scl  (shRNA  experiment)     Relative  to  Day  0 
 
 
Day 2 
Serum 
free 
Day 2 
shRNA 
Day 2 
shRNA 
+BMP4
Day 2 
Scramble
Exp 1  1.60 1.82 0.88 1.65 
Exp 2  0.85 0.60 0.79 0.94 
Exp 3  0.40 0.46 0.75 0.31 
Exp 4  1.25 1.30 1.47 1.25 
Exp 5  1.33 1.15 1.82 2.12 
Average  1.09 1.06 1.14 1.26 
P  0.5  0.893 0.686 0.345 
 
 
Day 4 
Serum 
free 
Day 4 
shRNA 
Day 4 
shRNA 
+BMP4
Day 4 
Scramble
Exp 1  0.41 0.54 0.30 0.36 
Exp 2  2.24 1.26 1.89 2.68 
Exp 3  0.18 0.17 0.14 0.07 
Exp 4  0.25 0.44 0.35 0.24 
Exp 5  0.33 0.23 0.06 0.07 
Average  0.68 0.53 0.55 0.68 
P 0.5  0.08  0.5  0.5 
 
 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  0.44 0.56 7.24 0.54 
Exp 2  0.20 0.46 5.83 0.21 
Exp 3  0.34 0.19 9.51 0.19 
Exp 4  0.45 0.33 11.79 0.22 
Exp 5  0.30 0.23 12.79 0.24 
Average  0.35 0.35 9.43 0.28 
P  0.043 0.043 0.043 0.043 
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Scl (shRNA experiment)    Relative to untreated control 
 
 
Day 2 
Serum 
free 
Day 2 
shRNA 
Day 2 
shRNA 
+BMP4
Day 2 
Scramble
Exp 1  1  1.14 0.55 1.03 
Exp 2  1  0.71 0.94 1.12 
Exp 3  1  1.15 1.88 0.77 
Exp 4  1  1.04 1.18 1.01 
Exp 5  1  0.86 1.37 1.59 
Average  1  0.98 1.18 1.10 
P    0.893 0.345 0.345 
 
 
Day 4 
Serum 
free 
Day 4 
shRNA 
Day 4 
shRNA 
+BMP4
Day 4 
Scramble
Exp 1  1  1.31 0.73 0.87 
Exp 2  1  0.56 0.85 1.20 
Exp 3  1  0.95 0.79 0.42 
Exp 4  1  1.74 1.39 0.95 
Exp 5  1  0.71 0.19 0.21 
Average  1  1.05 0.79 0.73 
P    0.893 0.345 0.225 
 
 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  1  1.25 16.30 1.21 
Exp 2  1  2.26 28.84 1.05 
Exp 3  1  0.57 28.25 0.56 
Exp 4  1  0.73 26.36 0.48 
Exp 5  1  0.78 43.41 0.83 
Average  1  1.12 28.63 0.83 
P    0.893 0.043 0.345 
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Gata2  (shRNA  experiment)     Relative  to  Day  0 
 
 
Day 2 
Serum 
free 
Day 2 
shRNA 
Day 2 
shRNA 
+BMP4
Day 2 
Scramble
Exp 1  0.58 0.68 0.73 0.82 
Exp 2  0.74 0.41 0.44 0.57 
Exp 3  0.27 0.25 0.34 0.20 
Exp 4  0.28 0.40 0.52 0.20 
Exp 5  0.18 0.36 0.17  X 
Average  0.41 0.42 0.44 0.45 
P  0.043 0.043 0.043 0.068 
 
 
Day 4 
Serum 
free 
Day 4 
shRNA 
Day 4 
shRNA 
+BMP4
Day 4 
Scramble
Exp 1  0.13 0.30 0.32 0.20 
Exp 2  0.10 0.08 0.13 0.07 
Exp 3  0.01 0.01 0.01 0.002 
Exp 4  0.01 0.01 0.01 0.004 
Exp 5  0.01 0.01 0.01 0.002 
Average  0.05 0.08 0.09 0.06 
P  0.043 0.043 0.043 0.042 
 
 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  0.53 0.22 0.97 0.34 
Exp 2  0.12 0.14 0.87 0.05 
Exp 3  0.08 0.06 0.98 0.04 
Exp 4  0.07 0.08 1.12 0.04 
Exp 5  0.06 0.06 1.10 0.03 
Average  0.17 0.11 1.01 0.10 
P  0.043 0.043 0.893 0.043 
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Gata2 (shRNA experiment)   Relative to untreated control 
 
 
Day 2 
Serum 
free 
Day 2 
shRNA 
Day 2 
shRNA 
+BMP4
Day 2 
Scramble
Exp 1  1  1.18 1.26 1.42 
Exp 2  1  0.55 0.60 0.78 
Exp 3  1  0.92 1.27 0.73 
Exp 4  1  1.47 1.91 0.74 
Exp 5  1  2.01 0.95 2.07 
Average  1  1.23 1.20 1.15 
P    0.345 0.5 0.686 
 
 
Day 4 
Serum 
free 
Day 4 
shRNA 
Day 4 
shRNA 
+BMP4
Day 4 
Scramble
Exp 1  1  2.23 2.39 1.46 
Exp 2  1  0.84 1.30 0.75 
Exp 3  1  0.92 1.10 0.20 
Exp 4  1  2.21 1.93 0.66 
Exp 5  1  0.86 0.68 0.27 
Average  1  1.41 1.48 0.67 
P    0.686 0.138 0.225 
 
 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  1  0.43 1.85 0.64 
Exp 2  1  1.14 7.09 0.37 
Exp 3  1  0.70 12.24 0.47 
Exp 4  1  1.06 15.60 0.56 
Exp 5  1  1.04 20.07 0.61 
Average  1  0.87 11.37 0.53 
P    0.686 0.043 0.043 
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Lmo2 (shRNA experiment)       Relative to Day 0 
 
 
Day 2 
Serum 
free 
Day 2 
shRNA 
Day 2 
shRNA 
+BMP4
Day 2 
Scramble
Exp 1  1.73 1.38 1.15 1.71 
Exp 2  1.31 1.22 0.98 1.36 
Exp 3  0.70 0.86 0.79 0.43 
Exp 4  2.71 2.86 2.23 2.66 
Exp 5  1.41 1.54 1.73 2.41 
Average  1.57 1.57 1.38 1.72 
P 0.08  0.08  0.345  0.138 
 
 
Day 4 
Serum 
free 
Day 4 
shRNA 
Day 4 
shRNA 
+BMP4
Day 4 
Scramble
Exp 1  3.09 2.75 1.25 1.36 
Exp 2  16.60 14.62 14.25 21.16 
Exp 3  1.27 1.50 0.77 0.47 
Exp 4  1.55 2.78 0.90 1.08 
Exp 5  2.16 1.94 0.58 0.80 
Average  4.93 4.72 3.55 4.97 
P  0.043 0.043 0.893 0.686 
 
 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  1.97 2.34 8.69 2.06 
Exp 2  1.37 1.55 6.93 1.10 
Exp 3  1.44 0.99 11.26 1.13 
Exp 4  1.50 1.53 11.31 1.05 
Exp 5  1.14 0.88 8.28 0.55 
Average  1.48 1.46 9.30 1.18 
P  0.043 0.225 0.043 0.345 
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Lmo2 (shRNA experiment)   Relative to untreated control 
 
 
Day 2 
Serum 
free 
Day 2 
shRNA 
Day 2 
shRNA 
+BMP4
Day 2 
Scramble
Exp 1  1  0.80 0.67 0.99 
Exp 2  1  0.94 0.75 1.04 
Exp 3  1  1.22 1.13 0.62 
Exp 4  1  1.06 0.82 0.98 
Exp 5  1  1.09 1.22 1.71 
Average  1  1.02 0.92 1.07 
P    0.686 0.5 0.893 
 
 
 
Day 4 
Serum 
free 
Day 4 
shRNA 
Day 4 
shRNA 
+BMP4
Day 4 
Scramble
Exp 1  1  0.89 0.41 0.44 
Exp 2  1  0.88 0.86 1.28 
Exp 3  1  1.19 0.61 0.38 
Exp 4  1  1.79 0.58 0.69 
Exp 5  1  0.90 0.27 0.37 
Average  1  1.13 0.54 0.63 
P    0.686 0.043 0.138 
 
 
 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  1  1.19 4.41 1.04 
Exp 2  1  1.13 5.08 0.81 
Exp 3  1  0.69 7.84 0.78 
Exp 4  1  1.02 7.55 0.70 
Exp 5  1  0.77 7.24 0.49 
Average  1  0.96 6.42 0.76 
P   0.686  0.043  0.08 
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Flow cytometry tables (shRNA experiment) 
 
Values are percentage of positive cell correct to 2 decimal places. 
 
CD34 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  0.03 0.65 0.04 0.04 
Exp 2  0.03 1.11 0.11 0.03 
Exp 3  0.32 0.80 0.05 0.06 
Exp 4  0.13 0.92 0.06 0.03 
Average  0.13 0.87 0.07 0.04 
P    0.01 0.47 0.26 
 
Sca-1 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  0.22 0.42 0.40 0.24 
Exp 2  2.54 1.15 0.69 0.49 
Exp 3  X  1.26 1.57 0.26 
Exp 4  0.31 0.55 0.84 0.22 
Average  1.02 0.85 0.88 0.30 
P    0.62 0.66 0.40 
 
Flk-1 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  0.89 1.60 3.90 0.68 
Exp 2  2.03 1.18 3.32 1.28 
Exp 3  X  2.41 4.68 1.75 
Exp 4  1.18 1.25 2.71 1.06 
Average  1.37 1.61 3.65 1.19 
P    0.96 0.07 0.21 
 
C-kit 
Day 6 
Serum 
free 
Day 6 
shRNA 
Day 6 
shRNA 
+BMP4
Day 6 
Scramble
Exp 1  0.32 0.31 1.76 0.24 
Exp 2  0.35 0.50 1.63 1.30 
Exp 3  X  0.85 2.53 0.25 
Exp 4  1.01 0.57 2.12 0.27 
Average  0.56 0.56 2.01 0.52 
P    0.63 0.01 0.94  
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